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Abstract 1 
The spinal cord is a clinically eloquent structure, commonly affected in multiple sclerosis 2 
(MS) and spinal neuroaxonal loss is an important cause of non-remitting, disability 3 
progression. Neuroaxonal loss in MS is likely to be multifactorial and caused by several 4 
disease pathways. In contrast, repair and adaptive mechanisms can ameliorate disability 5 
following clinical relapses. This thesis has explored some of these clinically relevant disease 6 
mechanisms by combining single-voxel proton spectroscopy (MRS) and Q-space imaging 7 
(QSI), two advanced MRI techniques, which have increased pathological specificity for 8 
neurodegeneration and myelin, and allow quantification of metabolites that reflect biological 9 
mechanisms, to study spinal neurodegeneration and repair in MS. 10 
 11 
In persons with early primary progressive MS (PPMS), spinal MRS and QSI exhibited 12 
increased sensitivity for detection of early disease changes than more conventional measures 13 
such as spinal cord atrophy and correlated with clinical disability measures suggesting these 14 
measures are functionally relevant. Region of interest analysis of the relationship between 15 
QSI indices in spinal white matter tracts and clinical scores which reflect the motor or 16 
sensory functions conveyed within those tracts, suggests a strong structure-function 17 
relationship exists between axonal integrity and disability. 18 
 19 
In persons with relapsing remitting MS (RRMS), with recent (within 4 weeks) symptoms 20 
suggestive of spinal cord relapse, serial imaging with spinal MRS and QSI over 6 months 21 
reflected clinical changes over that time. Specifically, rising spinal concentrations of total N-22 
acetyl-aspartate (tNAA) and restriction of QSI-derived perpendicular diffusivity, which I 23 
 
 
3 
 
hypothesise reflect, restoration of mitochondrial function and remyelination, respectively, 1 
underlie clinical recovery.  2 
 3 
Within the RRMS cohort, MRS and QSI measures at baseline were predictive of clinical 4 
outcomes at 6 months; elevated baseline spinal glutamate-glutamine (Glx), myo-inositol (Ins) 5 
and total creatine (tCr) concentrations and increased QSI-derived perpendicular diffusivity 6 
predicted poor outcomes and may reflect important mechanisms of disability progression 7 
such as; demyelination, neurodegeneration, astrogliosis and altered neuronal metabolism. 8 
Taken together the results suggest that mechanisms of disability following spinal cord relapse 9 
are complex and glutamate excitotoxicity, gliosis and axonal metabolic dysfunction may be 10 
important determinants of residual disability following relapses. 11 
  12 
This work suggests that newer, quantitative MRI techniques when applied to the spinal cord 13 
are sensitive markers of disease activity and progression and could be useful in monitoring 14 
therapies that aim to prevent neurodegeneration and enhance remyelination in MS. 15 
  16 
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1.1 Introduction 1 
 2 
Multiple Sclerosis (MS) is a debilitating, multifocal, central nervous system (CNS) disorder 3 
of unknown aetiology, but is widely believed to be an autoimmune disease arising as a 4 
consequence of genetic-environmental interaction in at-risk individuals, and is the most 5 
common cause of disability of young people in the developed world (Compston and Coles, 6 
2008). 7 
 8 
The UK prevalence of MS is estimated to be around 125,000 people (Mackenzie et al., 2014). 9 
Over the past few decades, the incidence has risen around the world, increasing the burden on 10 
patients, carers and healthcare systems. The socioeconomic impact of the disease is 11 
significant; from a patient perspective, each clinical relapse is associated with loss of earnings 12 
and a decline in health related quality of life and functional ability (Oleen-Burkey et al., 13 
2012). There are also significant costs to the national economy associated with healthcare 14 
provision, social services, diminishing productivity at work and earlier retirement, with one 15 
study estimating that the total lifetime costs of MS are in excess of £1 million per patient in 16 
the UK (McCrone et al., 2008).  17 
 18 
This introductory chapter will introduce the reader to MS and briefly cover aetiology, 19 
epidemiology, pathology, clinical course and diagnosis. 20 
 21 
  22 
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1.2 Aetiology 1 
 2 
1.2.1 Genetic Factors 3 
Evidence for a pre-determined genetic susceptibility to MS comes from familial studies 4 
which have compared disease recurrence rates amongst relatives of MS patients to the 5 
background population. Studies of European and North American populations have 6 
consistently shown an increased risk of approximately 3-5% amongst first degree relatives 7 
(Sadovnick and Baird, 1988; Carton et al., 1997; Ebers et al., 2000; Montomoli et al., 2002). 8 
Concordance between monozygotic twins is approximately 30% (Ebers et al., 1986; 9 
Sadovnick et al., 1993), whilst in dizygotic pairs, rates of 3-5% are typically seen, equal to 10 
non-twin first degree relatives (James, 1982; Kinnunen et al., 1988; Mumford et al., 1994). 11 
The marked drop in recurrence risks between monozygotic and other first degree relatives, 12 
strongly suggests that MS is a polygenic disorder. A study looking at familial risk in non-13 
biological relatives, looked at 1201 relatives of patients with MS and found only a single case 14 
which might be expected in the general population, suggesting environment alone, without 15 
genetic susceptibility is insufficient to trigger the onset of MS (Ebers et al., 1995). The 16 
human leukocyte antigen (HLA) DRB1*1501 has been consistently associated with MS and 17 
exerts the largest known genetic contribution to MS susceptibility in Caucasian, Northern 18 
Europeans (Martin et al., 1992; Fukazawa et al., 2000).  19 
 20 
1.2.2 Environmental factors 21 
The global distribution of MS cannot readily be explained by genetics alone. MS prevalence 22 
follows a latitude gradient suggesting environmental factors also play a role. An Australian 23 
study of disease prevalence in Australia and New Zealand shows MS prevalence increasing 24 
three-fold from the North (35°S) to the South (48°S) independently of ethnic background 25 
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(Taylor et al., 2010). The latitude gradient for MS prevalence, where those living at higher 1 
latitude are at increased risk of MS has been demonstrated in both Northern and Southern 2 
hemispheres (Miller et al., 1990; Vukusic et al., 2007; Ramagopalan et al., 2011) and MS 3 
risk is seen to drop on migration from high to low latitudes (Gale and Martyn, 1995). 4 
 5 
The strong correlation between latitude and MS prevalence has increased interest in vitamin 6 
D, which is produced in the skin following sunlight exposure as an important environmental 7 
factor determining MS risk. This hypothesis might explain why the prevalence of MS in 8 
some communities living at higher latitudes but have a diet rich in fatty fish which are rich in 9 
vitamin D have lower than expected risk of MS (Ascherio et al., 2010). Additionally 10 
variability in UVB exposure and vitamin D status during pregnancy may explain why season 11 
of birth effects MS risk (Disanto et al., 2012). Vitamin D specifically interacts with HLA-12 
DRB1*1501 to influence its expression which provides a potential explanation for the 13 
mechanisms by which vitamin D might modulate MS risk (Ramagopalan et al., 2009). 14 
 15 
An autoimmune response to a viral infection has also been proposed as an aetiological 16 
explanation for MS (Granieri and Casetta, 1997). Epstein Barr virus (EBV) is one of several 17 
infective agents that have been suggested to be linked with MS. Rates of EBV seropositivity 18 
approach 100% in MS patients compared to 90% in the general population (Bray et al., 1983; 19 
Munch et al., 1998; Wandinger et al., 2000). Additionally, geographical incidence of hospital 20 
admissions for infectious mononucleosis (IM), which is caused by EBV compares to the 21 
incidence to that of admissions for MS found that geographical distributions of IM and MS 22 
are significantly correlated  (Ramagopalan et al., 2011). 23 
 24 
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There is now also a substantial body of evidence that suggests that tobacco smoking is a 1 
modifiable environmental risk factor in MS.  The reported effects of smoking in MS vary 2 
with study design. In a small study looking at immediate effects of smoking on motor 3 
function, twenty one patients were exposed to cigarette smoke, and of those, sixteen patients 4 
experienced a transient deterioration in their motor function immediately after smoking, 5 
lasting for ten minutes (Emre and de Decker, 1992). Several retrospective studies have found 6 
an accelerated transition from RRMS to SPMS in ever smokers (Hernan et al., 2005; Koch et 7 
al., 2007) and accelerated cognitive decline in heavy smokers (Ozcan et al., 2014). Whilst in 8 
a retrospectively designed study of Austrian CIS patients, smoking was associated with a 9 
higher risk of conversion to clinically definite MS (HR =1.8; C.I. 1.2-2.1) (Di Pauli et al., 10 
2008).  11 
 12 
Fewer prospective studies have reported on smoking risk in MS. A study of 368 patients 13 
looking at the effects of smoking on MRI measures, smoking was associated with higher 14 
EDSS, more contrast enhancing brain lesions, larger T1 and T2 lesion volumes and lower 15 
brain parenchymal fractions in smokers than non-smokers, after adjusting for demographic 16 
factors and treatment duration  (Zivadinov et al., 2009).  Another prospectively designed 17 
cohort study from Southern Tasmania, showed smoking was associated with increased 18 
progression of clinical disability (Pittas et al., 2009). 19 
 20 
 21 
 22 
  23 
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1.3 Epidemiology 1 
MS is a global disease with an estimated 2.5 million affected people worldwide. The lifetime 2 
risk is thought to be approximately 1 in 400, making MS the commonest cause of progressive 3 
neurological disability affecting young people (Compston and Coles, 2002), but as discussed 4 
earlier, distribution of MS globally is not even. Although comparison of prevalence studies 5 
from different parts of the world is limited by differences in the sophistication of medical and 6 
diagnostic services, highest disease prevalence is consistently seen in Europe between 65 ° 7 
and 45 ° North latitude, the Northern United States and Southern Canada, New Zealand, and 8 
Southern Australia. Southern European, Northern Australian and South American 9 
populations carry an intermediate risk, whilst MS prevalence in Africa and Asia is relatively 10 
low (Kurtzke, 1977). 11 
 12 
1.4 Pathology of Multiple Sclerosis 13 
The pathological hallmarks of MS are the multi-focal MS lesions which occur in the cerebral 14 
grey and white matter as well as the spinal cord and consist of focal demyelination, 15 
inflammation, gliosis, and variable axonal destruction (Popescu and Lucchinetti, 2012). 16 
 17 
1.4.1 Inflammation 18 
In health, the blood–brain barrier (BBB) separates the brain and spinal parenchyma from 19 
circulating leucocytes and their inflammatory mediators (Pachter et al., 2003). It is composed 20 
of densely arranged endothelial cells with tight junctions along the length of the capillary 21 
network within the CNS. Endothelial cells are supported by astrocytes within the CNS 22 
(Minagar and Alexander, 2003) and the tight junctions act to prevent passage of large 23 
molecules into the parenchyma. In health, the tight junctions prevent the entry of immune 24 
cells from the periphery and there is limited risk of local immune reactions, which is thought 25 
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to be due to the low expression of major histocompatibility complex (MHC) molecules by 1 
antigen-presenting cells. 2 
 3 
In MS, pro-inflammatory cytokines produced by activated auto-reactive CD4+ cells are able 4 
to activate adhesion molecules (ICAM-1 and VCAM-1) within the endothelial cells at the 5 
BBB. Activated auto-reactive CD4+ cells express the respective counter receptors (LFA-1 6 
and VLA-4), which allows them to adhere to the endothelium of the BBB; following 7 
adhesion, they transmigrate into the brain parenchyma through cerebrovascular endothelial 8 
cells (Engelhardt and Ransohoff, 2005; Komiyama et al., 2006). Production of proteolytic 9 
enzymes by CD4+ cells and other co-ordinating inflammatory cells causes a breach in the 10 
integrity of the BBB which allows entry of circulating CD8+ T-cells, B-cells monocytes and 11 
mast cells from the periphery. Once CD4+ have access to the CNS, they become locally re-12 
activated (Flugel et al., 2001) and release pro-inflammatory chemokines and cytokines which 13 
is thought to be the first step in the formation of a new MS lesion.  Activation of astrocytes 14 
and microglia is then implicated in phagocytosis of myelin which serves to amplify the local 15 
inflammatory response, propagating further injury and setting up a pro-inflammatory loop 16 
(Compston and Coles, 2002). 17 
 18 
B-cells can only cross the BBB at sites where its integrity has been disrupted by focal 19 
inflammation. Once they enter the CNS, there is some evidence that they are involved in the 20 
pathogenesis of MS. Firstly, intrathecal synthesis of clonal IgG in the CSF, but not the serum 21 
(which gives rise to oligoclonal bands), increases during MS exacerbations and is less 22 
frequently observed in patients who run a more benign disease course (Zeman et al., 1996). 23 
Secondly, B-cell depletion with the anti-CD20 monoclonal antibody, Rituximab, reduces 24 
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relapse rates and formation of new gadolinium-enhancing lesions on MRI (both markers of 1 
disease activity) (Hauser et al., 2008). 2 
 3 
The acute MS lesion is characterised by marked perivenous infiltration of lymphocytes and 4 
large numbers of macrophages and clonally expanded memory B cells in lesions which 5 
suggests binding to a specific antigen (Baranzini et al., 1999).  Oligodendrocyte apoptosis 6 
and demyelination associated with microglia activation occurs early (Barnett and Prineas, 7 
2004). During the months following lesion formation, the cellular composition of the plaque 8 
changes and chronic plaques may show ‘smouldering inflammation’, but are often devoid of 9 
inflammatory cells and characterised by loss of myelin and axons, with relative increases in 10 
astrocytes, and gliotic tissue changes. 11 
 12 
An ongoing controversy within the MS research community relates to whether or not the 13 
inflammatory response seen in MS is a secondary phenomenon to a primarily 14 
neurodegenerative disease process (Trapp and Nave, 2008; Stys et al., 2012). The “inside-out 15 
model” of MS (Stys et al., 2012), that has been proposed, hypothesises that an initial 16 
degenerative process affects the myelin sheaths and oligodendrocytes and it is the host’s 17 
immune response to the highly autoantigenic break down products (Kanter et al., 2006; 18 
Moscarello et al., 2007)  that lead to the inflammatory attacks which are characteristic of  19 
MS. 20 
 21 
1.4.2 Axonal Degeneration 22 
Axonal injury in MS has been noted ever since the earliest descriptive pathological studies of 23 
the disease and is now known to occur early in the disease course (Brex et al., 2000; Filippi et 24 
al., 2003). In acute lesions, the number of infiltrated microglia, macrophages and CD8+ T 25 
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cells correlates with axonal injury (Bitsch et al., 2000) but axonal injury continues to develop 1 
in chronic lesions, once inflammation ebbs (Kornek et al., 2000) and in chronic established 2 
lesions axonal density is reduced on average by 60–70% (Mews et al., 1998; Bjartmar et al., 3 
2000). Axonal injury in MS is size selective; small calibre axons are more vulnerable to 4 
injury compared to thicker axons. Thus, in inactive chronic MS lesions thick axons are better 5 
preserved than thin ones (Evangelou et al., 2001). Histopathological studies have 6 
demonstrated that within NAWM, both axonal density and volume are also reduced by an 7 
average of 33% and 53% respectively, compared to aged matched controls (Evangelou et al., 8 
2000). Mechanisms of axonal loss in MS are discussed in greater detail in Section 1.5. 9 
 10 
 11 
1.4.3 Normal Appearing White Matter and “Dirty appearing” white matter 12 
The term ’normal appearing white matter’ (NAWM) in imaging studies has been defined to 13 
mean the white matter closest to and surrounding an MS plaque that is not abnormal in signal 14 
intensity on T2-weighted images (Guo et al., 2001).  NAWM has assumed increased 15 
importance over the past 30 years as it is thought that damage at these sites might explain the 16 
poor correlation between the location and size of MS plaques and clinical disability (see 17 
‘clinico-radiological paradox’, Section 3.2.5). 18 
 19 
Macroscopically invisible pathology within these tissues can be detected using sophisticated 20 
quantitative MRI techniques including magnetization transfer imaging which shows reduced 21 
MTR thought to represent changes in myelination (Leary et al., 1999). A decrease in NAA 22 
concentration seen on spectroscopy (Fu et al., 1998) suggestive of axonal loss and changes 23 
seen in diffusion characteristics suggesting abnormalities in the microstructural integrity of 24 
the tracts in these regions (Werring et al., 1999). 25 
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Histological examination of NAWM reveals demyelination, infiltration of macrophages filled 1 
with myelin, axonal spheroids, microglial cells with increased expression of MHC class I and 2 
II molecules, gliosis and some remyelination (Allen and McKeown, 1979; van Waesberghe et 3 
al., 1999; Vos et al., 2005). The axonal loss in NAWM can be variable and is thought to be 4 
partly explained by Wallerian degeneration following axonal transection in focal lesions 5 
(Evangelou et al., 2000; Lassmann, 2003). 6 
 7 
 8 
1.4.4 Spinal Cord 9 
Spinal cord involvement in MS is almost absolute, with one post-mortem study of MS 10 
patients from the United States, reporting spinal cord plaques in 99% of spinal cord samples 11 
(Ikuta and Zimmerman, 1976). Demyelinating lesions within the spinal cord show 12 
preponderance for the cervical cord, with the upper thoracic segment being the second most 13 
likely to be involved (Kidd et al., 1993). Lesions most frequently affect the lateral columns, 14 
followed by the posterior columns, with most cord atrophy occurring in the cervical cord 15 
(Oppenheimer, 1978; Bjartmar et al., 2000; Gilmore et al., 2006).  16 
 17 
Pure grey matter lesions in the spinal cord account for approximately 22% of all spinal cord 18 
lesions, with pure white matter lesions making up 33% and mixed white matter/grey matter 19 
lesions making 45% (Gilmore et al., 2006). The majority of atrophy seen in the cord is 20 
thought to be due to volume loss within the white matter compartment (Gilmore et al., 2005), 21 
where up to 84% of axons within chronic lesions may be lost (Bjartmar et al., 2000). 22 
Interestingly, Gilmore et al reported no difference in grey matter volumes in the spinal cord 23 
between MS patients and healthy controls (Gilmore et al., 2005).  24 
 25 
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1.5 Mechanisms of Neurodegeneration 1 
 2 
1.5.1 Inflammatory demyelination and axonal damage 3 
Within the active MS lesion, high numbers of transected axons can be seen (Trapp et al., 4 
1998). Trapp et al found that inflammatory infiltrates consisting of macrophages and 5 
activated microglia are seen in close contact with axons, that show signs of injury and that 6 
axonal loss correlated with inflammation and demyelination. It is therefore likely that one 7 
mechanism of axonal loss in MS is the consequence of direct immunologic attack on axons, 8 
from soluble inflammatory mediators, or from secondary effects of chronic demyelination 9 
(Trapp et al., 1998). In acute lesions, the number of infiltrated microglia, macrophages and 10 
CD8+ T cells correlates closely with the degree of axonal injury (Bitsch et al., 2000). 11 
 12 
1.5.2 Glutamatergic neurotransmission and excitotoxic axonal damage 13 
The amino acid, L-glutamate is the most abundant excitatory neurotransmitter in the 14 
mammalian nervous system. Glutamate has many important roles; synaptic plasticity at 15 
glutamatergic synapses is thought to underlie many aspects of regulated cortical function, 16 
including memory and learning (Headley and Grillner, 1990). Glutamate does not cross the 17 
blood brain barrier and therefore needs to be synthesised in neurones from precursors. The 18 
predominant precursor is glutamine which is released by glial cells and taken up by neuronal 19 
presynaptic terminals where it is metabolised to glutamate by the mitochondrial enzyme, 20 
glutaminase (Schousboe et al., 1993; Augustine, 2008).  21 
 22 
Once, glutamate is synthesised in the presynaptic terminal, it is packaged into synaptic 23 
vesicles and can then be released in to the synaptic cleft, where it binds to its post-synaptic 24 
receptors. On the postsynaptic cell, glutamate binds to either ligand gated ionotropic 25 
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glutamate receptors (iGluRs) or G-protein coupled metabotropic glutamate receptors 1 
(mGluRs) causing postsynaptic excitation. Glutamate in the synaptic cleft is removed by 2 
high-affinity, sodium-dependent excitatory amino acid transporters (EAATs) which transport 3 
glutamate to astrocytes (Rothstein et al., 1994). Here, it is converted back to glutamine by the 4 
enzyme glutamine synthase, thus completing the glutamate-glutamine cycle (Schousboe et 5 
al., 1993). Transfer of glutamine from astrocytes back to neurones is mediated by glutamine 6 
transporters; system N transport (SN1) in astrocytes allow release of glutamine into the 7 
interstitial fluid, where it is then taken up by system A transport (SAT/ATA) in neurones 8 
(Bröer and Brookes, 2001). In human white matter, oligodendrocytes have also been shown 9 
to express glutamate transporters and appear to be responsible for the majority of glutamate 10 
clearance in white matter (Pitt et al., 2003).  11 
 12 
Potentially toxic effects of excess glutamate where first reported in 1957 when paraenterally 13 
administered L-glutamate was seen to damage the neuroretinal layer in new born mice  14 
(Lucas and Newhouse, 1957). In 1969, John Olney discovered that this phenomenon was not 15 
restricted to the retina, but occurred throughout the brain (Olney, 1969; Olney and Sharpe, 16 
1969). Olney demonstrated that glutamate mediated injury was restricted to the postsynaptic 17 
cells, whilst sparing the presynaptic terminal, and that antagonists at glutamate receptors 18 
ameliorated glutamate mediated cell damage (Olney, 1971; Olney et al., 1971). Olney coined 19 
the term “excitotoxicity”, postulating that the mechanisms leading to injury where produced 20 
by prolonged activation of postsynaptic receptors. 21 
 22 
Alterations in normal extracellular concentrations of glutamate have since been reported to 23 
play a role in a number of neurodegenerative diseases, including stroke (Arundine and 24 
Tymianski, 2004), schizophrenia (Egerton et al., 2012; Ota et al., 2012), Parkinson’s disease 25 
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(Caudle and Zhang, 2009) and amyotrophic lateral sclerosis (Shaw and Ince, 1997). Neuronal 1 
excitotoxicity usually refers to the injury and death of neurons arising from prolonged 2 
exposure to glutamate and the associated excessive influx of ions into the cell. Excessive 3 
activation of glutamate receptors by excitatory amino acids leads to a number of deleterious 4 
consequences, including impaired calcium buffering, formation of free radicals, activation of 5 
the mitochondrial permeability transition and subsequent secondary excitotoxicity (Dong et 6 
al., 2009).  7 
 8 
Evidence supporting the excitotoxicity hypothesis in MS includes the presence of elevated 9 
plasma glutamate levels in RRMS (Pampliega et al., 2008) as well as elevated glutamate 10 
within the CSF of RRMS patients with active lesions (Stover et al., 1997; Gurwitz and 11 
Kloog, 1998). Interestingly, CSF glutamate levels are similar in controls and RRMS patients 12 
with silent lesions, which seems to suggest that dysregulation of glutamate homeostasis 13 
occurs during the active inflammatory phase of the disease. This is supported by the 14 
observation that microglia and macrophages within MS lesions show decreased expression of 15 
glutamine synthase and glutamate dehydrogenase, the enzymes that convert glutamate back 16 
to glutamine (Werner et al., 2001). Activated leukocytes and microglial cells, have also been 17 
shown in vitro to produce large quantities of glutamate by upregulating the glutamate 18 
producing enzyme glutaminase (Piani et al., 1991), which suggests that, infiltrating, 19 
inflammatory cells are the likely source of the glutamate causing excitotoxic damage in MS.  20 
 21 
A clinical, magnetic resonance spectroscopy (MRS) study in MS patients found elevated 22 
glutamate concentrations in acute brain lesions (Srinivasan et al., 2005). In a follow up study 23 
by the same research group, which included 382 MS patients, those with higher 24 
concentrations of glutamate quantified from normal appearing white matter (NAWM) and 25 
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grey matter using MRS showed faster rate of neurodegeneration over 12 month follow up 1 
demonstrated by greater decreases in the neuronal marker, N-acetyl-aspartate (tNAA) 2 
(Baranzini et al., 2010). There was increased prevalence in those patients of a common 3 
polymorphism (rs794185) within the gene sulphatase modifying factor 1 (SUMF1) which 4 
may indirectly regulate extracellular glutamate by altering the activity of steroid sulphatases 5 
(Baranzini et al., 2010). 6 
 7 
Whether or not, increased glutamate in MS is clinically relevant, however, remains to be 8 
established. Some supportive evidence comes from animal studies, where suppression of 9 
disease activity and reduction of axonal damage were seen in experimental autoimmune 10 
encephalitis (EAE) mice, treated with the AMPA/kainate antagonist, NBQX (Pitt et al., 11 
2000). In a small double-blinded, placebo controlled treatment trial, a reduction in relapse 12 
rate was seen in MS patients treated with amantadine, a weak NMDA receptor antagonist, 13 
though no difference in disability progression between the treated and placebo groups was 14 
seen (Plaut, 1987). However, a small, open label, pilot study of 16 patients with PPMS 15 
treated with Riluzole (Kalkers et al., 2002), a licensed therapy for ALS, which ameliorates 16 
EAE (Gilgun-Sherki et al., 2003) and is thought to reduce extracellular glutamate by 17 
reducing release of glutamate from pre-synaptic terminals (Killestein et al., 2005) and up-18 
regulating the major astrocyte glutamate transporter, GLT-1 (Carbone et al., 2012), did not 19 
report clinical outcomes. Instead, the study showed a non-significant reduction in the rate of 20 
cervical cord atrophy, and development of new hypointense lesions on T1 weighted MRI. 21 
The study was small, uncontrolled and unblinded but the results showed some promise and 22 
there are currently on-going trials of riluzole in patients with clinically isolated syndromes 23 
(CIS) and MS to establish efficacy as a neuroprotective agent. 24 
 25 
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1.5.3 Mitochondrial dysfunction and axonal damage 1 
Mitochondrial injury with subsequent energy deficiency seems to be an important factor in 2 
the induction of axonal injury in MS lesions (Trapp and Stys, 2009). Mitochondria are the 3 
site of aerobic respiration and ATP synthesis within cells; they meet the axons energy 4 
demands, hence, are crucial to their survival. In MS, reduced production of ATP as a 5 
consequence of mitochondrial dysfunction, occurs concurrently with increased energy 6 
demand which contributes to axonal loss (van Horssen et al., 2012). Several mechanisms are 7 
thought to contribute to mitochondrial dysfunction and lead to axonal injury. Firstly, during 8 
MS lesion formation, activated mononuclear cells produce reactive oxygen species (ROS) 9 
such as nitric oxide (NO) and inducible nitric oxide synthase (iNOS) is up-regulated, leading 10 
to further production of inducible nitric oxide. ROS inhibit mitochondrial respiration and 11 
ATP synthesis (Cross et al., 1997; Vladimirova et al., 1998; Brown and Borutaite, 2001). 12 
Secondly, elevated glutamate levels and activation of post-synaptic glutamate receptors, leads 13 
to an increase in intracellular calcium which activates phospholipases, endonucleases, and 14 
proteases, which damage mitochondrial DNA, disrupt the cytoskeleton, and alter membrane 15 
lipids within mitochondria (Su et al., 2009). Thirdly, the glutamate mediated pathway and 16 
NO mediated pathway converge onto a common pathway causing mitochondrial dysfunction; 17 
both mechanisms affect the electron transport chain, ATP synthesis, ionic homeostasis, and 18 
release of pro-apoptotic factors and it is thought that this convergence is present during 19 
inflammatory and progressive phases of the disease (Su et al., 2009). 20 
 21 
1.5.4 Sodium and axonal damage 22 
Demyelinated axons in MS are not as efficient at conducting electrical impulses due to 23 
interruption of normal salutatory conduction. This results in increased expression of voltage-24 
gated sodium channels in order to maintain conduction. The Nav1.6 subtype, which is 25 
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normally confined to the nodes of Ranvier, is redistributed along the demyelinated axon, 1 
where it is co-expressed with the Nav1.2 subtype (Craner et al., 2004b; Bouafia et al., 2014). 2 
What ensues is improved conduction but at the cost of a rising intra-axonal sodium (Smith, 3 
2007). Excess sodium would normally be cleared by the energy dependent Na+/K+ ATPase. 4 
However, in the energy deficient axon, following mitochondrial injury, not all sodium can be 5 
cleared by the energy dependent transporter and consequently, there is a reversal of the 6 
Na+/Ca2+ exchanger to clear excess sodium (Andrews et al., 2005). The resultant rise in 7 
intra-cellular calcium leads to multiple injurious pathways that involve calpain and other 8 
degrading enzymes (Stys and Jiang, 2002). Sodium channel blockade has therefore been 9 
proposed as a potential neuroprotective strategy in MS and has shown promise in animal 10 
studies (Lo et al., 2002; Bechtold et al., 2006; Black and Waxman, 2008) but, to date, human 11 
trials have not shown any clear benefit (Kapoor et al., 2010). 12 
 13 
 14 
1.6 Mechanisms of adaptation and repair 15 
Axonal degeneration leads to permanent, non-remitting, clinical deficits, but following an 16 
acute inflammatory event, repair mechanisms can lead to clinical improvement in 17 
approximately up to two-thirds of cases (Ciccarelli et al., 2010a). Resolution of 18 
inflammation, remyelination, electrophysiological adaptation and restoration of 19 
mitochondrial function may lead to tissue repair and may underlie clinical recovery (Craner 20 
et al., 2004a; Black et al., 2007; Ciccarelli et al., 2014; Hartley et al., 2014; Olsen and 21 
Akirav, 2014). 22 
 23 
  24 
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1.6.1 Remyelination  1 
Within inflammatory MS lesions, alongside the inflammatory changes, demyelination and 2 
axonal degeneration, there is often evidence of remyelination. Remyelination of axons 3 
enables normal salutatory conduction to resume which is both more efficient and saves 4 
energy (Keough and Yong, 2013). For remyelination to occur, adult oligodendrocyte 5 
progenitor cells (OPCs) must migrate and differentiate into oligodendrocytes that re-envelope 6 
the demyelinated axon with new myelin (Franklin and Ffrench-Constant, 2008; Franklin et 7 
al., 2012).  Cells from the subependymal zone can also contribute remyelinating cells to areas 8 
of injury (Menn et al., 2006; Franklin et al., 2012). The efficiency of remyelination in MS 9 
declines with increasing age (Franklin et al., 2012) which may explain why disease 10 
progression in MS appears to be so age-dependent (Confavreux and Vukusic, 2006a). 11 
Evidence from animal models suggests that remyelination slows down with ageing as a result 12 
of impaired recruitment of oligodendrocyte progenitors and subsequent differentiation into 13 
remyelinating oligodendrocytes (Sim et al., 2002). 14 
 15 
 16 
1.6.2 Electrophysiological adaptation  17 
As discussed in Section 1.5.4, following demyelination of an axon, the cell increases 18 
expression of voltage-gated sodium channels, of the Nav1.6 subtype to demyelinated 19 
segments of the axolemma, in order to maintain conduction (Craner et al., 2004b). What 20 
ensues is improved conduction but at the cost of a rising intra-axonal sodium (Smith, 2007). 21 
The effects of rising intra-cellular sodium are discussed in Section 1.5.4 22 
 23 
 24 
 25 
 
 
42 
 
1.6.3 Restoration of mitochondrial function 1 
Data from post-mortem and MR spectroscopy studies suggests that in MS lesions, 2 
upregulation of mitochondria occurs to meet increased energy demands and is associated with 3 
clinical recovery. Mitochondrial density in axons and astrocytes is increased in active 4 
demyelinating lesions (Mahad et al., 2008), and protective anti-oxidant enzymes and 5 
mitochondrial heat shock protein 70 (mtHSP70) are up-regulated, in particular in astrocytes 6 
and axons (Witte et al., 2009; Nijland et al., 2014) suggesting axons respond to the increased 7 
energy requirements through mitochondrial upregulation.  8 
 9 
Although, there is no method for directly measuring mitochondrial function in vivo, tNAA 10 
concentrations estimated with 
1
H-MRS, reflects neuronal number and is believed to have a 11 
bioenergetic role in neuronal mitochondria, thereby representing a unique marker for 12 
neuronal structure and neuronal (mitochondrial) metabolism in the CNS (Ciccarelli et al., 13 
2014). MRS studies have demonstrated reversible decreases in tNAA during recovery from 14 
acute MS brain lesions (Davie et al., 1994; De Stefano et al., 1995b; Mader et al., 2000; 15 
Tiberio et al., 2006), and acute MS spinal lesions (Ciccarelli et al., 2010a; Ciccarelli et al., 16 
2010b). This reversal of tNAA decreases in the brain (De Stefano et al., 1998) and spinal 17 
cord (Ciccarelli et al., 2010a; Ciccarelli et al., 2010b) were also associated with clinical 18 
recovery, suggesting that reversal of mitochondria  dysfunction, reflected by tNAA changes 19 
is a clinically important biological process.  20 
 21 
 22 
 23 
 24 
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1.7 Clinical Course and Diagnosis of Multiple Sclerosis 1 
1.7.1 Presentation: Relapse Onset MS 2 
Approximately 85% of patients with MS will present with acute or sub-acute onset 3 
neurological symptoms characteristic of CNS demyelination. This initial presentation is 4 
termed a ‘clinically isolated syndrome’ or ‘CIS’ (Confavreux and Vukusic, 2006b). To be 5 
termed CIS, the episode should last for at least 24 h and occur in the absence of fever or 6 
infection, with no clinical features of encephalopathy (Miller et al., 2008). By definition, CIS 7 
is isolated in time and clinically, it is often isolated in space (Miller et al., 2012). The 8 
commonest presentations include long tract symptoms and signs (46%), optic neuritis (21%), 9 
and brainstem syndromes (10%), with 23% presenting with multifocal abnormalities 10 
(Confavreux et al., 2000).  Typically, first presentation of CIS in patients who go on to 11 
develop MS occurs in the third and fourth decades of life, with a median age of onset of 29 - 12 
31 years (Confavreux et al., 1980; Weinshenker et al., 1989). 13 
 14 
1.7.2 Conversion from CIS to MS 15 
Conversion to RRMS depends on further clinical relapses disseminated in time and space. 16 
Approximately 63% of patients will convert to clinically definite MS within 20 years 17 
(Fisniku et al., 2008). Baseline MRI data can be helpful in risk stratifying patients at initial 18 
presentation. Studies following up cohorts of patients with CIS have revealed that subsequent 19 
further clinical relapses leading to a diagnosis of clinically definite MS (Poser et al., 1983) 20 
occur in 70–80% of patients with abnormal scans and in 20–25% with normal imaging 21 
(Fisniku et al., 2008; Group, 2008).  22 
 23 
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1.7.3 Clinical Course: Relapse Onset MS 1 
In the initial phase of RRMS, the disease is characterised by periods of clinical relapse, 2 
causing neurological symptoms, followed by partial or complete recovery and remission. As 3 
the disease progresses, relapse rates are seen to decrease (Weinshenker, 1994) and disability 4 
increases. In the majority of untreated patients, neurological and functional deficits will 5 
accumulate with each relapse. Early natural history studies, prior to the advent of disease 6 
modifying therapies estimate that 50% of patients with RRMS will go on to develop gradual 7 
progression in disability, independent of relapses after 10 years and approximately 90% will 8 
develop progressive disease after 25 years (Weinshenker et al., 1989). This progressive phase 9 
of the disease is known as ‘secondary progressive MS’ or ‘SPMS’ (Lublin and Reingold, 10 
1996). During this phase, relapses may continue on a background of progressive clinical 11 
decline. 12 
A proportion of patients will have relapses followed by complete recovery for most of their 13 
disease course and are said to have ‘benign MS’. Several definitions for benign MS exist, 14 
based on (Expanded) Disability Status Scale score at 10 or 15 years; arguably the most 15 
common definition is an EDSS score ≤ 3 at 10 years from onset (Sayao et al., 2007). The 16 
precise prevalence is unknown and there have been widely varying estimates ranging from 17 
five to forty percent (Hawkins and McDonnell, 1999). Several studies have confirmed that 18 
following a benign disease course for 15 years only a small percentage will later develop 19 
more rapid disability progression (Runmarker and Andersen, 1993; Pittock et al., 2004). 20 
  21 
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1.7.4 Prognosis: Relapse Onset MS 1 
From the Ontario cohort data, the median time to reach a Disability Status Scale (DSS) score 2 
of 6 (assistance required for walking) from onset of relapsing onset MS was 14.97 +/- 0.31 3 
years (Weinshenker et al., 1989) and disability was distributed bimodally, with peaks at DSS 4 
1 (no disability) and DSS 6.  However rate of progression is highly variable from patient to 5 
patient. The ability to predict an individual patients clinical course at time of diagnosis, based 6 
on the initial presentation and early features, would be invaluable and several clinical and 7 
radiological characteristics have been demonstrated to be of prognostic significance (Table 8 
1.1) but no disease biomarker is yet available to accurately predict future prognosis on an 9 
individual basis. 10 
 11 
Factors associated with good prognosis Factors associated with bad prognosis 
Young age at onset Older age at onset 
Female Male 
Onset with optic neuritis or isolated sensory 
symptoms 
Multifocal onset 
Full clinical recovery from attacks Motor or cerebellar symptoms 
Long interval between 1
st
 and 2
nd
 attack High relapse rate in first 5 years 
No disability after 5 years Substantial disability after 5 years 
Normal MRI or lower lesion load Abnormal MRI with large lesion load 
No posterior fossa lesions Posterior fossa lesions 
Table 1.1: Table summarising prognostic indicators in MS (Miller et al., 2005) 
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1.7.5 Presentation: Progressive onset MS 1 
Approximately 10-15% of patients with multiple sclerosis present with progressive 2 
neurological dysfunction from onset without an initial period of clinical relapses with 3 
remissions (Thompson et al., 1997). This disease pattern is called primary progressive MS 4 
(PPMS). Patients presenting with initial symptoms of PPMS, are likely to be older than those 5 
with RRMS, with a mean age of onset of 38.5 years compared with 28.6 years, respectively, 6 
in the Ontario study (Cottrell et al., 1999). MS with onset after the age of 40 years is 7 
progressive in over 60 percent of patients (Weinshenker, 1994). The incidence in males and 8 
females is similar, with a male to female ratio of 1:1.3 from the Ontario cohort. In general, 9 
women will develop PPMS at a later age (40-45years ) than men (30-35years) (Ebers, 2004), 10 
such that in PPMS with onset over the age of 50 years, the male to female sex ratio 11 
approaches 1: 2 (Noseworthy et al., 1983). The most common presentation is of progressive 12 
myelopathy, usually with spastic paraparesis (39%) or sensory impairment (33%), followed 13 
by cerebellar symptoms (16%) and brainstem syndromes (5%), whilst presentation with optic 14 
neuritis is rare (Thompson et al., 1997; Cottrell et al., 1999).  15 
 16 
 17 
1.7.6 Clinical Course and Prognosis: Progressive onset MS  18 
PPMS is characterised by a progressive disease course from onset without an initial period of 19 
relapses (Stevenson et al., 1999). The rate at which disability is accrued varies but generally 20 
disability accumulates more rapidly in PPMS than RRMS from disease onset with a median 21 
time to DSS 6 of 8 years (compared to 15 years in RRMS) and median time to DSS 8 of 18 22 
years (Cottrell et al., 1999). Sex, age of onset and symptoms at presentation don’t seem to 23 
affect prognosis, but those with 3 or more systems involved progress more rapidly (Cottrell et 24 
al., 1999).  25 
 
 
47 
 
 1 
1.8 Measuring disability in MS 6 
1.8.1 The expanded disability status scale (EDSS) 7 
The expanded disability status scale (EDSS) is a widely used and validated clinical scale for 8 
grading disability in persons with MS (Table 1.5) (Kurtzke, 1983). The score increases in 0.5 9 
point increments from 0 to10 depending on disease severity. The EDSS score is determined 10 
by the degree of dysfunction in eight functional systems (FS) which are assessed during the 11 
neurological examination (pyramidal, cerebellar, brainstem, sensory, bowel and bladder, 12 
visual, cerebral or mental, and other), with 0 indicating a normal neurological examination 13 
and 10 indicating death from MS (Table1.2). 14 
 15 
Advantages of the EDSS include that it is widely known, understood and is easy to apply. 16 
However, the EDSS does have some major disadvantages; it is not a linear scale, so each 17 
increment is not equivalent to the next, with some increments representing such significant 18 
clinical deterioration that it makes the scale insensitive to small clinical improvements or 19 
deterioration. This can be seen in clinical trial results, where the EDSS tends to generate a 20 
bimodal distribution of scores (Sharrack and Hughes, 1996). Another criticism of the EDSS 21 
has been that it is heavily weighted towards ambulation, with increasing disability in other 22 
domains poorly reflected in the score, once walking is limited. At lower levels of the scale, 23 
some studies have reported poor inter-rater agreement which may limit its reliability 24 
(Noseworthy et al., 1990). 25 
 26 
1.8.2 Towards more sensitive clinical scales 27 
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There is a need to incorporate more sensitive and objective clinical measures in clinical 1 
studies in MS. With respect to spinal cord studies, clinical scales which are more sensitive to 2 
changes in clinical functions mediated by spinal pathways than conventional clinical tests, 3 
such as the EDSS, need to be incorporated. Measures such as postural stability, vibration 4 
perception thresholds (VPT) and dynamometry are more responsive to small clinical changes 5 
due to damage in the spinal cord than the EDSS, and have been shown to be more strongly 6 
associated with MRI abnormalities in the spinal cord (Zackowski et al., 2009; Oh et al., 7 
2013b). 8 
 9 
Vibration perception threshold 10 
Vibration perception threshold (VPT) is a form of quantitative sensory testing used for 11 
quantifying impairment in vibratory perception.  A number of instruments exist for making 12 
these measurements including the Bio-Thesiometer (Biothesiometer USA), Vibrameter (SPM 13 
Instrument AB, Strängnäs, Sweden), Vibratron (Physitemp Instruments, Inc., Clifton, New 14 
Jersey, USA) and Neurothesiometer (Algeo Limited, Liverpool, UK). They all generally 15 
work on a similar principle; the vibrator is applied to a bony prominence such as the hallux or 16 
medial malleolus and a fixed frequency stimulus is generated. The voltage is then manually 17 
graduated by the clinician until the patient/test subject is able to perceive the vibration. VPT 18 
is defined as the lowest voltage at which vibration can be detected at least 50% of the time 19 
(Garrow and Boulton, 2006).  20 
 21 
Measures of postural stability 22 
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Several tests of functional performance exist for the assessment of balance; they include the 1 
Berg Balance Scale (BBS), Timed Up and Go (TUG), Balance Screening Tool (BST), and 2 
Fullerton Advanced Balance (FAB) scale. Although these assessments correlate with clinical 3 
symptoms, the inter-rater reliability can introduce unwanted bias (Ozinga and Alberts, 2014). 4 
Objective assessments of postural stability, that are independent of subject or rater bias can 5 
be more reliable but require significant investment in equipment, space and time and are 6 
therefore not always readily available. Force plate posturography, in which test subjects stand 7 
on a platform equipped with pressure sensitive sensors, allows measurement of vertical 8 
forces, typically at three separate sites on the platform. Force plate analysis quantifies centre 9 
of pressure displacement, which represents a weighted average of all the pressures over the 10 
plate, which when analysed in the time domain provides a quantifiable measure of stability 11 
(Ozinga and Alberts, 2014).  12 
 13 
An alternative to the force plate method is the use of body worn accelerometers and 14 
gyroscopes to obtain kinematic values. Accelerometers are used to quantify truncal motion in 15 
two planes; the Roll or medial–lateral plane and the Pitch or anterior–posterior plane, during 16 
stance (Ozinga and Alberts, 2014). This accuracy of this method is comparable to force plate 17 
analysis (Moe-Nilssen, 1998) but it also has the advantage of reduced costs, smaller space 18 
requirement and is mobile which allows measurements in multiple locations. For these 19 
reasons, this is the method chosen for use in this thesis. 20 
 21 
 22 
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Score Description 
0.0 Normal neurological examination 
1.0 No disability, minimal signs in one FS 
1.5 No disability, minimal signs in more than one FS 
2.0 Minimal disability in one FS 
2.5 Mild disability in one FS or minimal disability in two FS 
3.0 
Moderate disability in one FS, or mild disability in three or four FS. No impairment to 
walking 
3.5 
Moderate disability in one FS and more than minimal disability in several others. No 
impairment to walking 
4.0 
Significant disability but self-sufficient and up and about some 12 hours a day. Able to walk 
without aid or rest for 500m 
4.5 
Significant disability but up and about much of the day, able to work a full day, may otherwise 
have some limitation of full activity or require minimal assistance. Able to walk without aid or 
rest for 300m 
5.0 
Disability severe enough to impair full daily activities and ability to work a full day without 
special provisions. Able to walk without aid or rest for 200m 
5.5 
Disability severe enough to preclude full daily activities. Able to walk without aid or rest for 
100m 
6.0 Requires a unilateral walking aid to walk about 100m with or without resting 
6.5 Requires bilateral walking aids to walk about 20m without resting 
7.0 
Unable to walk beyond approximately 5m even with aid. Essentially restricted to wheelchair; 
though wheels self in standard wheelchair and transfers alone. Up and about in wheelchair 
some 12 hours a day 
7.5 
Unable to take more than a few steps. Restricted to wheelchair and may need aid in 
transferring. Can wheel self but cannot carry on in standard wheelchair for a full day and may 
require a motorised wheelchair 
8.0 
Essentially restricted to bed or chair or pushed in wheelchair. May be out of bed itself much of 
the day. Retains many self-care functions. Generally has effective use of arms 
8.5 
Essentially restricted to bed much of day. Has some effective use of arms retains some self-
care functions 
9.0 Confined to bed. Can still communicate and eat 
9.5 Confined to bed and totally dependent. Unable to communicate effectively or eat/swallow 
10.0 Death due to MS 
Table 1.2: The expanded disability status scale 
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  1 
Chapter Two 
Principles of magnetic resonance imaging 
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2.1 Introduction 1 
Magnetic resonance imaging (MRI), is a non-invasive medical imaging technique with 2 
multiple possible configurations and applications, able to provide structural, microstructural 3 
and functional information relating to healthy and pathological animal tissues in vivo. To 4 
provide a complete review of the fundamentals of MRI, would require an introduction to 5 
quantum physics which is beyond the scope of this thesis. Instead, this chapter will focus on 6 
introducing basic principles relating to MRI, with a more in-depth review of techniques 7 
relevant to this thesis. 8 
 9 
2.2 Nuclear Magnetic Resonance 10 
Nuclear magnetic resonance (NMR) is a physical phenomenon which describes the 11 
absorption and emission of electromagnetic radiation by magnetic nuclei within a magnetic 12 
field. The first successful NMR experiments were performed by Felix Bloch and Edward 13 
Purcell in 1946. Independently of each other, they observed that the magnetic moments of 14 
nuclei in solid matter will, under a constant magnetic field, polarize and that the application 15 
of a radiofrequency field at right angles to the constant field causes a forced precession at the 16 
Larmor frequency and that they re-emitted this energy when the nuclei transferred to their 17 
original state  (Bloch, 1946; Purcell et al., 1946). 18 
 19 
2.3 Basic Principles 20 
Within all atoms, the nucleic particles, neutrons and protons, spin about their axis. Pairs of 21 
protons and neutrons spin in opposite directions at the same rate. Therefore in atoms with an 22 
even atomic mass, the nucleus has a net spin of zero. In nuclei with unpaired nucleons, the 23 
spin directions are not equal and opposite so the nucleus has a net spin, and is said to exhibit 24 
nuclear magnetism. These nuclei are sometimes referred to as MRI active nuclei.  25 
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As the protons within the nucleus spin, they induce a magnetic field (Faraday’s law of 1 
electromagnetic induction) and behave as magnetic dipoles. Magnetic fields have both size 2 
and direction which are denoted as a magnetic moment (µ). The magnetic moment of a 3 
nucleus is the vector sum of the individual magnetic moments of nuclear protons. Therefore, 4 
nuclei which have larger numbers of protons generally have lower magnetic moments 5 
because of differences in alignment of nucleic protons. The hydrogen nucleus (
1
H), is made 6 
up of a single proton, which is positively charged giving 
1
H a relatively large magnetic 7 
moment which makes 
1
H particularly suitable for NMR experiments. 
1
H is the most abundant 8 
MRI active nuclei in the human body (in the form of water, fats and proteins etc) which also 9 
makes it the most relevant for human in-vivo imaging studies.  10 
 11 
Under normal conditions, the magnetic moments of protons in tissues are randomly 12 
orientated. Once the protons are placed in a strong external magnetic field (B0), their 13 
respective magnetic moments either align parallel to B0, in a low energy state or anti-parallel 14 
to B0 in a high energy state. Proportionally more protons will align parallel to B0 as this is the 15 
lower energy state giving a net longitudinal magnetisation (M) in the direction of B0 (Figure 16 
2.1). 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
Figure 2.1: Alignment of spins 
after application of an external 
magnetic field. There is a net 
longitudinal magnetisation in the 
direction of B0. 
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2.4 Precession 1 
Protons aligned in the magnetic field gyrate around their own axis in a motion known as 2 
precession (Figure 2.2). The rate of precession, known as the precession frequency depends 3 
on the strength of the magnetic field and can be calculated using the Lamor equation:  4 
𝜔0 = γ𝐵0 
Where 𝜔0 is the precession frequency given in Hz, γ is the gyromagnetic ratio and B0 is the 5 
strength of the magnetic field in Tesla.  6 
 7 
 8 
 9 
 10 
 11 
 12 
The gyromagnetic ratio is the ratio between the magnetic dipole moment to the angular 13 
momentum of each MR active nucleus. It is unique for each MR active nucleus and expressed 14 
in units of MHz/T (Table 2.1). It therefore follows that the stronger the magnetic field 15 
strength, the higher the precession frequency. 16 
 17 
 18 
  19 
 20 
 21 
 22 
 23 
 24 
Nucleus Precession frequency  (MHzT
-1
) 
Proton (
1
H) 42.576 
Phosphorus (
31
P) 17.235 
Sodium (
23
Na) 11.262 
Carbon (
13
C) 10.705 
 
 
B
Figure 2.2: Precession of a spin under the influence of B0. 
The large arrow represents the external field and the small 
arrow represents the magnetic moment of the nucleus  
 
Table 2.1: Precession (Lamor) frequencies of common MR active 
nuclei 
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2.5 Excitation 1 
Applying energy in the form of a brief, radiofrequency (RF) pulse which oscillates at the 2 
Lamor frequency of 
1
H, results in a number of measurable effects; i) it causes a transfer of 3 
energy to the hydrogen spins causing them to resonate. Other MR active nuclei aligned with 4 
B0 do not resonate as their precessional frequencies are different to that of hydrogen. ii) By 5 
adding energy into the system, it brings the spins out of equilibrium so that some low energy 6 
spins, originally aligned parallel to B0 gain sufficient energy to re-align, anti-parallel to B0 7 
which has the effect of reducing the net longitudinal magnetisation. iii) The RF pulse also 8 
brings precessing spins, which were previously out of phase, into phase (phase coherence) 9 
which generates a net transverse magnetisation.  10 
 11 
Exciting spins by applying an RF pulse will therefore affect the net magnetisation vector. The 12 
amplitude and duration of the RF pulse will determine the flip angle, which is the angle at 13 
which the net magnetisation deviates from B0. The subsequent movement of the magnetic 14 
field towards the transverse plane induces a voltage in the MR receiver coil which is the basis 15 
of the MR signal. 16 
 17 
2.6 Relaxation 18 
Once the RF pulse is turned off, spins release energy to their surroundings (lattice) in a 19 
process known as, relaxation. Upon releasing their energy, spins fall back under the influence 20 
of B0 and return to the equilibrium position, in alignment with B0 (spin-lattice relaxation). At 21 
the same time, by turning off the RF pulse, phase coherence is lost and spins de-phase. The 22 
dephasing of spins depends on the neighbouring spins (spin-spin relaxation). The net effects 23 
of relaxation are therefore; i) recovery of longitudinal magnetisation and ii) decay in 24 
transverse magnetisation. As the transverse magnetisation decays, so does the voltage 25 
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induced in the MR receiver coil and this reducing signal is known as free induction decay 1 
(FID). 2 
 3 
 4 
2.6.1 T1 Recovery (Spin-Lattice relaxation)  5 
Recovery of longitudinal magnetisation depends on spins losing energy gained from the RF 6 
pulse. Once the RF pulse is turned off, this recovery occurs exponentially (Figure 2.3) but 7 
the rate of recovery depends on tissue properties and varies between tissue types. The time 8 
constant, T1 can be viewed as the time required for the z-component of net longitudinal 9 
magnetisation to reach (1 − 1/e) or 63% of its maximum value (Figure 2.3). 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
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Figure 2.3 Showing the exponential T1 recovery curve: T1 relaxation time refers to the time 
taken for 63% of the longitudinal magnetisation to recover within the tissue  
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2.6.2 T2 Decay (spin-spin relaxation) 1 
On turning off the RF pulse, the spins are able to exchange energy with neighbouring spins. 2 
As one spin comes into proximity with another, it will have a slightly lower or higher 3 
magnetic field to its neighbour leading to small differences in their precessional frequencies 4 
and causing them to dephase. As spins come out of phase, the transverse magnetisation 5 
decays exponentially. This interaction is termed spin-spin relaxation and can be denoted 6 
using the T2 time constant which represents the time taken for 63% of the transverse 7 
magnetisation to be lost (Figure 2.4). 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
2.6.3 T2* Decay  22 
When the RF pulse is removed, a phenomenon known as T2* decay also occurs, which is 23 
rapid dephasing of spins, which occurs faster than T2 decay. T2* decay is the result of T2 24 
decay itself and dephasing of spins due to magnetic field inhomogeneity.  As the precession 25 
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Figure 2.4:  Showing the exponential T2 relaxation curve: T2 relaxation time refers to the time 
taken for the transverse magnetisation to decay to 37% 
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frequency of spins is affected by the magnetic field strength, inhomogeneity within the field 1 
results in spins precessing at differing frequencies causing loss of phase coherence, and 2 
therefore transverse magnetisation producing an FID signal. This resultant rapid loss of signal 3 
occurs before most tissues have had sufficient time to reach their T1 and T2 relaxation times. 4 
Therefore to measure relaxation times accurately, which is needed to produce good image 5 
contrast, a second re-phasing pulse is required and this will be discussed further in the section 6 
on pulse sequences. 7 
  8 
 9 
2.7 Signal Location and Image Formation 10 
 11 
2.7.1 Spatial encoding 12 
The receiver coil detects voltage from spins when they are in phase, in the transverse plane. 13 
Before an image can be formed, signals need to be located spatially in three dimensions. 14 
Spatial encoding is used to encode the NMR signal with spatial information. The process uses 15 
linear magnetic gradients in three planes (x,y,z). A frequency encoding gradient plus two 16 
orthogonally aligned phase encoding gradients are required. The frequency encoding gradient 17 
by convention is applied along the long axis of the anatomy and the phase encoding gradients 18 
along the short axes.  19 
 20 
2.7.2 Slice selection gradient 21 
Slice selection requires the application of a slice selection gradient (Gslice, Gz), a linear 22 
gradient which is orientated orthogonally to the plane the images are acquired in. The field 23 
strength is non-uniform across the gradient, and is highest at the top end and lowest at the 24 
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lower end. This has the effect of increasing the precession frequency of spins at the top end of 1 
the gradients and reducing the precession frequency of spins at the lower end of the gradient. 2 
An RF pulse can then be applied at the precession frequency of selected sections of the 3 
gradient to selectively excite spins in a pre-selected slice. 4 
 5 
Slice thickness is determined by thickness in space of the spins excited by the RF pulse.  The 6 
angle at which the slice selection gradient is applied will determine the differences in 7 
precessional frequencies of spins between a given distance. Steeper gradients produce larger 8 
differences in precessional frequencies, whilst shallow gradients produce smaller differences.  9 
The RF pulse which is applied needs to contain a range of frequencies (the bandwidth) to 10 
excite spins within two defined points. Therefore by varying the slope of the gradient and 11 
bandwidth it is possible to alter the slice thickness. 12 
 13 
2.7.3 Frequency encoding gradient 14 
Once a slice has been selected, a frequency encoding gradient (Gread, Gx) along the long axis 15 
of the anatomy is applied. When the frequency encoding gradient is turned on, the magnetic 16 
field along the axis of the gradient and precessional frequencies are altered in a linear 17 
manner. The signal can then be located along the length of the gradient by its frequency. 18 
 19 
2.7.4 Phase encoding 20 
A phase encoding gradient (Gphase, Gy) is applied perpendicular to the frequency encoding 21 
gradient and is needed to locate signal along the short axes. The gradient produced by the 22 
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phase encoding gradient, causes spins to precess at different frequencies such that phase 1 
coherence is lost along the gradient. The phase of the spins now depends on their position 2 
along the short axis and can be used to locate them. For this to be done accurately, this step 3 
needs to be repeated several times with increasing amplitudes, so that spins with a particular 4 
position can be identified by their combinations of phases. 5 
 6 
2.7.5 K-Space 7 
The signals detected by the receiver coil are made up of amplitudes, frequency shifts and 8 
phase shifts. Once this data is digitised, it is written to a data acquisition matrix called k-9 
space, which acts as a temporary memory of the spatial frequency information. K-space 10 
comprises a horizontal (frequency) axis and a vertical (phase) axis. 11 
 12 
One line of k-space is filled with each repetition time (TR). TR is discussed later. The phase 13 
gradient is altered with each TR, allowing a new line to be filled. There are, therefore as 14 
many lines to the k-space matrix as there are phase encoding steps. The slope of the gradient 15 
selects which line will be filled; steep gradients, select peripheral lines, while shallow 16 
gradients select the central lines.  17 
 18 
2.7.6 Fourier Transformation 19 
The data acquisition matrix contains raw data which needs to be converted to an image before 20 
it can be viewed. Each voxel is assigned a colour on the greyscale which corresponds to 21 
amplitudes of frequencies coming from that spatial location. Frequency amplitudes are in the 22 
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time domain and therefore need to undergo a mathematical conversion, known as a Fourier 1 
transformation to convert them to the frequency domain. 2 
 3 
2.8 Pulse Sequences 4 
MRI pulse sequences are composed of a set of pre-defined RF pulses, rephasing pulses and 5 
gradient pulses. Pulse sequence diagrams are usually used to illustrate the application of 6 
pulses and gradients. A simplified pulse sequence diagram is represented in Figure 2.5, 7 
where the horizontal axis represents time and vertical axis represents amplitude and illustrates 8 
the timing parameters common to all pulse sequences.  9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
  17 
Figure 2.5: Simplified pulse sequence diagram: Illustrating the timing parameters used in 
more sophisticated sequences; the Echo time (TE) is the interval between the application of 
the RF pulse to peak signal in the receiver coil and repetition time (TR) is the interval 
between RF pulses.  
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2.8.1 Spin Echo 1 
The spin echo effect was first described by Hahn (Hahn, 1950) and further developed by Carr 2 
and Purcell (Carr and Purcell, 1954). The sequence (Figure 2.6) delivers an initial 90 degree 3 
RF pulse which causes loss of longitudinal magnetisation and maximises transverse 4 
magnetisation, whilst placing the spins into phase. Once the RF pulse is turned off, 5 
longitudinal magnetisation recovers (T1 recovery) and spin-spin interactions cause the spins 6 
to dephase (T2 decay). To limit the effects of field inhomogeneity on spins (T2* decay), an 7 
180
o
 rephasing pulse is applied at time, t, which flips the spins through 180o, inverting the 8 
magnetisation vector. This has the effect of inverting the spins such that slower spins lead the 9 
main moment and the faster spins trail behind. As the spins continue to precess at a similar 10 
rate as prior to the 180
o
 pulse, the faster spins catch up, refocusing the spins and bringing 11 
them momentarily back into phase. At this moment there is maximal transverse 12 
magnetisation which induces a voltage within the receiver coil at time 2t. This signal is the 13 
spin echo which contains both T1 and T2 information, having eliminated the effect of T2*. 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
Figure 2.6: Pulse sequence diagram for a spin echo sequence. An 180
o
 pulse is applied at time t 
and an echo is detected at time 2t. 
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2.8.2 Dual Echo 1 
The dual echo sequence relies on similar principle to the spin echo, but utilises two 180
o
 RF 2 
pulses after the initial 90
o
 pulse to produce two echoes, allowing two images to be acquired 3 
with each TR. Most commonly, one image is acquired with a short TE, to produce a proton 4 
density image, and a second longer TE, provides a T2 weighted image. At shorter TE’s, little 5 
T2 decay has occurred, but with longer TE, more complete T2 decay has occurred, 6 
highlighting differences in T2 times between tissues. 7 
 8 
  9 
2.8.3 Fast Spin Echo 10 
The fast spin echo sequence is a spin echo pulse sequence that allows much shorter scan 11 
times than the conventional spin echo sequence. After the original 90
o
 RF pulse, multiple 12 
180
o
 pulses are applied, generating multiple spin echoes and generating an echo train. The 13 
number of pulses applied during each TR is called the Echo Train Length (ETL). 14 
 15 
However, were as in conventional spin echo only one phase encoding step is applied per TR 16 
on each slice, the fast spin echo sequence reduces scan time by performing more than one 17 
phase encoding step, filling multiple lines of k-space per TR. At each 180
o
 rephasing pulse, 18 
an echo is produced and a different phase encoding step is performed.  19 
 20 
 21 
2.8.4 Gradient Echo 22 
The gradient echo sequence differs from the spin echo in that the initial RF pulse typically 23 
produces a flip angle lower than 90°, which results in a reduction to the magnetisation in the 24 
transverse plane. An FID signal is produced once the RF pulse is withdrawn and longitudinal 25 
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magnetisation recovers. Smaller flip angles result in more complete recovery of longitudinal 1 
magnetisation for a given T1 and TR, whilst the opposite is true of larger flip angles.  2 
 3 
Once the RF pulse is turned off, spins within the transverse plane also begin to dephase due 4 
to T2* effects and therefore need to be re-phased. This is achieved using gradients. First, a 5 
negative, dephasing gradient is applied which has the effect of speeding up fast spins and 6 
slowing down slow spins. Secondly, a positive gradient is applied (Figure 2.7) which speeds 7 
up slow spins and decelerates fast spins, rephasing the spins and producing a voltage in the 8 
receiver coil. 9 
 10 
The main benefit of using smaller flip angles is that longitudinal magnetisation is able to 11 
recover faster, allowing shorter echo times and therefore repetition times and permitting 12 
shorter scan times. However, applying gradients for re-phasing, is not as effective as using an 13 
180
o
 RF pulse and doesn’t rephase all the spins. There is also larger field inhomogeneity 14 
when gradients are used leading to greater T2* effects.  15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
Figure 2.7: Pulse sequence diagram for a gradient echo sequence. An RF pulse producing a 
flip angle <90
o
 is applied followed by a dephasing and rephasing gradients to produce the 
echo. 
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2.8.5 Echo Planar Imaging (EPI) 1 
Echo planar imaging (EPI) (Mansfield and Pykett, 1978) allows rapid image acquisition by 2 
using highly efficient filling of k space. EPI  can acquire the data necessary to fill all lines of 3 
k space within a single TR from a single echo train (single shot EPI) or multiple TR’s (multi-4 
shot EPI). However, the EPI sequences have the disadvantage of image artefacts and image 5 
distortions that occur as a result of T2* decay and fat/water chemical shifts and the long 6 
readout time necessary to generate the echo train.  7 
 8 
Single-shot EPI sequences are often used for diffusion weighted imaging (Section 2.10) but 9 
high resolution images are difficult to achieve. A number of reduced field of view (FOV) EPI 10 
methods have been proposed to improve in plane resolution on spinal cord axial acquisitions 11 
(Wheeler-Kingshott et al., 2002; Wilm et al., 2007; Saritas et al., 2008). They also have the 12 
advantage of reducing susceptibility artefacts caused by differences between the spinal cord 13 
and surrounding bony structures and soft tissues. 14 
 15 
2.9 Magnetic Resonance Spectroscopy 16 
Unlike conventional MRI used for structural imaging, which relies on excitation of protons 17 
and signal localisation, Magnetic Resonance Spectroscopy (MRS) sacrifices signal 18 
localisation in order to quantify the number of protons from molecules of interest within a 19 
tissue sample.  20 
 21 
MRS detects magnetic resonance signals produced by atomic nuclei located within molecules 22 
in tissue. Quantification of the MRS signal amplitude can provide a means of estimating the 23 
tissue concentration of the signal generating molecules (Alger, 2010). The molecules that are 24 
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most readily detected by MRS in vivo are involved in metabolic pathways therefore making 1 
MRS a useful method of studying metabolic changes in tissues. In vivo biomedical 2 
applications of MRS largely focus on detection and quantification of proton (
1
H), phosphorus 3 
(
31
P) and carbon (
13
C) isotopes. The remainder of this section will therefore focus on 
1
H MRS 4 
and will introduce the technique of MRS, cover basic physics principles, and technical 5 
considerations. 6 
 7 
2.9.1 Chemical Shift 8 
As discussed earlier in this chapter, precession frequencies of spins are determined by the 9 
applied magnetic field (B0) and magnetic field gradients. However, nuclei are also susceptible 10 
to changes within their local environment. Neighbouring electrons and nuclei are able to exert 11 
a small, yet significant effect on the local net magnetic field. Electrons moving around 12 
adjacent nuclei create a small local field able to shield 
1
H spins from B0. This will in turn 13 
affect the precession frequency of local spins as determined by the Larmor equation and 14 
shielding electrons are therefore said to produce a chemical shift in the resonant frequency of 15 
the spins. It is based on this principle that MRS experiments work, as they try to separate and 16 
quantify metabolites of interest based on variations of precessional frequencies of nuclei 17 
within compounds. The x-axis of MR spectra (Figure 2.8) are displayed in parts per million 18 
(ppm) which refers to the frequency of resonance of spins in metabolites of interest relative to 19 
the resonant frequency of a reference chemical. Historically, 0.1% of tetramethylsilane 20 
(TMS) is used as a reference for calibrating the chemical shifts of spins belonging to 21 
metabolites of interest. The resonant frequency of spins in TMS lies at 0 ppm. 22 
 23 
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 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
2.9.2 Spin-Spin Coupling (J-coupling) 12 
MR spectra can sometimes contain doublet, triplet of multiplet peaks which occur as a 13 
consequence of splitting of a peak representing signal from a common hydrogen 14 
environment. The phenomenon arises from spin-spin coupling, also known as J-coupling. 15 
This occurs because adjacent spins will align either parallel or anti-parallel to B0 and 16 
subsequently effect the local field of the spin of interest. A good example is that of glutamate, 17 
which contains two methylene (CH2) groups and a methine (
2
CH) group which produce a 18 
resonance. The signal from the methine group appears as a doublet of doublets at 3.75ppm 19 
and signal from the four protons belonging to the methylene groups appears as multiplets 20 
between 2.04 and 2.35 ppm. 21 
 22 
Each methylene group contains two protons, which can align parallel or anti-parallel to B0, 23 
giving four possible orientations of the spins (Figure 2.9). If spins are paired and aligned 24 
with B0, this has the effect of increasing the field experienced by neighbouring spins in the 25 
Glx 
Figure 2.8: A typical post-processed spectrum from a healthy spinal cord. Chemical shift in 
ppm is plotted along the x-axis, with signal intensity on the y-axis. 
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second methylene group resulting in a decrease in chemical shift. When spins are paired and 1 
opposed to B0, they will reduce the field experienced by neighbouring spins resulting in a 2 
slight increase in chemical shift. When the two spins are aligned in opposite directions they 3 
exert no net effect on the field of neighbouring spins. It is these relatively small effects of the 4 
spin-spin coupling that produces the multiplet peaks. The spacing between these peaks has a 5 
fixed frequency value (Hz), called the J-coupling constant. 6 
 7 
 8 
 9 
 10 
2.9.3 Localisation 11 
In order for useful data to be acquired, it is necessary for the MR signal to be localised to a 12 
pre-defined volume of interest (VOI), most often, a cuboid voxel. Localisation techniques are 13 
used to excite predefined voxels which are prescribed by the operator in single-voxel MRS. 14 
Single-voxel spectra are usually acquired using either the STimulated Echo Acquisition 15 
Mode (STEAM) (Frahm et al., 1989) or Point RESolved Spectroscopy (PRESS) (Bottomley, 16 
1987) methods. In unlocalised spectra, often large signals from surrounding tissues cause 17 
contamination such that metabolites of interest can no longer be seen. Furthermore B0 18 
magnetic field is inherently harder to optimise over larger areas, resulting in broader 19 
Figure 2.9: The four possible orientations of 
methylene protons (represented by the black arrows) 
once an external magnetic field is applied. Spins can 
be both parallel, both anti-parallel, 1
st
 parallel and 
2
nd
 anti-parallel, or 1
st
 anti-parallel and 2
nd
 parallel 
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resonances and a reduction spectral resolution. Upon spatial localisation, large signals eg. 1 
from lipids can be minimised which improves spectral quality. 2 
 3 
 4 
2.9.3.1 PRESS (Point RESolved Spectroscopy) 5 
The PRESS localisation sequence is a multi-echo sequence. After an initial 90
0
 RF pulse, two 6 
180
0
 pulses are applied. Each pulse is accompanied with a slice selective gradient in each of 7 
the three axes so that only spins within the voxel experience all three RF pulses. Historically, 8 
longer sequence preparation times meant that PRESS was better suited to acquisitions with 9 
longer echo times, which allowed good visualisation of metabolites with longer relaxation 10 
times. More recently short echo times have also been used allowing quantification of 11 
metabolites not seen on long TE (Marliani et al., 2007; Ciccarelli et al., 2010a; Marliani et 12 
al., 2010). PRESS has an advantage over STEAM of superior SNR by a factor of two when 13 
similar voxel volumes, TR,TE, and number of averages are used (Barker, 2010) . 14 
 15 
 16 
2.9.3.2 STEAM (STimulated Echo Acquisition Mode) 17 
The stimulated echo acquisition mode (STEAM) is also a multi-echo sequence and is similar 18 
to PRESS except a 90-90-90 pulse sequence is used instead of 90-180-180. The “stimulated 19 
echo” is collected whilst all the spin echoes are dephased by a large crusher gradient (Barker, 20 
2010). The STEAM sequence suffers from lower SNR because the final stimulated echo 21 
yields only a fraction of the possible signal from the voxel. However it is more suited to short 22 
TE acquisition and on an MR system with strong field gradients, it has been demonstrated 23 
that highly resolved 
1
H spectra with metabolite linewidths of between 8-10 Hz can be 24 
obtained with a TE of 1ms (Tkac et al., 1999). Additionally STEAM is thought to have 25 
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slightly superior water suppression factors to PRESS because water suppression pulses can be 1 
added during the mixing time period which does not occur in PRESS (Barker, 2010). 2 
 3 
2.9.4 Voxel Positioning  4 
In spinal cord spectroscopy, the spectroscopic voxel is prescribed by the user (Figure 2.10) 5 
using coronal and sagittal structural imaging as a reference. The voxel size is limited by the 6 
small diameter of the cord. The spinal cord is surrounded by CSF, therefore careful 7 
positioning of the voxel within the spinal cord, avoiding CSF is necessary to reduce partial 8 
volume effects in order to provide more accurate tissue characterisation. 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
2.9.5 Shimming 21 
Shimming refers to the processes used for achieving magnetic field homogeneity over the 22 
volume of interest. Inherently, there will be some minor inhomogeneity in the magnetic field, 23 
which is exacerbated by placing a patient into the magnet due to magnetic susceptibility 24 
variations. The spinal cord is surrounded by CSF and vertebral bodies which cause distortions 25 
of the magnetic field along the spinal cord (Cooke et al., 2004). Shimming is achieved by 26 
Figure 2.10: Positioning of spinal spectroscopy 
voxel. Sagittal T2 weighted spinal cord image 
showing spectroscopy voxel (red) and shifted 
water voxel (orange) positioning within the upper 
cervical cord, avoiding the surrounding CSF to 
minimise partial volume effects 
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making subtle alterations to the field gradients prior to data acquisition. Homogeneity can be 1 
assessed by calculating the linewidth of the water resonance in Hz or ppm. Good shimming 2 
usually produces a narrow linewidth, whilst poor shimming broadens the linewidth. 3 
 4 
Accurate shimming is important as a poor shim, will result in a rapid T2* decay, resulting in 5 
broad spectral lines. In contrast, with good shimming, the signal in the time domain is present 6 
for a longer time, producing spectra with higher peaks and smaller linewidths. A poor shim 7 
will therefore not produce adequate signal to noise ratio for metabolite quantification. 8 
 9 
 10 
2.9.6 Water Suppression 11 
The concentration of water in the brain and spinal cord is several orders higher than the 12 
concentration of other metabolites. The large signal produced by water during an MRS 13 
experiment may disturb signals of the remaining resonances with lower intensities. In order to 14 
reliably quantify metabolites with lower intensities, it is therefore necessary to supress the 15 
water signal during in vivo MRS experiments. Several water suppression methods exist and 16 
selecting the correct method depends on the localisation sequence used and this will be 17 
discussed further in Chapter 3. 18 
 19 
2.9.7 Additional Technical Considerations for Spinal Cord Spectroscopy 20 
Each cardiac cycle produces a pulsation within the CSF and oscillation of the cervical cord in 21 
the craniocaudal direction (Mikulis et al., 1994; Loth et al., 2001) which can affect water 22 
suppression and reduce spectral quality. Pulse triggering has been suggested as method to 23 
reduce the effects of normal physiological motion (Cooke et al., 2004), though this will 24 
usually necessitate an increase in acquisition times.  25 
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 1 
Subject motion is possibly the largest limitation to producing good quality spinal cord 2 
spectra. Once the voxel has been prescribed, the subject needs to remain in the same position 3 
during the acquisition which can be difficult. Yiannakas et al recently reported reduction in 4 
motion artefacts in a long spinal cord imaging protocol by using an MR compatible cervical 5 
collar (Yiannakas et al., 2012) which could also have applications in MRS experiments.  6 
 7 
2.9.8 Signal to Noise Ratio and Signal Averaging 8 
Detection of a signal during an MRS experiment depends on both the signal amplitude and 9 
the degree of noise (the signal to noise ratio). The noise in the spectrum arises from the 10 
random thermal motion of electrons in the radiofrequency coil used to detect the signal and 11 
the subject being scanned. Since noise is random, signal averaging also enables a reduction in 12 
noise, relative to the signal.  13 
 14 
2.9.9 Choice of Echo Time (TE) 15 
The choice of echo time is important in spectroscopy experiments and will effect which 16 
resonances will be detected depending on their T2 relaxation properties. At long echo times 17 
(TE 136 to 288ms), three major resonances are detectable within the CNS; i) N-Acetyl-18 
aspartate (NAA), ii) Choline containing compounds (tCho), and iii) Creatine (Cr). At shorter 19 
echo times (TE 20–30 ms), metabolites with both short and long T2 relaxation times are 20 
observed, therefore allowing a larger numbers of metabolites to be quantified, and typically, 21 
glutamate (Glu) and myo-inositol (Ins) are seen in addition to NAA, tCho and Cr at short TE. 22 
 23 
 24 
  25 
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2.9.10 The Principal Metabolites: tNAA, tCho, tCr, Glu, Gln, Ins 1 
The resonance found at 2.02 parts per million (ppm) is produced by the N-acetyl group of 2 
NAA and to a lesser extent, of N-acetyl aspartyl glutamate (NAAG) (Aggarwal and 3 
Nicholson, 2002). NAA is a non-essential amino acid and, in health, produces the largest 4 
metabolite signal in the CNS. NAA is produced by the mitochondria from L-aspartate and 5 
acetyl-CoA and is dependent on normal mitochondrial metabolism (Clarke et al., 1975; Patel 6 
and Clark, 1979; Truckenmiller et al., 1985). However, despite the abundance of NAA in the 7 
CNS, its precise biological function remains unknown. It has been proposed that it might 8 
provide a source of acetyl groups for lipid synthesis, participate in osmotic regulation or 9 
regulate protein synthesis (Clarke et al., 1975; Birken and Oldendorf, 1989; Lee et al., 1994). 10 
In MRS experiments, NAA is generally regarded as a “neuronal marker” as it is thought to be 11 
found exclusively in the CNS, and is predominantly localised to neurones, axons and 12 
dendrites (Simmons et al., 1991). More recently, quantification of NAA using MRS has also 13 
been suggested as a surrogate marker of mitochondrial function in a study of multiple 14 
sclerosis (Ciccarelli et al., 2010a). Decreases in NAA have therefore been interpreted to 15 
indicate underlying axonal loss or injury, impaired neuronal mitochondrial metabolism or 16 
both.  17 
 18 
In acute MS lesions a drop in NAA is typically seen, with several studies reporting partial 19 
recovery months later (Arnold et al., 1994; De Stefano et al., 1995a; Ciccarelli et al., 2010a). 20 
Given that axonal regrowth seems an implausible explanation for the recovery in NAA, the 21 
two most likely explanations include dilution of NAA due to tissue oedema at the time of 22 
relapse followed by resolution of oedema and subsequent rise in NAA concentration after 23 
recovery, or recovery of mitochondrial function following resolution of inflammation. A 24 
recent study examining changes in water content and NAA concentrations in new MS lesions 25 
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over six months found that water content changes were insufficient to account for all of the 1 
recovery of NAA after relapse  (Vavasour et al., 2011). This would suggest at least some of 2 
the recovery was due to recovery of mitochondrial function as demonstrated by Cicceralli et 3 
al (Ciccarelli et al., 2010a) or due to alterations in NAA relaxation time as a consequence of 4 
alterations to tissue chemistry or proliferation of oligodendrocyte progenitor cells (which 5 
contain NAA) to enhance remyelination (Davie et al., 1994). 6 
 7 
The methyl and methylene portions of creatine (Cr) and phosphocreatine (PCr) produce the 8 
second largest resonance in the CNS and form a composite peak at 3.03 ppm. Cr and PCr are 9 
important intermediaries of energy metabolism and are involved in the creatine kinase 10 
reaction to generate ATP. Creatine concentrations in the brain are thought to remain fairly 11 
constant with aging (Saunders et al., 1999) and are unaffected in many diseases. For this 12 
reason creatine is sometimes used as an internal reference standard to normalise the intensity 13 
of other resonances. However caution is needed when using creatine as an internal reference 14 
when studying patients with MS, as brain creatine concentrations were shown to be higher in 15 
RRMS (Inglese et al., 2003).  16 
 17 
In vitro, glial cells contain two to four times higher concentrations of creatine than neurons 18 
(Urenjak et al., 1993). Elevated Cr in MRS experiments has therefore often been interpreted 19 
to represent increased gliosis and possibly remyelination (Inglese et al., 2003). 20 
A resonance from the methyl protons of choline containing compounds is seen at 3.2 ppm. 21 
The resonance for total choline (tCho) is contributed to by glycerophosphorylcholine and 22 
phosphorylcholine and possibly betaine and taurine (Brenner et al., 1993). Choline containing 23 
compounds are normal constituents of myelin and membrane phospholipids and changes in 24 
the resonance intensity of choline has been suggested to reflect increases in the steady state 25 
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levels of membrane phospholipids released during myelin breakdown, for example in active 1 
demyelinating disease (Davie et al., 1993; Tartaglia et al., 2002; Gonzalez-Toledo et al., 2 
2006), acute stroke (Dani et al., 2012) and neoplasms (Horska and Barker, 2010). In MS, 3 
cerebral Cho is elevated in NAWM (Inglese et al., 2003) and Cho/Cr ratio rises have been 4 
reported in areas of NAWM which later develop into focal lesions (Tartaglia et al., 2002) and 5 
thought to return to normal with resolution of inflammation and onset of remyelination 6 
(Degaonkar et al., 2002). 7 
 8 
The resonance, split into a doublet of doublets centred at 3.52 ppm comes from the 
1
CH and 9 
3
CH protons of Ins, a cyclic sugar alcohol, which can be made in cells from glucose. It is a 10 
ubiquitous sugar and can be found in cells in most organ systems. In the CNS it has been 11 
proposed as a glial marker (Chard et al., 2002) and in multiple sclerosis, elevated Ins has 12 
been seen in early disease (Chard et al., 2002) and clinically isolated syndromes (Fernando et 13 
al., 2004), with the highest levels seen in acute lesions (Srinivasan et al., 2005) suggesting 14 
that, in the brain,  glial proliferation plays a role in early disease as well as during the active 15 
disease phase. 16 
 17 
Glutamate (Glu) is the most abundant amino acid in the CNS, and as discussed in Chapter 1, 18 
is the major excitatory neurotransmitter in the mammalian nervous system and is the 19 
precursor for the major inhibitory transmitter GABA. Glu has two methylene groups and a 20 
methine group that are strongly coupled which gives Glu a complex spectrum, with the 21 
proton from the methine group appearing as a doublet of doublets at 3.75 ppm and the signal 22 
from the other four protons appearing as multiplets between 2.04 ppm and 2.35 ppm. 23 
Glutamine (Gln) is structurally similar to Glu and also has one methine and two methylene 24 
groups and therefore has similar coupling interactions to Glu. The four protons from the 25 
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methylene groups produce a resonance that appears as multiplets between 2.12 and 2.46 ppm 1 
whilst the methine group produces a triplet at 3.76 ppm. Gln also has two further resonances 2 
at 6.82 and 7.73 ppm which are rarely used for quantification in vivo. 3 
 4 
Due to the similarities in their spectra, Glu and Gln are virtually indistinguishable at lower 5 
magnetic field strengths, and using conventional localisation sequences they have previously 6 
only been separated at field strengths of 7T or higher (Tkac et al., 2001). Being able to 7 
separate the metabolites allows much more accurate quantification of Glu which is thought to 8 
be involved in the pathogenesis of many diseases. Most MRS studies of neurological diseases 9 
to date have focused on quantifying glutamate + glutamine (Glx) complex (Hattori et al., 10 
2002). More recently, a modified PRESS localisation sequence was described that could 11 
separate Glu and Gln at 2.35 ppm at 3T (Hurd et al., 2004). Subsequently, these modified 12 
protocols have been used to demonstrate elevated Glu levels in acute MS brain lesions 13 
(Srinivasan et al., 2005).  14 
 15 
 16 
2.9.11 Spectral Fitting 17 
The spectrum (Figure 2.8) is a plot of signal intensity on the Y-axis, which approximates 18 
metabolite concentration against chemical shift on the x-axis, which is usually denoted in 19 
parts per million (ppm). In vivo NMR signal processing can now be performed using several 20 
line fitting algorithms that incorporate prior knowledge of metabolites used, such as LC 21 
model (Provencher, 1993), jMRUI (Naressi et al., 2001a; Naressi et al., 2001b) and others. 22 
Recent advances have made it easier to quantify metabolites from a predefined area within 23 
the spinal cord using simulated basis sets and LCmodel (Provencher, 2001).  24 
 25 
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The reliability of spectral fitting in LCModel is dependent on adequate SNR, which increases 1 
with voxel size and acquisition time. Optimising field homogeneity using shimming will also 2 
reduce width of peaks and therefore their resolution from adjacent signals. Within the output 3 
file produced by LCModel, some data is provided to help the user assess the reliability of the 4 
fit; i) FWHM (full width at half-maximum) provides an estimate of the line width of the 5 
spectrum, ii) signal to noise ratio (S/N), estimated standard deviations (Cramér-Rao lower 6 
bounds) expressed in percent of the estimated concentrations. 7 
 8 
 9 
2.10 Diffusion Imaging 10 
2.10.1 Introduction 11 
Molecular diffusion or Brownian motion refers to the random movement of molecules in 12 
solution. The process is thermally driven and can be described by the diffusion co-efficient 13 
(D), which is dependent on temperature, viscosity of the solution and the molecular weight of 14 
the diffusing particle. Diffusion which occurs when mixing two liquids or gases will occur 15 
along a concentration gradient from areas of relatively high concentration, to regions of lower 16 
concentration, whilst diffusion of water molecules in biological tissues, is thermally agitated 17 
and is described as self-diffusion (Wheeler-Kingshott et al., 2003). In either case, the random 18 
movement of molecules can be described statistically using the displacement distribution 19 
which describes the proportion of molecules travelling over a particular distance in a given 20 
direction. The displacement distribution for unrestricted water molecules is a Gaussian 21 
function whereas water diffusing within highly ordered and organised structures may be non-22 
Gaussian. 23 
 24 
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Studying water diffusion is a useful method for studying integrity of white matter tracts. 1 
During health, white matter tracts consist of closely packed, myelinated axons connecting 2 
two regions within the CNS, which are therefore orientated in a similar direction. Diffusion 3 
of water molecules within axons and in the extracellular space between fibres preferentially 4 
occurs parallel to fibres, rather than perpendicular to them due to microstructures and cell 5 
membranes acting as barriers (Wheeler-Kingshott et al., 2003). This ordered, directional 6 
diffusion is known as anisotropic diffusion. Anisotropy is reduced when there is disruption to 7 
the microstructural integrity of white matter tracts, which allows water molecules to diffuse 8 
more freely in directions other than the main orientation of the tract.  9 
 10 
2.10.2 Diffusion Weighted Imaging 11 
Diffusion weighted imaging (DWI) is performed by spatially labelling spins (from water 12 
molecules) at two time points, between which, the displacement of spins is measured. This 13 
time interval is known as the diffusion time (Δ) and the net displacement of water molecules 14 
is called the apparent diffusion coefficient (ADC). The pulsed gradient spin echo sequence 15 
(PGSE) developed by Stejskal and Tanner (Stejskal and Tanner, 1965) is one of the earliest 16 
methods for measuring diffusion and consists of a spin echo sequence, with two equal and 17 
opposite magnetic field gradients applied either side of the 180
o
 pulse. Addition of the 18 
gradients, as discussed earlier will mean that precession speed of spins will be dependent on 19 
their spatial location along the direction of the gradient. Spins will also acquire different 20 
phase shifts dependent on their location. The stronger the field gradient, the more marked the 21 
phase changes will be across the subject, causing an increased sensitivity to diffusion. The ‘b-22 
value’ which is proportional to the square of the gradient strength is used to describe the 23 
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diffusion weighting of a sequence. In the PGSE sequence the b-value has units of mm
2
/sec 1 
and is given by: 2 
𝑏 =  γ2G2δ2 (𝛥 −  𝛿/3)  3 
Where G is the gradient amplitude, δ is the duration the gradient is applied and Δ is the 4 
diffusion time. 5 
 6 
The 180
o
 RF pulse between the two gradient pulses reverses the phase changes caused by the 7 
first gradient. Hence, once the second gradient is applied, spins which stayed in their original 8 
position will experience no net change in phase, whilst those that diffuse will see their phase 9 
altered dependent on the distance over which diffusion has occurred over. Therefore due to 10 
the individual spins being out of phase, the signal produced is attenuated, provided that 11 
sufficient diffusion weighting is applied. The degree of signal attenuation will therefore 12 
depend on diffusion properties of the tissue as well as sequence parameters determining the 13 
size of the gradient and the diffusion time. The greater the degree of motion the more signal 14 
attenuation occurs ie. lower signal is detected. 15 
 16 
2.10.3 Diffusion Tensor Model 17 
The Diffusion tensor model is a better mathematical model of water diffusion within white 18 
matter tracts. It is superior to the simple ADC as it provides information about direction of 19 
diffusion, and whereas the ADC is dependent on the direction in which it is measured, the 20 
diffusion tensor can characterise multi directional diffusion. The tensor model is represented 21 
mathematically by a 3 x 3 matrix with nine elements as below, with the diagonal elements of 22 
the matrix (Dxx, Dyy and Dzz) corresponding to diffusivity in three orthogonal planes, and 23 
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off-diagonal elements showing information regarding the correlation between displacements 1 
in the three orthogonal planes. For example the Dyz correlates diffusion along the y and z 2 
axes. 3 
  Dxx Dxy Dxz 4 
D =      Dxy Dyy Dyz 5 
  Dxz Dyz Dzz 6 
 7 
2.10.4 The Eigensystem and Measuring Anisotropy 8 
The orientation of the three orthogonal axes, are denoted by the three eigenvectors; ε1, ε2, 9 
and ε3. The diffusivities along each of the three orthogonal axes are denoted by the 10 
eigenvalues; λ1, λ2, and λ3. The eigenvector associated with the largest eigenvalue is taken to 11 
be the principal eigenvector ε1, and as such the tensor is orientated parallel to this (Jones, 12 
2009). The corresponding diffusivity, λ1, is known as the longitudinal diffusivity or the axial 13 
diffusivity (AD). The radial diffusivity (RD) is calculated by calculating the mean of the 14 
diffusivities along the two minor axes (λ2, and λ3), whilst the mean diffusivity (MD) is 15 
calculated by averaging, the three eigenvalues.  The most commonly used anisotropy index is 16 
the fractional anisotropy (FA) which measures the fraction of diffusion within a given voxel 17 
can be ascribed to anisotropic diffusion (Basser and Pierpaoli, 1996). 18 
 19 
 20 
 21 
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2.10.5 Relevance of Anisotropy Indices and Application in Spinal Cord Studies 1 
FA, which is derived by the DTI, reflects the underlying tissue microstructure within spinal 2 
white matter tracts (Gulani et al., 2001), whilst animal studies have shown that demyelination 3 
often leads to an increase in RD, and axonal loss leads to a rise in AD (Song et al., 2002). It 4 
is difficult to extrapolate the findings from these animal studies to patient studies, so findings 5 
on axial and radial diffusivities in patient studies must be interpreted with caution. However, 6 
the spinal cord DTI-derived parameters have the potential to be used as biomarkers of both 7 
myelin and axonal integrity, and have been demonstrated to significantly change over time 8 
after an acute injury, such as an acute demyelinating lesion (Freund et al., 2010).  9 
 10 
MD is very sensitive to general change in tissue microstructure that allows water molecules 11 
to move less or more freely; for example, a reduction of the MD has been detected following 12 
acute neurological insults, but in chronic neurological disease, or where cellular necrosis 13 
leads to increased membrane permeability, a relative increase in the MD value can be seen 14 
(Gass et al., 2001). 15 
 16 
FA, RD, AD, and MD can all be measured within the spinal cord using regions-of-interest, 17 
which can be drawn on the basis of the user’s anatomical knowledge. Additionally, they can 18 
be measured within tracts, which are reconstructed using fibre tracking (FT) algorithms. 19 
Probabilistic tractography algorithms allow the user to obtain an estimate of white matter 20 
connectivity within the spinal cord tracts, which may change with pathology.   21 
 22 
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2.10.6 Practical Considerations 1 
Spinal cord DTI studies in patients have been performed with the assumption that DTI 2 
measures do not change across spinal cord levels. Wheeler-Kingshott et al. (Wheeler-3 
Kingshott et al., 2002) confirmed a uniform MD along the cervical spinal cord, but found a 4 
higher FA in the mid and lower section of the cervical cord compared with the upper cervical 5 
cord. Regional differences in DTI metrics of the cervical cord have also been reported by 6 
Mamata et al who found higher mean FA and ADC in the upper segments of the cervical 7 
cord (C2- C3) than in lower segments (C4- C7) in healthy volunteers (Mamata et al., 2005). 8 
These findings suggest that regional DTI measures should be compared between patients and 9 
controls whenever possible, since averaging values of DTI measures may dilute the effect of 10 
focal pathology. 11 
 12 
2.10.7 Technical Considerations 13 
Although the DTI model has proven a valuable tool for the study of numerous neurological 14 
diseases, it suffers from several technical limitations. Firstly, in brain regions where fibres 15 
might be crossing, fibres within a given voxel may not be orientated in the same direction. 16 
The effect of signal averaging across such voxels can result in inaccurate representation of 17 
true tract orientation and integrity (Tuch et al., 2002). Secondly, the DTI model assumes a 18 
Gaussian distribution for the displacement distribution function which is unlikely to reflect 19 
true diffusion characteristics within neuronal tissue, which is structurally complex and risks 20 
underestimating the slow diffusion component within the intra-axonal compartment (Assaf et 21 
al., 2002). 22 
 23 
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2.10.8 Q-Space Analysis 1 
In DTI analysis, the mathematical model assumes that the displacement distribution function 2 
has a Gaussian distribution. Q-space analysis differs in that it employs a Fourier 3 
transformation of the signal attenuation curve to determine the displacement distribution 4 
without assuming a Gaussian distribution. Q-space imaging (QSI) is a model free diffusion 5 
weighted imaging (DWI) technique (Callaghan et al., 1988) which employs Q-space analysis 6 
to provide displacement probability profiles of water molecules within each voxel, hence 7 
allowing the user to study water diffusion characteristics in multiple regions of interest.  8 
 9 
When the signal attenuation curve is Fourier transformed, the user obtains the probability 10 
density distribution of the diffusion from which we are able to derive summary statistics, 11 
most commonly the full width of half maximum (FWHM) and zero displacement probability 12 
(P0). Figure 2.11 outlines the steps in Q-space imaging analysis. The FWHM and P0 13 
functions describe the width and height of the displacement distribution function. A high P0 14 
and low FWHM are generally indicative of restricted diffusion, whilst a wider FWHM and 15 
lower P0 are suggestive of less restricted diffusion. 16 
 17 
 18 
Figure 2.11: Summary of steps in Q-space imaging analysis. The signal attenuation curve (a) 
from the raw Q-space imaging data is Fourier transformed to give the probability density 
function (b) from which summary statistics can be derived (c). 
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In early experimental work on biological samples, Q-space analysis was successfully applied 1 
to accurately measure the dimensions of yeast cells (Cory and Garroway, 1990), by using a 2 
wide range of b-values and diffusion times to assess the effects on the displacement 3 
distribution function. It had therefore been predicted that similar techniques might allow 4 
measurement of mean axonal diameters, however interpretation of Q-space metrics in CNS 5 
samples for this purpose has proven difficult due to the compartmentalisation of water in the 6 
CNS by membranes of varying permeability, such that it is impossible, currently, to isolate 7 
individual compartments for study (Assaf and Cohen, 2000). However, because q-space 8 
parameters are contributed to from areas with non-Gaussian diffusion, it is a more sensitive 9 
technique for detecting restricted diffusion (Assaf and Cohen, 2000; Assaf et al., 2002). 10 
Therefore, it is assumed, from Q-space theory, that compartments that show slower diffusion, 11 
such as intra-axonal fluid might contribute more to Q-space metrics than DTI metrics 12 
(Schneider and Wheeler-Kingshott, 2014). 13 
 14 
The spinal cord makes an ideal model for Q-space imaging because myelinated axons in the 15 
spinal cord are organised in tightly packed tracts, predominantly orientated in a single 16 
direction which allows diffusion weighting gradients to be oriented parallel and perpendicular 17 
to ascending and descending tracts, which would be more difficult to achieve in the brain to 18 
the complexity of its white matter architecture. 19 
 20 
2.10.9 Technical Considerations 21 
Q-space imaging requires much higher diffusion weighting (b-value) than DTI which can be 22 
difficult to achieve on clinical scanners. Large gradients and short gradient pulses needed to 23 
 
 
85 
 
perform true Q-space imaging (which requires δ<< Δ) cannot be achieved due to hardware 1 
limitations of currently available systems, but several studies have attempted to compensate 2 
for this by using smaller gradients and longer gradient pulses which has the effect of 3 
narrowing the PDF produced by Q-space analysis (Assaf et al., 2002; Nossin-Manor et al., 4 
2005) which leads to longer scan times and can underestimate the FWHM. It has therefore 5 
been proposed that these should be considered as “apparent values” (Assaf et al., 2005; 6 
Farrell et al., 2008). Additionally the use of heavy diffusion weighting has the effect of 7 
reducing SNR.  8 
  9 
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Chapter Three 
Spinal cord imaging in MS 
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3.1 The Spinal Cord 1 
The spinal cord extends from the cranial border of the atlas to the lower level of the L1 2 
lumbar vertebrae. Superiorly, it is continuous with the medulla and inferiorly the spinal cord 3 
terminates at the conus medullaris. Once adulthood is reached, the average length of the 4 
human spinal cord is 45cm in the male and 42 cm in the female. The corresponding average 5 
length of the spinal column is approximately 70cm (Williams and Warwick).  6 
 7 
 8 
3.1.1 Cross Sectional Anatomy of the Spinal Cord 9 
In cross-section (Figure 3.1), the spinal cord contains central grey matter, in a modified “H” 10 
shape, surrounded by white matter tracts. The grey matter is organised as two lateral 11 
columns, each having a dorsal horn, lying dorsolaterally and a ventral horn lying 12 
ventrolaterally.  The central canal runs through the centre of the grey commissure and the 13 
grey matter dorsal to the central canal is referred to as the dorsal grey commissure and the 14 
grey matter lying ventral to the canal is the ventral grey commissure.  15 
 16 
The white matter tracts surrounding the grey matter are separated into three columns in each 17 
half of the cord by the grey matter and the intramedullary portions of the spinal roots as 18 
follows: i) the posterior column lies between the posterolateral sulcus and the posterior 19 
median sulcus, ii) the anterior column between the anterior median fissure and the most 20 
lateral of the anterior nerve roots and iii) the lateral column between the dorsolateral and 21 
ventrolateral sulci.  22 
 23 
The columns compartmentalise the major ascending and descending tracts of the spinal cord. 24 
The ascending, afferent tracts carry sensory input to the brain whilst descending motor tracts 25 
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exert their effects on motor neurons. Afferent sensory input enters the spinal cord via the 1 
dorsal roots where fibres bifurcate within the zone of Lissauer. The axons of second order 2 
neurons decussate over several spinal segments through the ventral white commissure to the 3 
anterolateral cord, where they ascend as the lateral spinothalamic tract in the lateral column, 4 
conveying pain and temperature sensation. Fibres carrying information regarding light touch 5 
ascend in the ventral spinothalamic tract after decussating. Discriminative senses such as 6 
joint position sense, vibration sense and weight perception are conveyed in the posterior 7 
column. Other ascending tracts include the anterior and posterior spinocerebellar tracts and 8 
the cuneocerebellar and rostrocerebellar tracts which carry unconscious proprioceptive 9 
information from the lower part and upper part of the body respectively. 10 
 11 
 12 
  13 
Figure 3.1: Cross sectional anatomy of the spinal cord showing main spinal cord tracts (Image 
from www.acbrown.com). 
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There are five descending tracts within the spinal cord; i) the corticospinal tract, ii) the 1 
corticorubrospinal tract, iii) the lateral reticulospinal tract, iv) the medial reticulospinal tract 2 
and v) the vestibulospinal tract. The corticospinal tract arises from fibres from the primary 3 
motor cortex, lateral premotor cortex and the supplementary motor cortex of the contralateral 4 
hemisphere. The fibres descend through the corona radiata to the posterior limb of the 5 
internal capsule and pons, to reach the ventral medulla where they form two large pyramids. 6 
When the fibres reach the caudal medulla, approximately 90% will decussate to form the 7 
lateral corticospinal tract, which runs in the lateral column. The remaining 10% of fibres 8 
descend in the ipsilateral anterior column in the anterior corticospinal tract. The axons of the 9 
upper motor neuron connect via interneurons and rarely, direct synapses with the lower motor 10 
neurones within the ventral horn of the spinal cord.  11 
 12 
The corticorubrospinal tract is formed from cells in the primary motor cortex which project to 13 
the ipsilateral red nucleus, before decussating in the brainstem and descending through the 14 
brainstem tegmentum and the lateral column of the spinal cord. The lateral reticulospinal tract 15 
is an extrapyramidal motor tract which descends from the reticular formation within the 16 
medulla down the ipsilateral lateral column. The medial reticulospinal tract arises from 17 
pontine and medullary reticular formation and descends in the ipsilateral anterior column. 18 
The vestibulospinal tract fibres originate in the lateral vestibular nucleus and run anteriorly, 19 
in the lateral column where they produce corrective motions of the head, body and limbs in 20 
response to afferent input from the eighth cranial nerve. 21 
 22 
 23 
 24 
 25 
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3.1.2 Blood Supply and Venous Drainage of the Spinal Cord 1 
The anterior two thirds of the spinal cord receives its blood supply from the anterior spinal 2 
artery which arises from the radiculomedullary arteries and runs along the mid-line of the 3 
anterior surface of the spinal cord. The posterior spinal arteries are smaller, paired branches 4 
of the intracranial vertebral arteries and provide the blood supply to the posterior column and 5 
posterior horn.  Anastomotic radicular arteries, mainly branching from the aorta also feed the 6 
posterior and anterior arterial systems at various levels. 7 
 8 
Venous drainage of the spinal cord follows the arterial system ie. the posterior and anterior 9 
segments have dedicated drainage systems. The anterior spinal vein runs in the anterior 10 
sulcus, adjacent to the anterior spinal artery and the posterior spinal veins are run parallel to 11 
the posterior spinal arteries and drain the posterior column. 12 
 13 
 14 
3.1.3 Spinal Cord Physiology 15 
The spinal cord is bathed in the cerebrospinal fluid (CSF) produced by the choroid plexus in 16 
lateral, III, and IV ventricles in the brain. From the fourth ventricle, CSF flows down through 17 
the foramen of Lusha into the pontine cisterns and cisterna magna to reach the upper cervical 18 
cord. The CSF is contained within the subarachnoid space between the pia and arachnoid 19 
mater. CSF enters the spinal cord through the Virchow-Robbins spaces that surround blood 20 
vessels penetrating the cord. It then diffuses to the spinal canal where it is taken up, flows 21 
back, upwards towards the brain. Secretory mechanisms in the choroid plexus transport water 22 
soluble micronutrients, including vitamin C, folates, deoxyribonucleosides, vitamin B6 and 23 
certain trace elements into the CSF for eventual delivery to the brain and spinal cord 24 
(Johanson, 2008). 25 
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3.2 Application of spinal MRI to multiple sclerosis 1 
 2 
3.2.1 Spinal Cord MRI in MS 3 
Spinal cord imaging comes with specific technical challenges. As discussed in chapter two, 4 
the spinal cord is a small region of interest and motion artefact is caused by oscillation of the 5 
cervical cord in the craniocaudal direction after each cardiac systole (Mikulis et al., 1994). 6 
Truncation (Gibbs) artefacts which occur at the interface between high and low signal as a 7 
consequence of under-sampling of data in the phase direction can cause misrepresentation of 8 
the CSF/spinal cord interface within the image and appear as parallel lines adjacent to 9 
cerebrospinal fluid interfaces, within the spinal cord and canal, degrading image quality 10 
(Bronskill et al., 1988; Levy et al., 1988). It is, however possible to reduce most of the 11 
motion artefacts during spinal cord imaging, using cardiac triggering and saturation bands 12 
and the development of phased-array receiver coils and fast imaging techniques has led to 13 
more reliable imaging of the spinal cord and has improved the quality of quantitative data 14 
(Filippi and Rocca, 2011). Technical improvements in spinal cord imaging have led to an 15 
increase in clinical studies focusing on the spinal cord in MS which has led to the inclusion of 16 
spinal imaging in the MS diagnostic criteria since 2005 (Polman et al., 2005; Polman et al., 17 
2011). 18 
 19 
3.2.2 Imaging Spinal Cord Lesions 20 
Spinal cord imaging sequence selection in MS depends on the purpose of the scan. The dual 21 
fast spin-echo (FSE) sequence remains the reference standard for imaging the spinal cord in 22 
MS (Hittmair et al., 1996).  Both short and long echo times can be used to detect focal lesions 23 
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(Lycklama a Nijeholt et al., 1997), but diffuse lesions are usually only seen with short echo 1 
times (Hittmair et al., 1996). The short inversion time inversion-recovery (STIR) sequence 2 
shows good lesion to cord contrast and has particularly good sensitivity for detecting diffuse 3 
spinal cord pathology (Hittmair et al., 1996). However STIR is more susceptible to flow-4 
related artefacts and reduced image quality than conventional sequences and cannot therefore 5 
be used as substitute for other sequences, rather it should be used to supplement imaging 6 
protocols (Hittmair et al., 1996). The phase sensitive inversion recovery (PSIR) sequence is a 7 
T1-weighted inversion prepared 3D gradient echo (turbo field echo) sequence which provides 8 
good contrast between grey matter and white matter in the spinal cord and can improve 9 
detection of lesions when used in combination with FSE sequences (Poonawalla et al., 2008). 10 
Although PSIR has been used successfully in the brain to detect pure grey matter lesions 11 
(Sethi et al., 2012), a recent PSIR study failed to detect pure grey matter lesions in the spinal 12 
cord (Kearney et al., 2013a). The double inversion recovery (DIR) sequence has recently 13 
been demonstrated to improve detection of small spinal cord lesions in MS (Riederer et al., 14 
2014). Fluid attenuated inversion recovery (FLAIR) sequences which are commonly used for 15 
brain imaging in MS have low sensitivity for detecting spinal cord lesions, with only 6 – 73% 16 
of spinal lesions seen on T2 weighted FSE sequences detected using FLAIR sequences 17 
(Keiper et al., 1997; Stevenson et al., 1997).  18 
 19 
3.2.3 Characteristics of MRI detectable Spinal Cord Lesions in Multiple Sclerosis 20 
MRI-detectable spinal cord MS plaques (Figure 3.2) are seen in up to 82% of newly 21 
diagnosed MS patients (Bot et al., 2004) and up to 90% of patients with more established 22 
disease (Lycklama et al., 2003). Spinal cord involvement in the absence of brain lesions is 23 
rare but has been reported in up to 10% of cases (Honig and Sheremata, 1989; Bot et al., 24 
2002). Interestingly, spinal cord lesions occur independently from brain lesions (Bot et al., 25 
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2004) which suggests that the mechanisms behind the development of spinal cord lesions and 1 
brain lesions may be different.  2 
 3 
Lesions are most often located in the cervical cord and are characteristically peripherally 4 
located, most frequently affecting the posterior columns, are typically less than two vertebral 5 
segments in length, and occupy less than half the cross-sectional area of the cord (Kearney et 6 
al., 2013a; Riederer et al., 2014). Acute spinal cord lesions and those occupying greater than 7 
50% of the cross sectional area can be associated with vasogenic oedema, seen as cord 8 
swelling (Tartaglino et al., 1995; Thielen and Miller, 1996). In contrast, chronic lesions rarely 9 
alter cord morphology but can sometimes be associated with local volume loss (Tartaglino et 10 
al., 1995). 11 
 12 
Unlike the brain, T1 “black holes” at the site of tissue loss are rarely seen in the spinal cord, 13 
but T1 relaxation time is longer in the cervical cord of MS patients compared to healthy 14 
controls and signal intensity from the cervical cord on T1-weighted MRI correlates with cord 15 
atrophy and disability in PPMS patients (Nijeholt et al., 1998). In RRMS and SPMS patients 16 
T1 relaxation also correlates well with EDSS (Vaithianathar et al., 2003). 17 
 18 
Focal lesions within the spinal cord are thought to be similar in number between MS sub-19 
types but in progressive forms of MS, more confluent lesions are seen (Thorpe et al., 1996). 20 
The spinal cord is a particularly important region to study in PPMS as patients have 21 
prominent spinal cord symptoms and relatively fewer T2-weighted brain lesions than in other 22 
MS subtypes (Thompson et al., 1990). The majority of lesions affect the white matter 23 
columns and extend to involve grey matter (Tartaglino et al., 1995; Thielen and Miller, 1996) 24 
which is supported by findings from histological studies (Gilmore et al., 2006). 25 
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 1 
3.2.4 Gadolinium Enhancement 2 
Contrast methods using gadolinium-diethylenetriamine pentaacetic acid (DTPA) are able to 3 
define areas of active blood-brain barrier breakdown thought to represent areas of acute   4 
inflammation. A longer delay following gadolinium injection, giving time for adequate 5 
circulation and using larger doses of contrast agent can improve detection rates (Tartaglino et 6 
al., 1995). Spinal cord enhancement in one study was found to accompany enhancement 7 
within the brain suggestive of global disease activity (Silver et al., 2001) but more 8 
commonly, spinal cord lesions enhance (Figure 3.2) in conjunction with the onset of spinal 9 
cord relapse (Thorpe et al., 1996).  In a study of 25 MS patients presenting with acute spinal 10 
cord relapse, 13 patients (52%) had a total of 15 enhancing spinal cord lesions at relapse 11 
onset, of which 72% had resolved by 2 month follow up (Trop et al., 1998). 12 
 13 
Figure 3.2:  Sagittal PD-weighted image of the spinal cord showing expansile MS lesion at C2/3 
(left) and GAD enhanced T1-weighted sequence in the same patient showing enhancement of lesion 
at onset of a relapse (right) 
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3.2.5 The clinico-radiological paradox 1 
As the most visually evident imaging abnormality in MS, focal T2 lesions might be expected 2 
to be the predominant substrate of disability but spinal cord lesion load does not correlate 3 
well with disability (Kidd et al., 1993), even when disability is determined using a clinical 4 
measure such as the EDSS which is heavily weighted towards spinal cord functions such as 5 
ambulation. In fact, spinal cord T2 lesions are often clinically silent. Asymptomatic spinal 6 
cord lesions have been reported in about 50% of patients with CIS and early MS (O'Riordan 7 
et al., 1998; Lycklama a Nijeholt et al., 2000).  8 
 9 
This clinico-radiological paradox might partly be explained by difficulties in accurately 10 
quantifying neurological dysfunction (Barkhof, 2002), but it is more likely to be explained by 11 
the lack of sensitivity and specificity of conventional MRI techniques for detecting 12 
microscopic histopathological change. Axonal loss, which is the principle substrate for 13 
chronic, irreversible disability in MS (Tallantyre et al., 2010), occurs largely independently 14 
of T2 weighted lesions (Bergers et al., 2002). The development of new quantitative MRI 15 
techniques which are more sensitive to change in underlying tissue microstructure and 16 
metabolism within the spinal cord show much better correlation with disability (Ciccarelli et 17 
al., 2007; Benedetti et al., 2010; Freund et al., 2010) and can more accurately discriminate 18 
between patients with similar T2 lesion load on the basis of disability (Benedetti et al., 2010). 19 
 20 
3.2.6 Spinal Cord Atrophy in Multiple Sclerosis 21 
Axonal loss has been noted in both NAWM and lesions within the spinal cord (Lin et al., 22 
2004). Additionally, histopathology studies demonstrated that spinal cord atrophy in MS 23 
occurs predominantly in the white matter, with similar grey matter volumes between patients 24 
and controls (Gilmore et al., 2005). It is therefore thought that spinal cord atrophy in MS 25 
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predominantly reflects underlying axonal loss in the spinal cord as a consequence of 1 
destructive pathological changes within lesions and in the NAWM.  2 
 3 
Spinal cord atrophy can be an early feature of MS and progresses with time. In patients 4 
presenting with CIS suggestive of MS, evidence of cord atrophy can be seen even in the 5 
absence of spinal cord symptoms (Brex et al., 2001). However, spinal cord volume loss is 6 
most marked in progressive forms of MS and greatest in SPMS (Losseff et al., 1996). In 7 
clinical studies of MS of long disease duration, spinal cord atrophy remains significantly 8 
associated with disability (Bonati et al., 2011; Cohen et al., 2012; Kearney et al., 2014a). In 9 
the largest of these MS cohort studies, Kearney et al found that cervical cord atrophy in 10 
patients with ≥ 20 years disease duration was independently associated with EDSS and was 11 
more closely associated with disability than measures of brain atrophy (Kearney et al., 12 
2014a). Interestingly, the rate of spinal cord atrophy in PPMS does not correlate with rate of 13 
brain atrophy which further supports the presence of two independent disease processes 14 
causing injury to the brain and spinal cord (Ingle et al., 2003). 15 
 16 
Spinal cord atrophy measured using MRI is reproducible and has been demonstrated to 17 
correlate strongly with EDSS in cross-sectional studies; (r = -0.7, P < 0.001) (Losseff et al., 18 
1996); (r = -0.52, p = 0.005) (Stevenson et al., 1998), making it a potentially useful tool for 19 
measuring disease progression and as an endpoint in clinical trials of neuroprotective agents. 20 
To date two MS clinical trials have included cord cross sectional area as an exploratory 21 
endpoint (Kalkers et al., 2002; Lin et al., 2003), and as an outcome measure, shows promise 22 
for use in future clinical trials.  23 
 24 
 25 
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3.2.7 Spinal Cord Spectroscopy in MS 1 
Over the past decade, developments in imaging acquisition and post-processing, have made it 2 
possible to use MRS in clinical studies of spinal cord pathology, giving insights into 3 
pathogenesis. Reliable quantification of metabolites from the spinal cord using 1.5 tesla (T) 4 
scanners had been limited to a few metabolites (Gomez-Anson et al., 2000; Kendi et al., 5 
2004). High (3T) field strength scanners should in theory allow increased separation of 6 
metabolite peaks, and allow the study of metabolites of relevance to the pathogenesis of MS, 7 
such as Glu and Ins.  8 
 9 
3.2.8 Insights from Spinal Cord MRS Studies in MS 10 
As discussed in Chapter 2, N-acetylaspartate (NAA) is synthesised by neuronal mitochondria 11 
(Patel and Clark, 1979), and commonly used as a marker of axonal integrity in neuroimaging 12 
studies. All cross sectional, spinal cord MRS studies in MS published to date (Table 3.1) 13 
have reported a reduction in NAA compared to healthy controls, which is thought to reflect 14 
axonal loss (Kendi et al., 2004; Blamire et al., 2007; Ciccarelli et al., 2007; Marliani et al., 15 
2007; Henning et al., 2008). In one study, cervical cord NAA was shown to correlate with 16 
clinical disability (Ciccarelli et al., 2007), but most of the early exploratory studies have not 17 
reported clinical findings.  18 
More recently, a study modelling NAA concentration in the spinal cord with other markers of 19 
axonal integrity, such as cross sectional cord area, demonstrated that mathematically derived 20 
estimates of mitochondrial function can be made from spectroscopic data (Ciccarelli et al., 21 
2010a). Development of such imaging biomarkers of mitochondrial function has implications 22 
for studying mitochondrial dysfunction in MS. Ciccarelli et al. demonstrated that following 23 
cervical cord relapse, NAA levels are low, compared to controls but, as patients recover from 24 
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their relapse, the NAA concentration can recover. Using a model that uses cord area as a 1 
surrogate marker of axonal density, they demonstrated that changes in NAA were not entirely 2 
due to axonal loss but also reflected mitochondrial dysfunction and concluded that recovery 3 
in NAA following relapse was partially explained by recovering mitochondrial function. 4 
An increase in the spectral peak for choline-containing compounds (Cho), in patients with 5 
MS is considered to reflect breakdown of cell membranes. In a study of patients with chronic 6 
spinal cord lesions, cervical cord Cho/Cr ratio was elevated (Marliani et al., 2010) which may 7 
reflect ongoing remyelination within plaques, though this finding has not been reproduced in 8 
other cohort studies. Unlike the brain where elevated Cr has been reported, Cr has not been 9 
shown to change in the spinal cord (Table 3.1).  10 
Myo-Inositol (Ins) is the best available in-vivo glia-specific marker (Brand et al., 1993). 11 
Elevated m-Ins is seen in the brain of patients with CIS who convert to MS, suggesting that 12 
gliosis may be a process of pathogenic importance in MS (Fernando et al., 2004). In the 13 
cervical cord, m-Ins is marginally increased in patients with MS at the onset of a spinal cord 14 
relapse and was shown to correlate with disability in one study (Ciccarelli et al., 2007). 15 
Another study showed a reduced Ins concentration in the spinal cord of a single MS patient 16 
(Henning et al., 2008).  17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
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Study Cohort 
size 
Patient group Field 
strength 
TE 
(ms) 
Calibration 
method 
tNAA tCho tCr Ins Glx 
Kendi et al 2004 9 MS 
12HC 
Normal 
appearing 
cervical SC 
1.5 T 35 Quantification 
Not reported 
       
  ? 
Ciccarelli et al 
2007 
14 MS 
13 HC 
Acute cervical 
SC lesion 
1.5 T 30 External 
phantom 
       
  ? 
Blamire et al 
2007 
5RR, 
6SP, 
11HC 
Not specified 2 T 30 Unsuppressed 
water 
     
  ? 
Henning et al 
2008 
1MS 
11HC 
Active C6/7 
lesion 
3 T 42 Ratio Cr and 
Cho 
    
  ? 
   
  ? 
Marliani et al 
2010 
15MS 
10HC 
Chronic 
cervical 
lesions 
3 T 35 Ratio Cr    
  ? 
  
  ? 
 1 
 2 
 3 
 4 
 5 
3.2.9 Q-space Imaging Studies of Relevance to the Study of MS 6 
Early, pre-clinical Q-space imaging studies examining diffusion in ex-vivo rat spinal cord of 7 
varying stages of maturation and myelination demonstrated the technique was highly 8 
sensitive to the myelination status of rat spinal axons  (Assaf et al., 2000). In the mature 9 
spinal cord, very good white matter/grey matter contrast can be achieved owing to differences 10 
in diffusion characteristics. Mature, intact myelinated spinal cord, was associated with slower 11 
diffusion and exchange of water. Similarly, increased perpendicular diffusion was seen in the 12 
white matter of myelin deficient rats (Biton et al., 2006). This sensitivity to myelin status 13 
makes Q-space a potentially useful tool for the study of demyelinating diseases such as MS 14 
(Assaf et al., 2000). 15 
 16 
Table 3.1: Findings from cross sectional spinal cord spectroscopy studies in MS. Comparison 
between studies must be made with caution and allow for differences in calibration methods, 
patient group, field strength and acquisition parameters. 
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Although the large gradients and short gradient pulses required to perform true Q-space 1 
imaging are unachievable on clinical scanners, due to hardware limitations, Q-space metrics 2 
have still been successfully derived from experiments on clinical systems by increasing 3 
gradient pulses to compensate for the low gradients (Assaf et al., 2002; Assaf et al., 2005; 4 
Latt et al., 2007b).  However, patient studies on clinical scanners have so far been limited. 5 
The earliest attempt to apply Q-space analysis to brain DWI to study a cohort of MS patients 6 
found that the slow diffusion component of water is diminished in NAWM compared to 7 
white matter from healthy controls (seen as a decrease in the amplitude and broadening of the 8 
displacement distribution profile) and is lost in lesional white matter. Interestingly, some of 9 
the diffusion abnormalities detected in NAWM were not detected on conventional DTI and it 10 
has been suggested that Q-space might therefore be able to give a better indication of disease 11 
load than conventional DTI, though clinical relevance of these findings were not assessed 12 
(Assaf et al., 2002). The modifications to gradients and gradient pulse length necessary to 13 
enable the use of clinical scanners has the advantage of exaggerating the contribution of slow 14 
diffusing water to Q-space metrics (Assaf et al., 2002) which may also make it more sensitive 15 
to axonal damage than conventional DTI (Assaf et al., 2002; Assaf et al., 2005).  More 16 
recently, Assaf et al, using Q-space analysis have also reported decreased anisotropy of white 17 
matter tracts affected by MS lesions and in the peri-lesional white matter and demonstrated 18 
that Q-space indices were also correlated with NAA/Cr quantified using 
1
H MRS across 19 
multiple brain regions (Assaf et al., 2005).  20 
 21 
A single clinical study using Q-space analysis to study spinal cord pathology in four MS 22 
patients has demonstrated the feasibility of such a study in the spinal cord (Farrell et al., 23 
2008). The study demonstrated the sensitivity of Q-space metrics to white matter damage in 24 
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the spinal cord. In keeping with findings from animal studies (Assaf and Cohen, 2000; Assaf 1 
et al., 2000) and studies of MS brain (Assaf et al., 2005), a decrease in anisotropy was seen in 2 
areas of demyelination. Schneider et al from UCL have recently demonstrated good 3 
reproducibility of Q-space metrics for studying diffusion parallel and perpendicular to the 4 
major ascending and descending tracts in healthy spinal cord (Schneider et al., 2011) which 5 
now shows promise as a technique for the study of spinal cord pathology in MS.  6 
  7 
 
 
102 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
The role of spinal cord spectroscopy in studying MS pathophysiology has been discussed in 11 
Chapter 3. One major limitation of spinal spectroscopy studies in MS to date has been that 12 
glutamate, a potential mediator of axonal loss has not been quantified. In order for us to 13 
improve our understanding of the role of glutamate in axonal degeneration in MS, there is a 14 
need for new spinal spectroscopy protocols to be optimised for the detection of glutamate.  15 
Within this chapter I will describe experiments performed to optimise a novel spinal 16 
spectroscopy protocol for detection of glutamate-glutamine (Glx) from the spinal cord 17 
(Section 4.1), investigate whether or not age and gender are associated with spinal metabolite 18 
concentrations (Section 4.2), and finally I have indirectly investigated differences in 19 
metabolite concentrations between the spinal grey and white matter by examining the 20 
associations between metabolite concentrations and the spinal grey matter volume fraction, 21 
which reflects the ratio of grey matter : white matter (Section 4.3).  22 
Chapter Four 
Optimising a spinal cord spectroscopy protocol 
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4.1 Optimisation of a Spinal Cord Proton Spectroscopy Protocol for Quantification of 1 
Glutamate-Glutamine. 2 
 3 
4.1.1 Introduction 4 
Glutamate (Glu) is the major excitatory neurotransmitter in the central nervous system 5 
(CNS). As discussed in Chapter 1, excess extracellular Glu has been shown to cause damage 6 
to neurons and oligodendrocytes through activation of neurotoxic cascades and has been  7 
implicated  in neuronal injury in several neurodegenerative diseases (Rothstein et al., 1992; 8 
Hugon et al., 1996; Arundine and Tymianski, 2004), including MS (Srinivasan et al., 2005; 9 
Pampliega et al., 2008).  10 
 11 
In the brains of patients with early PPMS, glutamate-glutamine (Glx) is reduced in the 12 
cortical grey matter but not the normal appearing white matter (NAWM) (Sastre-Garriga et 13 
al., 2005). In SPMS, measurements from NAWM showed mean annualised declines of 14 
−4.2% (Glu), −7.3% (Gln), and −5.2% (Glx) which suggests that as disease progresses, Glu 15 
makes up proportionally more of the Glx signal (MacMillan et al., 2015). In contrast, in early 16 
RRMS there is no change in brain Glx concentrations (Tiberio et al., 2006). But in acute 17 
brain lesions, Glu is elevated (Srinivasan et al., 2005) and higher brain Glu concentrations are 18 
predictive of accelerated axonal loss (Baranzini et al., 2010). However, it is not known if 19 
Glu-mediated excitotoxicity is also an important mechanism of neurodegeneration in the 20 
spinal cord. To answer this question, it is necessary to develop a 
1
H-magnetic resonance 21 
spectroscopy (MRS) protocol that can accurately measure changes in Glu concentration in 22 
vivo using standard commercial scanners.  23 
 24 
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As discussed in Chapter 2, measurement of Glu using 
1
H-magnetic resonance spectroscopy 1 
(MRS) is challenging at lower field strengths. Resolving Glu from the glutamine (Gln) peak 2 
at 3T in the brain has been the focus of a number of studies (Hurd et al., 2004; Mayer and 3 
Spielman, 2005; Hancu, 2009). Strategies such as 2D J spectra and spectral editing 4 
techniques that exploit the scalar coupling of Glu have been shown from spectral simulations 5 
and in vivo investigations to be selective for Glu. However, these methods also result in the 6 
reduction of absolute signal amplitude, which compounds the inherently low signal-to-noise 7 
ratio (SNR) of Glu and could potentially result in the loss of other valuable metabolic 8 
information including, N-acetylaspartate (tNAA), total creatine (tCr), total choline (tCho) and 9 
myo-inositol (Ins).  10 
 11 
In 2009, Hancu simulated 11 different sequences for detection of non-edited Glu and showed 12 
that Carr-Purcell point resolved spectroscopy (CPRESS) with a minimal echo time (TE) and 13 
short-TE (TE = 35 ms) point resolved spectroscopy (PRESS) give the most reproducible 14 
measurements, while JPRESS, an MRS technique to detect J-coupled metabolites, showed 15 
better accuracy when tested in vivo (Hancu, 2009). To date, little progress has been made on 16 
protocols capable of quantifying Glu or Glx from the spinal cord. A single spinal cord study 17 
in patients with spinal cord tumours reported Glu concentrations using a simulated echo 18 
acquisition mode sequence (STEAM TE = 30 ms, 1.5 T), reporting a considerable rise in Glu 19 
and drop in tNAA at the tumour site (Kim et al., 2004).  20 
 21 
Glx detection in the cervical cord is more challenging because, a) the spinal cord is less 22 
homogeneous than the brain, due to the proximity of multiple tissue types and b) CSF and 23 
physiological movement artefacts are more pronounced. Additionally, the majority of spinal 24 
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cord spectroscopy studies have used smaller volume voxels (≤ 2 ml) (Cooke et al., 2004; 1 
Marliani et al., 2007), exacerbating the low SNR associated with Glx. This study therefore 2 
aims to optimise a spinal cord spectroscopy protocol for the quantification of Glx in the upper 3 
spinal cord by i) using a longer spectroscopy voxel to optimise SNR, ii) optimising RF coil 4 
and water suppression settings, iii) evaluating the sensitivity of two commercially available 5 
MRS sequences (PRESS and STEAM) for measurement of Glx in the healthy upper cervical 6 
spinal cord and iv) assessing the reproducibility of these sequences. 7 
 8 
4.1.2 Methods 9 
4.1.2.1 Study Participants 10 
Nine healthy participants with mean age 31(SD ± 7) years (six male, three female) were 11 
prospectively recruited. Of the nine subjects, four (mean age 28 ± 2 years, 3 males) took part 12 
in the RF coil comparison and water suppression optimisation studies. The other five subjects 13 
(mean age 32 ± 3 years, 3 males) were scanned in the PRESS vs STEAM experiment and 14 
three of the five were re-scanned in the reproducibility experiment. All subjects provided 15 
written, informed consent prior to taking part in the research which was approved by the local 16 
research ethics committee. 17 
 18 
4.1.2.2 Scanner  19 
All scans were performed using a 3T Achieva system (Philips Medical Systems, Best, 20 
Netherlands). To reduce motion artefacts during scanning, an MR compatible cervical collar 21 
(Bodymedics Range, TalarMade™ Ltd, Chesterfield, UK) was worn by all volunteers as this 22 
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has been shown to reduce motion artefacts (Yiannakas et al., 2012) and to lengthen the 1 
straight section of the cord allowing easier voxel placement. 2 
 3 
4.1.2.3 MRI and MRS Protocol  4 
All subjects underwent conventional structural imaging of the upper cervical cord with: (a) 5 
Spin-echo T2w sequence, with TR = 4000 ms; TE = 100ms; echo train length = 24 echoes; 6 
FOV= 160 x 250 mm
2
; voxel size = 0.6 x 0.6 x 3.0 mm
3
;number of excitations (NEX) = 2; 13 7 
contiguous coronal slices, and (b) Dual-echo PD/T2w sequence with TR = 4000 ms; TE = 8 
15/80ms; FOV= 256 x 160 mm
2
; voxel size = 1.0 x 1.0 x 3.0 mm
3
; NEX = 2; 12 contiguous 9 
sagittal slices. 10 
 11 
Using the structural images to guide voxel placement, single voxel MRS data was then 12 
acquired by positioning a 2.1 ml (5 x 7.8 x 55mm
3
) cuboid spectroscopy voxel within the 13 
cervical cord at the C1-C3 spinal level, centred at the C2/3 intervertebral disc (Figure 4.1). 14 
The tNAA voxel was chosen as the plan metabolite voxel instead of Glu because the position 15 
of the entire spectrum used for analysis could be covered using the lower tNAA chemical 16 
shift of 2.01 ppm and water. Both the tNAA voxel and the shifted water voxel were visible 17 
when planning the spectroscopy scan; they were positioned such that both voxels lay within 18 
tissue without CSF contamination.  19 
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 1 
 2 
 3 
 4 
 5 
 6 
 7 
Four outer volume suppression (OVS) slabs were orientated in the anterior-posterior (AP) 8 
and rostro-caudal (RC) directions. All scans were cardiac triggered following every third 9 
heartbeat with a 350-ms delay using a peripheral pulse unit (PPU) device that resulted in a 10 
TR of approximately 3000ms. Shimming was performed on the water signal from the voxel 11 
of interest itself.  12 
 13 
4.1.2.4 RF Coil Comparison 14 
Optimisation was performed on four healthy controls with a mean age of 28 (SD ±2) years (3 15 
males, 1 female). We compared two multi-element head coils; the manufacturer’s 32-channel 16 
head coil and the manufacturer’s 16-channel neurovascular coil using only the 4 neck 17 
Figure 4.1: Spectroscopy voxel placement. Coronal (left) and sagittal (right) views of the cervical cord, 
showing voxel placement. The tNAA voxel (red) is centred on the C2/3 intervertabral disc, avoiding 
surrounding CSF. The white voxel illustrates the chemical shift displacement of water. Keeping  both the 
red voxel (on resonance, 2ppm) and white voxel (4.7ppm)  within the cord, ensures that metabolites 
between 2 and 4.7ppm (tNAA, Cr, tCho, Glx, Ins) also arise from within the spinal cord and chemical shift 
displacement of each metabolite need not be an issue. 
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elements. Each volunteer was scanned once with each coil (sequence parameters are shown in 1 
Table 4.1). The SNR of the tNAA peak derived from LCModel was used to compare coils.  2 
 3 
Table 4.1: Sequence parameters for the optimisation scans and PRESS vs STEAM sequence 4 
comparison 5 
 6 
4.1.2.5 Water Suppression Optimisation 7 
The same four volunteers were re-scanned using each of the five available water suppression 8 
options on the Philips system; frequency selective excitation (Morris and Freeman, 1978) and 9 
inversion (Patt and Sykes, 1972), chemical shift selective suppression (CHESS) (Haase et al., 10 
1985), multiply optimised insensitive suppression train (MOIST) and variable pulse power 11 
and optimised relaxation delays (VAPOR) (Tkac et al., 1999) were tested once on each of the 12 
four volunteers. In addition, an unsuppressed reference scan was acquired. Using the 13 
suppressed and unsuppressed scans, the residual water peak as a percentage was calculated 14 
and used to determine the optimal water suppression module. Table 4.1 shows the parameters 15 
for each of the scans. 16 
  17 
Experiment Sequence Voxel size 
(mm) 
Water 
suppression 
TR/TE/TM 
(ms) 
NSA Coil OVS 
slabs 
Coil Comparison PRESS 5 x 7.8 x 50 MOIST 3RR/36 192 32Ch RC-AP 
PRESS 5 x 7.8 x 50 MOIST 3RR/36 192 NVn RC-AP 
Water 
Suppression 
PRESS 5 x 7.8 x 50 Inversion 3RR/36 8 NVn RC-AP 
PRESS 5 x 7.8 x 50 Excitation 3RR/36 8 NVn RC-AP 
PRESS 5 x 7.8 x 50 VAPOR 3RR/36 8 NVn Circular 
PRESS 5 x 7.8 x 50 CHESS 3RR/36 8 NVn RC-AP 
PRESS 5 x 7.8 x 50 MOIST 3RR/36 8 NVn RC-AP 
PRESS v STEAM PRESS 5 x 7.8 x 55 MOIST 3RR/36 376 NVn RC-AP 
STEAM 5 x 7.8 x 55 MOIST 3RR/11/17 376 NVn RC-AP 
NSA = number of signal averages, OVS = Outer volume suppression 
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4.1.2.6 PRESS Vs STEAM 1 
Five of the nine recruited volunteers (mean age 32 ±3 years, 3 males, and 2 females) were 2 
scanned with PRESS and STEAM sequences acquired on two separate occasions. Sequence 3 
parameters are shown in Table 4.1. Both sequences were acquired with 376 averages in a 4 
similar scan time of approximately 20 minutes. An additional unsuppressed water scan was 5 
also collected for quantification. The unsuppressed water was collected from the plan 6 
metabolite voxel; in this case, the position of the tNAA voxel. To assess intra-subject 7 
variability, the PRESS sequence was performed twice in 3 of the 5 volunteers. Using 8 
screenshots of the voxel placement taken during the first scan, the voxel was placed in the 9 
same region in the second scan. 10 
 11 
 12 
4.1.2.7 Post-Processing 13 
Metabolite concentrations were quantified using the user-independent LCModel (version 6.3) 14 
package (Provencher, 1993). PRESS data were analysed using a basis set created using the 15 
GAMMA simulation package (Smith et al., 1994). For the STEAM sequence, twenty-four 16 
metabolites were simulated in MATLAB R2012a (The MathWorks, Inc. Natick, MA). Data 17 
was analysed with water scaling to get concentrations in mmol/l. The SNR reported by 18 
LCModel for each spectrum was used an indicator of overall spectral quality and Cramér–19 
Rao lower bounds (CRLB) values provided by LCModel were used as a measure of 20 
reliability of the Glx and tNAA fit. Spectral quality and fit were assessed using the quality 21 
indicators provided by LCModel; spectra were excluded when SNR was < 3 and FWHM > 22 
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0.13 and metabolite concentrations were considered reliable only when CRLB ≤ 20% 1 
(Provencher, 2014).  2 
 3 
4.1.2.8 Statistical Analysis 4 
All statistical analyses were performed using IBM SPSS statistical package version 22.0 5 
(IBM Corporation, Armonk, NY, USA) and a P-value < 0.05 was considered significant. To 6 
assess differences in spectral quality obtained using the 2 RF coils, a paired t-test was used to 7 
assess differences in SNR obtained with each coil. A paired t-test was also used to assess 8 
differences in % residual water using each of the water suppression modules.  9 
To assess differences in the reliability of metabolite fitting between the PRESS and STEAM 10 
protocols, differences in CRLB’s between STEAM and PRESS sequences were assessed 11 
using a non-parametric bias-corrected bootstrap method (Carpenter and Bithell, 2000). Scan, 12 
re-scan reproducibility was assessed by calculating the mean percentage change following 13 
each subject’s second scan.  14 
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4.1.3 Results 1 
Example of post-processed spectra obtained using the neurovascular and 32-Channel coils are 2 
shown in Figure 4.2. The mean ratio of SNRNV: SNR32-Ch was 1.4 (SD ±0.7). Although the 3 
difference was not statistically significant (P = 0.13), given the small number of subjects, the 4 
results were sufficiently encouraging to select the neurovascular coil for use in the later 5 
optimisation experiments.  6 
 7 
Figure 4.2:  Representative spectra obtained from a single volunteer using (a) the 32 channel 8 
coil and (b) the neurovascular coil.  9 
 10 
Table 4.2 shows the residual water peak as a percentage for each water suppression module 11 
in all 4 subjects and Figure 4.3 illustrates differences in water signal in a single volunteer. 12 
The module with the lowest % residual water peak was MOIST. Residual water peaks 13 
obtained using the MOIST module were significantly smaller than those using the inversion 14 
and VAPOR modules (P <0.05) but there was no statistical difference between the MOIST, 15 
CHESS and excitation modules. 16 
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Subject CHESS Excitation Inversion MOIST VAPOR 
Subject 1 2.7 0.91 22.92 0.77 1.19 
Subject 2 0.35 0.80 7.23 0.23 1.50 
Subject 3 2.94 0.89 16.5 0.37 1.10 
Subject 4 0.90 0.91 6.98 0.96 1.70 
Mean (SD) 1.73 (1.29) 0.87 (0.05) 13.4 (7.73) 0.58 (0.34) 1.37 (0.28) 
 1 
Table 4.2: Percentage residual water for each of the four subjects scanned using each of the 5 2 
water suppression modules. The module with lowest mean residual water was MOIST. 3 
 4 
 5 
 6 
Figure 4.3: Water suppression optimisation.  Residual water heights as a percentage of reference 
water signal for each subject shown for CHESS, Excitation, Inversion, MOIST and VAPOR water 
suppression techniques.  
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Typical spectra obtained using the PRESS and STEAM protocols are shown in Figure 4.4 1 
and CRLB values for Glu, Glx and tNAA using PRESS and STEAM sequences for each of 2 
the five healthy controls are detailed in Table 4.3. Data acquired with the PRESS sequence 3 
showed a reliable fit (CRLB ≤ 20%) for Glx and tNAA, but not Glu in all 5 subjects. In 4 
contrast, Glx quantification with STEAM did not meet these reliability criteria. The 5 
improvement in metabolite quantification using the PRESS sequence was significant (P < 6 
0.01). SNR was also higher using PRESS; STEAM averaged 34.6% lower than PRESS (P < 7 
0.01).  8 
 9 
Results from the reproducibility study are shown in Table 4.4. Intra-subject variability in 10 
tNAA concentration was 8.1 % and for Glx concentration was 19.9%. These values however 11 
are potentially biased by the relatively poor spectral quality of the second spectrum obtained 12 
from subject 4. 13 
Figure 4.4: PRESS vs STEAM 
Typical spectra obtained from a single volunteer using 
the PRESS sequence (above) and the STEAM sequence 
(below).  
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 CRLB % (PRESS) CRLB % (STEAM) 
 Glu Glx tNAA SNR Glu Glx tNAA SNR 
Subject 1 30 20 7 5 48 48 13 3 
Subject 2 30 16 9 5 59 59 20 4 
Subject 3 25 16 7 7 NA 33 11 3 
Subject 4 25 15 11 3 59 59 15 3 
Subject 5 21 19 6 6 89 48 10 4 
Mean (SD)  26.2 (1.6) 17.2 (0.8) 8.0 (.08) 5.2 (0.6) 63.8 (7.1)* 49.4 (4.4)* 13.8 (1.6)* 3.4 (0.2)* 
CV (%) 6 5 10 11 11 9 12 6 
Table 4.3: Reliability of metabolite fit. Table shows CRLB values for water-scaled 1 
metabolite concentrations; PRESS vs STEAM. Significant differences between reliability of 2 
fit are marked. * P < 0.01  3 
 4 
Subject Scan tNAA mmol/l Glx mmol/l tCho mmol/l tCr mmol/l 
Subject 3 1 6.26 5.84 1.28 3.59 
2 5.47 5.53 1.01 3.88 
Subject 4 1 6.82 7.10 0.98 3.46 
2 2.85 3.17 0.98 3.06 
Subject 5 1 4.86 4.86 1.29 4.41 
2 4.41 5.31 1.34 4.61 
Mean % difference  8.1% 19.9% 5.4% 12.1% 
 5 
Table 4.4: Scan/re-scan reproducibility. Subjects 3-5 were scanned and re-scanned using the 6 
PRESS sequence. Metabolite quantification from both scans and mean percentage change in 7 
metabolite concentration is shown. Scan 2 from subject 4 is highlighted and was of poor 8 
quality (low SNR and linewidth broadening) and therefore the concentrations should be 9 
treated cautiously. 10 
 11 
  12 
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4.1.4 Discussion 1 
The results from these experiments demonstrate the feasibility of Glx detection in healthy 2 
human spinal cord, in vivo, using a short-TE PRESS localisation sequence on a clinical 3 
scanner, within acceptable (approximately 25 minutes) scan times. However, the fit of Glu 4 
itself did not satisfy the requirement of a ≤ 20% CRLB threshold. These findings represent a 5 
step forward in the development of routine Glx detection in spinal cord.  6 
 7 
 8 
Protocol Optimisation 9 
The C1-C3 segment of the spinal cord was chosen as the region of interest in this study as 10 
this has previously been demonstrated to be the optimum spinal level for spectroscopy 11 
experiments since this region of the cord lies in the most homogenous part of the B0 field 12 
(Henning et al., 2008). The C1-3 level is also the most commonly affected by spinal cord 13 
pathology in MS as discussed in Chapter 3. Cardiac triggering was used for all scans to 14 
further improve spectral quality (Cooke et al., 2004). The triggered iterative shimming 15 
process, which utilises the gradient coils in the X, Y and Z directions to optimise field 16 
homogeneity by iteratively running through different combinations of gradients in the X, Y 17 
and Z directions, achieved consistently good results using a voxel of this size (range of 14-22 18 
Hz for FWHM of water resonance).  19 
 20 
Although the difference in SNR achieved between the neurovascular coil and 32 channel coil 21 
did not reach statistical significance, the neurovascular coil did appear to perform better in 22 
vivo than the 32 channel coil. The close-fitting shape and selection of the 4 neck elements 23 
results in a reduction of noise accumulation from elements of the coil distant from the 24 
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selected voxel which would explain the relatively higher SNR seen with the neurovascular 1 
coil. When comparing the water suppression modules, MOIST gave consistently good water 2 
suppression. This could have reflected relative insensitivity to differences in T1 3 
characteristics of different tissues within the region of interest, when compared to other water 4 
suppression modules. Alternatively, or additionally, the timing of the triggering of the PRESS 5 
sequence (see Chapter 2), relative to the monitored cardiac waveform may be important. 6 
Triggering was set at the beginning of water suppression rather than the beginning of PRESS 7 
excitation. The length of the water suppression pulse may therefore be important. The 8 
MOIST module was ~ 190 ms, which is similar to the second best performing module; the 9 
excitation module (~150 ms). The poorer performing inversion, CHESS and VAPOR profiles 10 
had different delays, with the short inversion module being just 36 ms long, whilst CHESS 11 
and seven-pulse VAPOR were longer (~ 230 and 745 ms long respectively). This would 12 
suggest that the timing of the water suppression module in PRESS sequences is an important 13 
determinant of the effectiveness of water suppression and subsequent spectral quality. 14 
 15 
PRESS vs. STEAM Sequence Comparison 16 
In the comparison between the STEAM and PRESS sequences, the PRESS sequence was 17 
able to reliably fit Glx (CRLB ≤ 20%) in all five volunteers whilst the STEAM did not meet 18 
the reliability criteria in any of the volunteers. By using each subject as their own control and 19 
performing a paired-difference analysis; a statistically significant difference in reliability 20 
between PRESS and STEAM was shown (P < 0.01). Spectra obtained using the STEAM 21 
sequence also had lower SNR compared to PRESS (P < 0.01). As discussed in Chapter 2, the 22 
STEAM sequence suffers from lower SNR because the final stimulated echo yields only a 23 
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fraction of the possible signal from the voxel. This intrinsic loss in signal associated with the 1 
STEAM sequence could not be recovered through shorter TE and extra averaging.  2 
Voxel definition could also have been different in PRESS, since two of the 90º pulses used 3 
for STEAM localisation were replaced with 180º pulses for refocusing. The differing extent 4 
of chemical shift displacements gives rise to slightly different volumes per metabolite, 5 
contributing to the spectrum for each sequence. However, as much as possible, this was 6 
anticipated and remedied whilst positioning the spectroscopy voxels before the scan by 7 
ensuring that the chemically shifted tNAA and water voxels were both fully within the cord 8 
and similar shim values were attained.  9 
 10 
It is interesting, that in contrast to previously reported findings by Kim et al, the STEAM 11 
sequence here was unsuitable for detection of Glx (Kim et al., 2004). These investigators 12 
reported a rise in Glu in spinal meningiomas using a STEAM sequence (TE = 30ms) on a 1.5 13 
T GE system using a surface coil (Kim et al., 2004). It is certainly known from spectroscopy 14 
studies in the brain, that cerebral tumours can be associated with very significant rises in Glu 15 
and Glx (Rijpkema et al., 2003; McKnight, 2004). It is therefore possible that similar very 16 
large rises in Glu occur in spinal tumours which might make it easier to detect in that patient 17 
group. The differences in RF coil used between this study and that of Kim et al may also be 18 
an explanation for the apparent improved detection in that study. However, a potential 19 
limitation of the Kim et al study was that the authors did not report the Cramér–Rao lower 20 
bound (CRLB) of the metabolites quantified nor was any other indication given for reliability 21 
of fit.  22 
 23 
Overall, the findings in this study are in agreement with those of Hancu, who concluded that 24 
a short-TE PRESS sequence was optimal for Glu detection in the brain (Hancu, 2009). In this 25 
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study, a slightly shorter TE was used (TE = 30ms as opposed to 35ms used in the Hancu 1 
report), to minimise T2 relaxation but whether this improved spectral quality or not was not 2 
specifically examined. 3 
 4 
Scan, Re-scan Reproducibility 5 
The reproducibility study involving volunteers 3, 4 and 5 (Table 4.4) shows that there was a 6 
reliable fit and good reproducibility between initial and follow up scans for subjects 3 and 5. 7 
Subject 4, however, had a poorly resolved spectrum with significant line-broadening which 8 
may have been due to subject motion or higher susceptibility. 9 
 10 
Limitations  11 
A potential limitation of the study is that T1 and T2 corrections were not performed. 12 
Although T1 and T2 for water protons have been reported in the spinal grey and white matter, 13 
the corresponding T1 and T2’s for metabolites have not yet been determined (Smith et al., 14 
2008). A spinal MRSI study has previously used the values found in brain as an 15 
approximation (Edden et al., 2007) but for this to have been applied correctly in the current 16 
study, it would have been necessary to segment the grey and white matter within the 17 
spectroscopy voxel which would be technically challenging. 18 
 19 
The LCModel derived CRLB for Glu was 26%, which may be sufficiently reliable for 20 
detecting changes in Glu of about 40%, as are seen in some pathologies (Provencher, 2014), 21 
however reliability would need to improved significantly to detect more subtle changes. 22 
Although spectral quality could potentially be improved by prescribing shorter voxels (Cooke 23 
et al., 2004; Edden et al., 2007), this would be at the cost of SNR and may deleteriously 24 
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impact on Glx quantification. A further key limitation of the study was the small cohort size, 1 
and for the reproducibility studies, only 2 scans were acquired. 2 
Future Directions 3 
Although Glx detection using our protocol can be performed reliably within scan times that 4 
should be acceptable to patients with MS and other neurodegenerative diseases, future work 5 
should focus on developing faster and more specific sequences to detect Glu in the cervical 6 
cord and to increase reliability and reproducibility. Alternative Glu-specific sequences need 7 
to be assessed for use in the cervical cord. Hurd et al. reported low inter-subject variation (7-8 
9%) for Glu in the brain, with good visual separation of Glu using a TE-averaged PRESS 9 
sequence (Hurd et al., 2004). However, to apply a similar sequence to the spinal cord would 10 
not be straight forward; the voxel volume used by Hurd et al. was four times larger than the 11 
voxel used in this study and reducing the voxel size to fit within the spinal cord would result 12 
in a loss of signal.  13 
 14 
The B0 inhomogeneity of the spinal cord region together with the smaller voxels required for 15 
spinal cord MRS may also limit the use of more sophisticated sequences proposed for Glu 16 
and Gln detection (Hurd et al., 2004; Hancu, 2009; O'Gorman et al., 2011). By combining the 17 
optimised protocol presented here with a J-edited PRESS sequence, which combines PRESS 18 
localisation with two frequency-selective editing pulses to filter out J-coupled metabolites 19 
such as Glu, on the basis of their specific coherence evolution, it could be possible to directly 20 
measure Glu with no Gln overlap. This would allow more accurate evaluation of disruption to 21 
glutamatergic pathways in MS and other neurodegenerative diseases. 22 
 23 
 24 
 25 
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 1 
 2 
4.2 Effect of Age and Gender on Spinal Metabolite Concentrations  3 
 4 
4.2.1 Introduction 5 
Normative spinal cord metabolite concentrations have previously been reported in earlier 6 
studies (Cooke et al., 2004; Marliani et al., 2007), but it has not yet been reported whether 7 
there is any variation in spinal metabolite concentrations with ageing or gender as has been 8 
shown to occur in the brain (Batra et al., 2008; Haga et al., 2009; Zahr et al., 2013). It might 9 
be expected that healthy ageing is associated with changes in spinal cord metabolites as many 10 
of the changes in physical performance associated with normal ageing such as, decline in 11 
motor agility (Murray et al., 1969; Wolfson et al., 1990), impairment of sensory perception 12 
(Deneeling et al., 1994; Robbins et al., 1995) and increased bowel, bladder and erectile 13 
dysfunction (Marcio et al., 1993; Kaiser, 1999; Siroky, 2004; Aversa et al., 2010), could 14 
possibly be explained by age-related neurodegeneration of the spinal cord. There is evidence 15 
for age-related degeneration of the spinal cord from studies of humans and rodents which 16 
have shown that advancing age is associated with aberrations of spinal myelin, proliferation 17 
of astrocytes and reduced axonal number and diameter within spinal sensory and motor tracts 18 
(Burek et al., 1976; Cruz-Sanchez et al., 1998; Nonaka et al., 2008). In fact, diffusion MRI 19 
has shown that diffusion anisotropy in the upper cervical cord declines with normal ageing, 20 
with loss of fibre coherence beginning from the age of ten (Agosta et al., 2007). 21 
Understanding whether commonly quantified spinal metabolites also change with age is 22 
potentially important if serial MRS investigations are performed in patients with 23 
neurodegenerative diseases to monitor disease progression and/or response to treatments as 24 
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periodic imaging is potentially vulnerable to temporal changes in metabolite concentrations 1 
associated with healthy ageing, rather than disease progression. It is therefore important to 2 
understand how spinal metabolites change with age to inform interpretation of interval 3 
changes. 4 
In the brain, differences in metabolite concentrations have also been reported between men 5 
and women. More specifically, gender differences are seen in the concentrations of Glu and 6 
GABA (Sailasuta et al., 2008; O'Gorman et al., 2011). It has been proposed that hormonal 7 
differences between men and women may contribute to the observed variance. This is 8 
supported by observations of varying Glu/Cr ratios in women during the different stages of 9 
the menstrual cycle (Batra et al., 2008). It is therefore feasible that similar changes could be 10 
present in the spinal cord and knowledge of such differences would be important when 11 
planning spinal cord spectroscopy studies. This study therefore aims to apply the MRS 12 
protocol that was developed and optimised in Section 4.1 to (i) investigate whether, in healthy 13 
adults, age is associated with changes in concentrations of commonly quantified metabolites 14 
and (ii) explore the effect of gender on metabolite concentrations. 15 
 16 
4.2.2 Methods 17 
 18 
4.2.2.1 Study Participants 19 
Healthy volunteers were prospectively recruited from amongst university staff and 20 
respondents to adverts within the university and neurology outpatient clinic. A minimum of 21 
two subjects per decade of life (between the ages of 20 and 65) were recruited in order to 22 
achieve a good spread of ages. Participants found to have severe spondylitic changes (Thorpe 23 
et al., 1993), compression of the cord or an intrinsic cord lesion were excluded from the 24 
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study. All subjects provided written, informed consent prior to taking part in the research, 1 
which was approved by our local research ethics committee. 2 
4.2.2.2 MRI Protocol  3 
All scans were performed using a 3T Achieva system (Philips Medical Systems, Best, 4 
Netherlands), with the manufacturer’s 16-channel neurovascular coil. An MR compatible 5 
cervical collar was worn by all volunteers (Yiannakas et al., 2012).  All subjects initially 6 
underwent conventional structural imaging of the upper cervical cord with: (a) Spin-echo 7 
T2w sequence, with TR = 4000 ms; TE = 100ms; echo train length = 24 echoes; FOV= 160 x 8 
250 mm
2
; voxel size = 0.6 x 0.6 x 3.0 mm
3
;number of excitations (NEX) = 2; 13 contiguous 9 
coronal slices, and (b) Dual-echo PD/T2w sequence with TR = 4000 ms; TE = 15/80ms; 10 
FOV= 256 x 160 mm
2
; voxel size = 1.0 x 1.0 x 3.0 mm
3
; NEX = 2; 12 contiguous sagittal 11 
slices. 12 
 13 
Single voxel MRS data was then acquired using the MRS protocol optimised in section 4.1. 14 
Cuboid volumes of interest (VOI) with dimensions of approximately 5.4 x 7.76 x 55mm
3
 (2.3 15 
ml) were prescribed and centred on the C2/3 intervertebral disc (Figure 4.1) using the 16 
previously acquired coronal and sagittal T2w and PD/T2w reference scans.  The dimensions 17 
of the VOI were adjusted in the anterior-posterior (AP) dimension dependent on the size of 18 
each subjects spinal cord (mean VOI 2.02 ml; SD ±0.22ml). MRS data was acquired using a 19 
point resolved spectroscopy (PRESS) localisation sequence, with triggered iterative 20 
shimming, MOIST water suppression, 4 outer volume suppression (OVS) slabs in the AP and 21 
rostrocaudal directions and cardiac gating (TR = 3 R-R intervals ≈ 3000 ms) using a 22 
peripheral pulse unit (350ms delay from R-wave peak), TE = 30 ms, number of averages =  23 
376. 24 
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 1 
4.2.2.3 Post processing 2 
Structural scans were assessed by Dr Khaled Abdel-Aziz for the presence of intrinsic cord 3 
lesions, spondylitic changes or disc protrusions that may have affected the measurements, and 4 
subsequently the interpretation of the MRS data.  5 
Metabolite concentrations were quantified using the LCModel (version 6.3) package 6 
(Provencher, 1993) and a set of basis spectra simulated using GAMMA (Smith et al., 1994), 7 
comprising seventeen metabolites including NAA, N-acetylaspartyl glutamate (NAAG), 8 
gamma-Aminobutyric acid (GABA), Ins, tCr, Cho, Glu, Gln, lactate, alanine and aspartate. 9 
Quantification of metabolites was performed by using the unsuppressed water signal obtained 10 
from the same voxel (Gasparovic et al., 2006). NAA + NAAG (hereafter, tNAA), tCho, tCr, 11 
Ins and Glx concentrations formed the focus of our analysis. SNR and full width of half 12 
maximum (FWHM) of the tNAA peak provided by LCModel were used to assess spectral 13 
quality and Cramér–Rao Lower Bounds (CRLB) values < 20% for each metabolite were used 14 
to assess the reliability of the spectral fit. Poor quality spectra were excluded from the 15 
analysis. Criteria for exclusion were poor water suppression or FWHM > 0.13 with SNR <3. 16 
 17 
4.2.2.4 Statistical Analysis 18 
All statistical analyses were performed using IBM SPSS statistical package version 22.0 19 
(IBM Corporation, Armonk, NY, USA). Associations between metabolites and age were 20 
examined using linear regression of the metabolite as response variable on age, with gender, 21 
FWHM and voxel volume covariates; a quadratic term in age was also entered to examine 22 
evidence of non-linearity and removed if p > 0.1. Gender differences reported from these 23 
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models are adjusted for age, FWHM and voxel volume.  P values of < 0.05 were taken to be 1 
statistically significant.  2 
4.2.3 Results 3 
Twenty-five healthy participants were prospectively recruited and scanned.  Assessment of 4 
the structural spinal cord imaging excluded any significant spondylitic change/cord 5 
compression or intrinsic cord lesions which could have affected metabolite quantification in 6 
all subjects. Four participants were excluded from the analysis due to poor spectral quality. 7 
Therefore, twenty-two healthy participants (15 females) with a mean age of 40.5 years, 8 
standard deviation (SD) 13.1, range 23-65 were included in the final analysis. 9 
 10 
Figure 4.5 shows examples of spectra which were excluded from the analysis and Figure 4.6 11 
shows typical examples of post-processed spectra included in the final analysis. The FWHM 12 
and SNR estimated by LCModel (reported as mean ± SD) were 0.11 ± 0.02 ppm and 5.05 ± 13 
1.75 respectively. Cramér–Rao lower bounds (CRLBs) indicated a reliable fit for tNAA, 14 
tCho, and tCr. A reliable fit was achieved for  Glx in 19 out of 22 spectra and for Ins in 20 15 
out of 22 spectra (Provencher, 2014). Mean CRLBs for each metabolites were; tNAA (7%), 16 
tCr (11%), tCho (10%), Ins (11%) and Glx (17%). 17 
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 1 
 2 
 3 
 4 
 5 
There was no statistical evidence of a non-linear relationship between metabolite 6 
concentrations and age. Older age predicted lower spinal tNAA concentration (0.049 mmol/L 7 
lower per additional year of age, p = 0.010) and lower Glx concentration (0.054mmol/L 8 
lower per additional year of age, p = 0.002) (Table 4.5). Age was not significantly associated 9 
with the other metabolites (Figure 4.7).  10 
Figure 4.5: Examples of spectra excluded from the analysis due to poor spectral quality. (A) Spectrum 
with strong baseline distortion as a consequence of poor water suppression. (B) Spectrum with linewidth 
broadening likely due to subject motion during the scan. 
 
Figur  4.6: Representative sp tra btained using LCModel from (right) a 23 year old healthy female, 
(centre) a 32 year old healthy male and (left) a 54 year old healthy female.  
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 1 
Glx concentration was significantly higher in men, mean (SD) 7.27 (0.97) mmol/L, than 2 
females, mean (SD) 5.73 (1.05) mmol/L (p = 0.010, adjusting for age, FWHM and voxel 3 
volume), but no gender differences were seen with other metabolites (Table 4.6). 4 
 5 
 6 
 7 
. 8 
 9 
 10 
Metabolite concentrations (mmol/L) by gender 
  
All subjects (n=22) 
 
Male (n=7) 
 
Female (n=15) 
tNAA 5.69 (1.24) 6.05 (1.37) 5.52 (1.18) 
Glx 6.21 (1.24) 7.27 (0.97) 5.73 (1.05)* 
tCho 1.30 (0.35) 1.36 (0.53) 1.27 (0.25) 
Ins 4.70 (1.23) 5.36 (1.83) 4.42 (0.79) 
tCr 3.76 (1.11) 4.15 (1.47) 3.60 (0.90) 
 11 
Association between age and metabolite concentrations 
 Regression 
coefficient 
Standardised 
regression  
coefficient 
95% CI for 
regression 
coefficient 
p-value 
     
tNAA -0.049 -0.522 -0.085, -0.013 0.010 
Glx -0.054 -0.579 -0.085, -0.022 0.002 
tCho 0.001 0.026 -0.014, 0.015 0.920 
Ins -0.006 -0.067 -0.055, 0.043 0.791 
tCr -0.003 -0.040 -0.046, 0.039 0.867 
Figure 4.7: Scatter plots of relationship between age and (A) tNAA, (B) Glx, (C) tCho, (D) Ins and (E) 
tCr concentrations from the upper cervical cord. Regression lines are shown where there was a 
significant association (A, B). No significant association was seen between age and tCho, Ins or tCr (C - 
E). 
 
Table 4.6: Mean (SD) water scaled metabolite concentrations derived with LCModel for all 
subjects and by gender. *Significant difference in Glx concentration between male and females (p 
= 0.010, after adjusting for age, linewidth and voxel volume) 
Table 4.5: Associations between age (predictor) and metabolite concentrations (response variable). 
Unstandardised and standardised regression coefficients calculated from the multivariate model are 
reported with 95% confidence intervals and p-values. The regression models adjusted for gender, 
FWHM and voxel volume 
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4.2.4 Discussion 1 
 2 
MRS studies of the brain have previously shown that cerebral metabolite concentrations 3 
change are affected by age  (Moreno-Torres et al., 2005; Zahr et al., 2008; Haga et al., 2009) 4 
and  gender (Sailasuta et al., 2008; O'Gorman et al., 2011). The aim of this study was 5 
therefore to evaluate whether, or not age and gender had a similar effect on metabolite 6 
concentrations of the upper cervical cord. The results suggest that older age was strongly 7 
associated with lower concentrations of tNAA (R
2
 = 0.285) and Glx (R
2
 = 0.45) and that 8 
there were significantly lower Glx concentrations in female subjects compared to males.  9 
 10 
By employing the MRS protocol optimised in Section 4.1, it was possible to achieve 11 
sufficiently high SNR to reliably quantify spinal Glx. After elimination of the poor spectra, 12 
other spectral quality indicators, such as FWHM and CRLB, were comparable to those 13 
published by other groups (Marliani et al., 2007; Henning et al., 2008). 14 
 15 
Age-related Changes in Metabolite Concentrations 16 
As previously discussed in Chapter 2, axonal numbers closely correlate with NAA levels 17 
quantified by immunoassay (Bjartmar et al., 2000), and NAA levels decrease in the presence 18 
of inhibitors of complexes I, III, IV and V of the mitochondrial respiratory chain (Bates et al., 19 
1996). Therefore, in MRS studies, concentrations of tNAA are commonly interpreted as 20 
reflecting neuroaxonal integrity and/or mitochondrial energy production (Moffett et al., 21 
2007). In the current study, there was a linear decrease in tNAA concentration in the upper 22 
cervical cord with ageing, which may reflect age-related neuroaxonal loss and mitochondrial 23 
dysfunction. In fact, mitochondrial DNA (MtDNA) deletions and point mutations accumulate 24 
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during normal CNS ageing (Lin et al., 2002; Beal, 2005) and, together with increased 1 
production of reactive oxygen species (Gupta et al., 1991; Keller and Mattson, 1998; Butler 2 
and Bahr, 2006), are thought to be responsible for age-related neuroaxonal degeneration.  3 
 4 
Healthy brain ageing is associated with reductions in tNAA in grey matter regions (Charles et 5 
al., 1994; Lim and Spielman, 1997; Brooks et al., 2001; Moreno-Torres et al., 2005), but 6 
rarely seen in the white matter (Charles et al., 1994; Chang et al., 1996; Saunders et al., 7 
1999; Moreno-Torres et al., 2005). This  may, at least in part, be explained by a slower  rate 8 
of ageing-related white matter volume loss in the brain when compared with grey matter (Ge 9 
et al., 2002). Studies including older subjects have demonstrated that cerebral white matter 10 
volume loss does accelerate from the age of 70 (Raz et al., 2005), it is therefore possible that 11 
tNAA decline might be more apparent in that age group. In the study by Kadota et al, the 12 
tNAA/Cho ratio increased rapidly in the cerebral white matter during the first decade of life 13 
before peaking in the second or early third decade. This was followed by a steady decline 14 
starting in the latter half of the third decade of life, whilst in the grey matter, the tNAA/Cho 15 
ratio enters a steady decline from childhood (Kadota et al., 2001). Although this study did not 16 
assess whether the age-related decline in tNAA in the spinal cord is also tissue dependent, it 17 
is certainly possible that tNAA concentration declines faster in spinal grey matter than white 18 
matter and this warrants future research. 19 
 20 
Glutamate (Glu), plays a major role in the coordination of basic propulsive movement 21 
synergy for locomotion at the spinal level (Grillner et al., 2008) and processing and 22 
transmitting sensory information in the spinal cord (Todd, 2010). As discussed in section 4.1, 23 
Glu, as opposed to Glx, is difficult to measure in the spinal cord. However, between 75 - 86% 24 
of the Glx signal is thought to come from Glu (Baker et al., 2008), with the rest coming from 25 
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coupled Gln. The results demonstrate an age-related decline in spinal Glx which could be 1 
explained by ageing-related neuroaxonal degeneration. Glu in the extracellular compartment 2 
and glial cells is present in very low concentration and therefore contributes very little to the 3 
spectroscopy signal (Rothstein et al., 1992; Kaiser et al., 2005). The majority of Glu is 4 
present in neurones at synaptic terminals and it would therefore be expected that Glu (and 5 
therefore Glx) will decrease where there is neuronal loss. In fact within our cohort of healthy 6 
adults, there was a significant correlation between Glx and tNAA concentrations (r = 0.534, p 7 
= 0.027), suggesting that Glx, in part, reflects neuronal density.  8 
 9 
The observed association between age and Glx in the spinal cord is in keeping with previous 10 
MRS investigations in the brain which have consistently shown declining concentrations of 11 
Glu with older age in multiple brain regions including the frontal white matter, parietal grey 12 
matter, motor cortex, anterior cingulate cortex, hippocampus, basal ganglia and striatum 13 
(Schubert et al., 2004; Kaiser et al., 2005; Choi et al., 2006; Zahr et al., 2008; Chang et al., 14 
2009).   15 
 16 
In the present study, no evidence of association was seen between tCho, tCr and Ins 17 
concentrations in the spinal cord and age. Although changes have been reported in these 18 
metabolites in the brain with ageing and have been interpreted as reflecting changes in glial 19 
proliferation, those changes are not thought to occur uniformly in the brain, with regional 20 
variation commonly reported. tCho concentrations have been reported to be higher in the 21 
corpus callosum, parietal lobe, frontal grey matter and pons in older people (Chang et al., 22 
1996; Soher et al., 1996; Moreno-Torres et al., 2005; Haga et al., 2009), but remain stable in 23 
the frontal, occipital and temporal lobes and the basal ganglia in other studies (Christiansen et 24 
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al., 1993; Brooks et al., 2001) and decline in the midbrain (Moreno-Torres et al., 2005). 1 
Similarly, tCr was seen to increase in the parietal, frontal grey and white matter (Chang et al., 2 
1996; Schuff et al., 2001; Haga et al., 2009), but other studies found no change in tCr with 3 
ageing (Christiansen et al., 1993; Brooks et al., 2001). Fewer brain studies have assessed Ins 4 
levels with ageing; a single study found an increase in the frontal grey matter (Chang et al., 5 
1996), whilst another study reported that Ins/Cr ratios decreased in the frontal grey matter, 6 
basal ganglia, and occipital grey matter (Fan et al., 2003). A recent meta-analysis of 18 7 
spectroscopy studies assessing regional metabolite changes in healthy brain ageing found that 8 
there were significant increases in parietal tCho and tCr; although fewer studies assessing 9 
changes in Ins had been carried out, levels were not seen to change significantly in the brain 10 
with age (Haga et al., 2009). Methodological differences in studies addressing the change of 11 
these metabolites in the brain with ageing means conclusions about changes in tCho, tCr and 12 
Ins with age cannot yet reliably be made 13 
 14 
Effect of Gender on Metabolite Concentrations 15 
An interesting observation in the current study was that of higher concentrations of Glx in 16 
men than women. MRS studies in the brain measuring Glx and Glu concentrations have been 17 
inconclusive on whether gender differences exist. Higher levels have been reported in men 18 
compared to women in the parietal grey matter and dorsolateral prefrontal cortex (Sailasuta et 19 
al., 2008; O'Gorman et al., 2011), whilst other studies have reported higher concentrations in 20 
women in the cerebellum and striatum (Zahr et al., 2013). Kaiser et al. however found no 21 
differences in Glu and Gln concentrations between men and women in the corona radiata and 22 
mesial motor cortex (Kaiser et al., 2005). Hormonal factors may be responsible for some of 23 
the observed gender differences in our study. An examination of the medial prefrontal cortex 24 
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during the follicular phase and the luteal phase of the menstrual cycle found that Glu/Cr 1 
ratios were significantly lower during the luteal phase compared with the follicular phase 2 
(Batra et al., 2008). Additionally, blood Glu levels vary during the menstrual cycle such that 3 
blood Glu levels are inversely correlated to levels of plasma oestrogen and progesterone 4 
(Zlotnik et al., 2011), but interestingly in the work by Zlontik et al, Glu levels were 5 
significantly higher in men than women at any stage of the menstrual cycle. Unfortunately 6 
the current study was not designed or adequately powered to assess whether or not the stage 7 
of menstruation in female subjects effects Glx quantification. It will need to be determined 8 
whether higher concentrations of spinal Glx are detectable during the follicular phase as is 9 
seen in some brain regions. 10 
 11 
Limitations  12 
A limitation of the study is that the sample age range only starts at 23 years. It has therefore 13 
not been possible to ascertain whether or not age-related changes in the spinal cord occur 14 
before the early twenties. Within the sample age range of 23 - 65, we did not find a quadratic 15 
association between age and the concentrations of tNAA and Glx, which suggests the decline 16 
in these metabolites with age, within the studied age range, is linear. However it is also 17 
possible that subjects older than 65 could show accelerated decline of tNAA which would not 18 
have been identified by restricting the age limit for the study to 65. 19 
 20 
Future Directions 21 
Future longitudinal studies will be required to determine the rate of change in metabolites 22 
over time in healthy ageing and whether metabolite concentrations decline at differing rates 23 
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in spinal grey matter and white matter. Furthermore, studies of brain ageing have previously 1 
shown that age-related metabolite changes are not uniform and can vary between brain 2 
regions, and it is possible that metabolite changes during ageing occur at dissimilar rates at 3 
different spinal levels which will also require further investigation. Finally, future studies 4 
should also include older participants to assess whether or not the trajectory of metabolite 5 
decline changes at the extremes of age. 6 
 7 
  8 
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4.3 Study of Effect of Grey Matter Volume Fraction on Metabolite Ratios. 1 
 2 
4.3.1 Introduction 3 
As discussed earlier within this chapter, when planning spectroscopy voxel placement in 4 
spinal MRS, a compromise must be reached between maximising SNR and minimising 5 
partial volume effects from surrounding CSF.  All in vivo spinal cord MRS studies published 6 
so far in human subjects, spectroscopy voxels have taken up most of the cross-sectional area 7 
of the spinal cord and incorporate both grey matter (GM) and white matter (WM). However, 8 
this approach is potentially problematic as it is not known whether or not metabolite 9 
concentrations vary between GM and WM in the spinal cord as they do in the brain (Kreis et 10 
al., 1993; Saunders et al., 1999; Degaonkar et al., 2005; Choi et al., 2006; Baker et al., 2008).  11 
 12 
Recent imaging advances have demonstrated that WM and GM segmentation in the spinal 13 
cord is feasible (Yiannakas et al., 2012). This segmentation enables calculation of the spinal 14 
cord GM volume relative to the total spinal cord volume (i.e., GM volume fraction). 15 
Understanding the relationship between spinal cord GM volume fraction (GMVF) and 16 
metabolite levels is important, as significant inter-subject variability in GMVF has been 17 
shown to exist between healthy subjects in imaging and post-mortem studies (Bjartmar et al., 18 
2000; Yiannakas et al., 2012). This variability in turn, may influence quantification of 19 
metabolite concentrations. If a link between GMVF and spinal cord metabolites were to exist, 20 
it would be important to routinely calculate GMVF in clinical studies of neurodegenerative 21 
diseases, where spinal cord atrophy predominantly occurs in one tissue compartment. For 22 
example, in amyotrophic lateral sclerosis (ALS), there is MRI evidence at very high field for 23 
predominant GM atrophy, which may reflect  anterior horn cell degeneration (Cohen-Adad et 24 
al., 2013). As  discussed in Chapter 1, in patients with MS, post-mortem analysis has 25 
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suggested that WM volume loss accounts for the majority of spinal cord atrophy (Gilmore et 1 
al., 2005). This study therefore aims to assess the degree of variance in GMVF between 2 
healthy subjects and whether there is a relationship between GMVF and relative metabolite 3 
concentrations at 3 T. 4 
 5 
4.3.2 Methods 6 
4.3.2.1 Study Participants 7 
Fifteen healthy participants, mean age 38.7 years (SD ± 12.4) (10 females) were 8 
prospectively recruited for the study. All subjects provided written, informed consent prior to 9 
taking part in the research which was approved by our local research ethics committee. 10 
 11 
4.3.2.2 MRI Protocol  12 
All scans were performed using a 3T Achieva system (Philips Medical Systems, Best, 13 
Netherlands), with the manufacturer’s 16-channel neurovascular coil. To reduce motion 14 
artefacts during scanning, an MR compatible cervical collar was worn by all volunteers 15 
(Yiannakas et al., 2012).   16 
 17 
Single voxel MRS data was acquired using the protocol described in Section 4.2.2.2. VOIs 18 
with dimensions of approximately 5.4 x 7.76 x 55mm
3
 (2.3 ml) were prescribed using the 19 
reference images and centred on the C2/3 intervertebral disc (Figure 4.8A).  The dimensions 20 
of the VOI were adjusted in the AP direction dependent on the size of each individual’s 21 
spinal cord (mean VOI 2.08 ml; SD 0.19).  22 
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For volumetric measurements, the cervical cord was imaged in the axial plane, perpendicular 1 
to the axis of the cord with the imaging volume centred on the C2/3 intervertebral disc, using 2 
a fat-suppressed 3D slab selective fast field echo (FFE) sequence with TR = 23 ms; TE = 3 
5ms; flip angle α = 7°; FOV= 240 x 180 mm2; voxel size = 0.5 x 0.5 x 5 mm3; NEX = 8; 11 4 
axial contiguous slices. In order to match the position and orientation of the volumetric scan 5 
to the spectroscopy voxel, the prescription values used for the MRS acquisition were copied 6 
and manually entered by the operator when setting up the 3D FFE scan (Figure 4.8B).  7 
 8 
Figure 4.8: Planning of 9 
spectroscopy and volumetric scans. 10 
Sagittal and coronal T2w images 11 
of the upper cervical cord in a 12 
healthy subject showing a) 13 
Placement of PRESS VOI (5.4 x 14 
7.76 x 55 mm
3
) centred on the 15 
C2/3 intervertebral disc and b) 16 
Planning of the 3D FFE imaging 17 
volume to match the angulation 18 
and orientation of the spectroscopy 19 
VOI. 20 
 21 
 22 
 23 
4.3.2.3 Post Processing 24 
Image segmentation and volumetric measurements were performed using the 3D-FFE dataset 25 
in Jim 6.0 Software (Xinapse systems, Northants, England, www.xinapse.com). The spinal 26 
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cord was segmented (Figure 4.9A) using the active surface model method (Horsfield et al., 1 
2010). The total cord volume (TCV) for the 55mm section of cervical cord studied was 2 
calculated by multiplying total cord area (TCA) by slice thickness. Spinal cord GM was then 3 
segmented using a combination of the fuzzy connector algorithm and manual editing within 4 
Jim 6.0 as recently described (Yiannakas et al., 2012) (Figure 4.9B). The total grey matter 5 
volume (TGMV) was calculated by multiplying total grey matter area (TGMA) by slice 6 
thickness. GMVF was then derived, such that GMVF = (TGMV/TCV) x100%. Since the 7 
TCV has been assumed to consist of only total GM and WM volumes for practical purposes, 8 
we have not specifically reported, in this paper, associations between WM volume fraction 9 
and metabolite ratios, as the associations will be equal, but opposite, to the those of GMVF. 10 
 11 
Figure 4.9: Axial 3D-FFE images (resolution 0.5 x 0.5 x 5mm
3
) through the C2/3 12 
intervertebral disc showing a) segmentation of the spinal cord using the active surface model 13 
to calculate total cord volume (TCV) and b) segmentation of the spinal cord grey matter to 14 
calculate total grey matter volume (TGMV). 15 
 16 
Metabolite concentrations were quantified using the user independent LCModel package 17 
(Provencher, 1993) and a set of basis spectra simulated using GAMMA (Smith et al., 1994) 18 
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as described in Section 4.2.2.3. Total creatine (tCr) concentration was used as an internal 1 
reference and tNAA/tCr, Cho/tCr, Ins/tCr and Glx/tCr ratios were the focus of our analysis. 2 
Overall spectral quality was assessed using the SNR and FWHM values provided by 3 
LCModel. Cramér-Rao lower bounds (CRLBs), for each metabolite were used to assess the 4 
reliability of the metabolite fit. CRLBs of < 20% were taken to represent a reliable fit 5 
(Provencher, 2014). 6 
 7 
4.3.2.4 Statistical analysis 8 
All statistical analyses were performed using IBM SPSS statistical package version 22.0 9 
(IBM Corporation, Armonk, NY, USA). Gender differences in GMVF were tested using an 10 
unpaired t-test. Multiple linear regressions were used to explore the relationship between the 11 
metabolite ratios (response variables) and the GMVF (predictor) with age, gender, FWHM 12 
and voxel volume as additional covariates. A P value of < 0.05 was taken to be significant. 13 
 14 
4.3.3 Results 15 
Spectral Quality 16 
The FWHM and SNR estimated by LCModel (reported as mean ± SD) were 0.11 ± 0.02 ppm 17 
and 5.3 ± 1.9 respectively. Cramér–Rao lower bounds (CRLBs) indicated a reliable fit for 18 
tNAA/tCr, tCho/tCr and Ins/tCr. A reliable fit was achieved for Glx/tCr in 14 out of 15 19 
spectra (Provencher, 2014). Mean CRLBs for metabolite ratios were; tNAA/tCr (6.6%), 20 
tCho/tCr (9.2%), Ins/tCr (10.5%) and Glx/tCr (16.4%). 21 
 22 
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Normative values for GMVF 1 
Visual inspection of the scans did not show any evident motion; there was good GM/WM 2 
contrast on the axial FFE images for GM segmentation. GMVF in our healthy participants 3 
ranged between 16.1% and 24.8% (mean 19.8 ± 2.4%). The distribution of GMVF by gender 4 
is shown in Figure 4.9. There were no gender differences in GMVF, nor did it vary with age. 5 
 6 
 7 
Associations between GMVF and metabolite ratios 8 
There was a significant positive association between GMVF and tNAA/tCr and Glx/tCr. A 9 
one percentage point increase in GMVF significantly predicts a tNAA/tCr increase of 0.12 10 
(95% confidence interval (CI) 0.04, 0.19, p = 0.006) and a Glx/tCr increase of 0.15 (95% CI 11 
0.07, 0.23, p = 0.004) independently of voxel volume, FWHM, age and gender.  However, 12 
there was no association between GMVF and Ins/tCr or Cho/tCr ratios (Figure 4.10 and 13 
Table 4.7). Table 4.8 summarises predicted metabolite ratios based on variation of GMVF. 14 
 15 
Figure 4.9: Distribution of grey matter 
volume fraction (GMVF) by gender. 
Range (all subjects) was 16.1 to 24.8%. 
No significant gender differences were 
seen.  
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Metabolite Regression 
coefficient 
Standardised regression 
coefficient 
p-value 95% CI for 
regression coefficient 
tNAA/tCr 0.12 0.93 0.006 0.04 to 0.19 
Cho/tCr -0.002 -0.12 0.701 -0.02 to 0.01 
Ins/tCr -0.03 -0.20 0.546 -0.12 to 0.07 
Glx/tCr 0.15 0.91 0.004 0.07 to 0.23 
 1 
Table 4.7: Associations between GMVF (predictor) and metabolite ratios (response 2 
variable). Unstandardised and standardised regression coefficients for GMVF are reported 3 
with 95% confidence intervals and p-values. The regression models adjusted for age, gender 4 
and voxel volume. 5 
 6 
 7 
GMVF (%) 
 15 16 17 18 19 20 21 22 23 24 25 
tNAA/Cr  0.918 1.038 1.158 1.278 1.398 1.518 1.638 1.758 1.878 1.998 2.118 
tCho/Cr 0.352 0.350 0.348 0.346 0.344 0.342 0.340 0.338 0.336 0.334 0.332 
Glx/Cr 0.797 0.947 1.097 1.247 1.397 1.547 1.697 1.847 1.997 2.147 2.297 
Ins/Cr 1.398 1.368 1.338 1.308 1.278 1.248 1.218 1.188 1.158 1.128 1.098 
 8 
Table 4.8: Predicted metabolite ratios with variation of GMVF after adjusting for age, gender 9 
and voxel volume. 10 
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 1 
Figure 4.10: Graphs showing correlations between grey matter volume fraction (GMVF) and 2 
metabolite ratios. Regression lines and R
2
 values denoting the strength of association are 3 
marked. GMVF was significantly associated with tNAA/tCr and Glx/tCr but not other 4 
metabolite ratios.  5 
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4.3.4 Discussion 1 
This study examined the relationship between normative metabolite ratios in the spinal cord 2 
and GMVF. A positive association was found between GMVF and both tNAA/tCr and 3 
Glx/tCr ratios, suggesting that GMVF should be calculated and corrected for when estimating 4 
these metabolite ratios in the spinal cord, since changes between groups in metabolite ratios 5 
could be secondary to differences in GMVF. The impact of such a correction is likely to be 6 
most significant in studies of neurodegenerative spinal cord diseases where tissue loss occurs 7 
predominantly in either white matter or grey matter because in both instances the GMVF will 8 
be abnormal. 9 
 10 
At present, MRS of separate GM and WM compartments in the human spinal cord is not 11 
feasible in vivo, using currently available techniques. This study demonstrated that higher 12 
GMVF predicts higher tNAA/tCr ratios which could reflect higher concentrations of tNAA in 13 
the spinal cord GM than WM. Numbers of mitochondria (where NAA is synthesised), are 14 
highest in areas with high demands for ATP, such as presynaptic and postsynaptic terminals, 15 
active growth cones and nodes of Ranvier (Ruthel and Hollenbeck, 2003). However, 16 
distribution of NAA within neurones will depend upon its biological function, which remains 17 
uncertain. Immunohistochemical studies have demonstrated that NAA concentrations are 18 
substantially higher in cerebral GM than in WM (Moffett et al., 2007). Previous MRS studies 19 
reporting GM/WM differences in tNAA in the brain have described conflicting results, with 20 
some studies reporting higher tNAA in the WM than GM (Pouwels and Frahm, 1998), whilst 21 
the majority report modestly increased tNAA in the GM (Michaelis et al., 1993; Chard et al., 22 
2002; Kaiser et al., 2005).  23 
 24 
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In their 1D MRSI study in the spinal cord, Edden et al demonstrated an upward trend in tCr 1 
concentration and downward trend in tNAA concentration between the C1 segment and C2/3 2 
segment of the cervical spine (Edden et al., 2007).  This might be explained by the changing 3 
cross-sectional morphology from the upper to mid-cervical cord; specifically highest GMVF 4 
at the C1 level with a gradient reduction in GMVF into mid-cervical cord (Williams and 5 
Warwick). 6 
 7 
With regard to Glx levels, a relative increase in Glx in GM could be assumed as Glu and Gln 8 
would be expected to co-localise in close proximity to synapses where they serve their 9 
physiological function of synaptic neurotransmission; greater Glx levels in the GM than WM 10 
have been detected in the brain (Pan et al., 1996; Pouwels and Frahm, 1998; Choi et al., 11 
2006; Baker et al., 2008). Overall, MRS studies of the brain have reported smaller differences 12 
in tNAA than Glx between WM and GM (Michaelis et al., 1993; Pan et al., 1996; Chard et 13 
al., 2002; Choi et al., 2006; Baker et al., 2008). Similarly, in this study we found an increase 14 
in GMVF produced a much larger rise in Glx/tCr ratio (regression coefficient = 0.15) than 15 
tNAA/tCr ratio (regression coefficient = 0.12), suggesting that the difference in Glx 16 
concentration between the GM and WM is higher than for tNAA.  17 
 18 
In the cerebrum, tCr concentration decreases by approximately 15% in the WM and increases 19 
by approximately 12% in the GM from the anterior to the posterior pole (Baker et al., 2008). 20 
Consequently there is higher tCr concentration in the WM in the frontal lobes and higher 21 
concentration in the GM in the occipital lobe.  In this study there was a positive linear 22 
association between GMVF and both tNAA/tCr and Glx/tCr ratios. As already postulated, 23 
this is likely to reflect higher tNAA and Glx concentrations in the spinal GM. However, it is 24 
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also possible, if tCr concentration in the cervical cord is higher in WM than GM that this may 1 
be driving the relationship seen between GMVF and tNAA/tCr and Glx/tCr. 2 
 3 
In the brain, tCho is consistently reported as higher in the WM than GM (Kreis et al., 1993; 4 
Michaelis et al., 1993; Soher et al., 1996; Baker et al., 2008). In contrast, in this study there 5 
was no association between GMVF and tCho/tCr in the spinal cord. Neither was there a 6 
significant association between GMVF and Ins/tCr ratio suggesting that there is no significant 7 
difference in Ins concentration between GM and WM in the spinal cord, unlike the brain 8 
where Ins concentration is thought to be higher in the GM (Pouwels and Frahm, 1998; Baker 9 
et al., 2008). 10 
 11 
GMVF was calculated using the methods recently published by Yiannakas et al (Yiannakas 12 
et al., 2012) which highlighted considerable variation in GMVF between healthy controls. 13 
The mean recorded GMVF of 19.8% (SD ±2.4) is slightly higher than those reported in 14 
previous work by Yiannakas et al, who noted a mean GMVF of 17% (SD ±1) (Yiannakas et 15 
al., 2012). However, a larger number of subjects was studied (15 vs 10) and a longer segment 16 
of the cervical cord was imaged (55mm vs 15mm) in the current study which may account for 17 
some of the difference. Measurements from a post-mortem study of lower cervical cord (C4 – 18 
8) samples from 6 adults not known to have suffered with a neurological illness showed that 19 
spinal cord GM makes up 22.4% (SD ±1.3) of the cross-sectional area of the cervical cord at 20 
that level (Bjartmar et al., 2000). GMVF would be expected to vary with spinal cord level 21 
and reflects changing cross sectional morphology of the cord in the rostrocaudal direction; it 22 
is therefore important to measure the GMVF at the same level as the VOI when performing 23 
an analysis which combines volumetric data with MRS data. 24 
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Spinal cord volume loss (or atrophy) occurs in many common neurological diseases and 1 
correlates with disability in amyotrophic lateral sclerosis (ALS) (Cohen-Adad et al., 2013), 2 
multiple sclerosis (MS)(Losseff et al., 1996; Stevenson et al., 1998; Liu et al., 1999) and 3 
spinocerebellar ataxias (Chevis et al., 2013). However, volume loss is not always uniform 4 
across GM and WM compartments. In post-mortem spinal cord samples from MS patients, 5 
atrophy is largely due to WM volume loss (Gilmore et al., 2005), whereas in ALS, segmental 6 
GM volume loss, as measured with MRI at very high field, is thought to occur and explains 7 
the level of motor deficits (Cohen-Adad et al., 2013). Spinal cord MRS studies in patients 8 
with MS have detected decreases in tNAA levels of between 21 and 39% compared to 9 
healthy controls (Blamire et al., 2007; Ciccarelli et al., 2007; Marliani et al., 2010). Lower 10 
tNAA/tCr ratios have also been reported in the cervical cord of patients with cervical 11 
spondylitic myelopathy (Holly et al., 2009) and ALS (Carew et al., 2011). These observed 12 
changes in tNAA are often interpreted as reflecting both neuroaxonal injury and impaired 13 
metabolic mitochondrial energy production (Moffett et al., 2007). However, it is unclear from 14 
those studies, whether (and to what extent) these changes depend on tissue specific volume 15 
loss. Our study results indicate that measuring GMVF may be an important methodological 16 
consideration when planning similar MRS studies of spinal cord diseases in future. 17 
 18 
Limitations and Future Directions 19 
Although no significant difference in GMVF was seen between men and women in this 20 
group. However, it is possible this may be due to the small sample size; this work should 21 
therefore be repeated in the future with a larger sample size to investigate gender differences 22 
further. This study was also limited due to GM fraction not being determined within the VOI; 23 
instead we used GMVF of the cord to look at associations with metabolite ratios. We 24 
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considered using the spatial information of the VOI contained within the headers of the MRS 1 
data files to create a binarised mask of the VOI, which can be multiplied by a binarised mask 2 
of the spinal cord GM to give the GMVF within the VOI. However, due to the small size of 3 
the spinal cord, any subject motion during the 58 minutes of scanning could affect results and 4 
could not be corrected for. We therefore opted to use the more objective cord GMVF to look 5 
for associations. Visual inspection of the scans did not show any evident motion. 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
  14 
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 15 
In this chapter I have used the spinal cord MRS protocol optimised in Chapter 4 along with a 16 
high b-value Q-space imaging (QSI) protocol optimised for the spinal cord (discussed in 17 
Chapter 2) to assess the degree of early spinal injury in PPMS. I have then assessed how 18 
closely these new measures reflect clinical disability. 19 
  20 
Chapter Five 
Measuring early spinal neuronal loss in PPMS 
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5.1 INTRODUCTION  1 
As discussed in Chapter 1, the clinical phenotype of primary progressive multiple sclerosis 2 
(PPMS) is characterised by sustained disability progression from disease onset and is 3 
typically associated with severe locomotor disability (Thompson et al., 2000a), with a median 4 
time to DSS 6 (walking with a cane) of between 6 to 8.5 years (Runmarker and Andersen, 5 
1993; Cottrell et al., 1999; Confavreux et al., 2000). The rate of disability progression is 6 
highly variable, but occurs more quickly early in the disease course and reflects, in part, 7 
neuroaxonal loss and neuronal dysfunction in the spinal cord (Bjartmar et al., 2000). There 8 
would be great value in applying the imaging markers of neurodegenerative processes 9 
discussed in earlier chapters to the spinal cord in early PPMS in order to improve our 10 
understanding of the early pathological events that occur in the injury pathway responsible 11 
for clinical disability. This step is considered to be crucial in the translational pathway that 12 
aims to validate biomarkers that predict clinical outcomes and treatment response in clinical 13 
trials in PPMS (Fox et al., 2012). 14 
 15 
Advanced quantitative MRI (qMRI) has already been applied in the brain in early PPMS and 16 
has improved our understanding of the mechanisms leading to tissue damage, beyond that 17 
associated with macroscopic T2 lesions (Wheeler-Kingshott et al., 2014). Measures provided 18 
by diffusion tensor imaging (DTI)  and 
1
H-MR spectroscopy (
1
H-MRS), have been shown to 19 
correlate with disability (Sastre-Garriga et al., 2005; Ramio-Torrenta et al., 2006; Bodini et 20 
al., 2013), and to predict progression (Khaleeli et al., 2007; Khaleeli et al., 2008). Applying 21 
similar techniques to the spinal cord has been technically challenging (Wheeler-Kingshott et 22 
al., 2014).  However, as discussed in Chapter 3, recent developments have led to applications 23 
of advanced qMRI in the spinal cord in relapsing-remitting multiple sclerosis (RRMS) and 24 
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have provided insights into underlying spinal tissue pathology (Ciccarelli et al., 2007; Farrell 1 
et al., 2008; Marliani et al., 2010; Ciccarelli et al., 2013; Kearney et al., 2014b).  2 
Two promising qMRI techniques are high b-value Q-space imaging (QSI) and 
1
H magnetic 3 
resonance spectroscopy (MRS) (see Chapter 2). A small pilot study in relapse-onset MS 4 
demonstrated the feasibility of using high b-value QSI in the spinal cord with improved 5 
detection of abnormal diffusion compared with the conventional DWI acquisition and 6 
analysis (Farrell et al., 2008). Spinal cord MRS studies in patients with RRMS and 7 
neuromyelitis optica (NMO), have consistently shown neuronal loss and metabolic 8 
dysfunction, as reflected by reduced concentration in tNAA in the cervical cord of patients 9 
compared to controls (Ciccarelli et al., 2007; Marliani et al., 2007; Ciccarelli et al., 2013), 10 
however to date neither of these spinal cord imaging techniques have been applied to patients 11 
with PPMS. 12 
 13 
Besides the need to utilise more pathologically specific in vivo spinal cord imaging 14 
techniques in PPMS, there is also a need to incorporate objective clinical measures, which are 15 
more sensitive to changes in clinical functions mediated by spinal pathways than 16 
conventional clinical tests, such as the Expanded Disability Severity Scale (EDSS) (Kurtzke, 17 
1983). Measures such as postural stability, vibration perception thresholds (VPT) and 18 
dynamometry are more responsive to small clinical changes due to damage in the spinal cord 19 
than the EDSS, and have been shown to increase the sensitivity for detecting correlations 20 
between MRI abnormalities in the spinal cord and disability (Zackowski et al., 2009; Oh et 21 
al., 2013a).  22 
 23 
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In this chapter, I will apply the new MRS protocol (described in Chapter 4) in combination 1 
with a spinal cord QSI protocol to investigate changes in the cervical cord which underlie 2 
disability in patients with early PPMS, to test two hypotheses; i) MRS and QSI demonstrate 3 
early pathological changes in the upper cervical cord in patients with PPMS before the 4 
occurrence of spinal cord atrophy; ii) in patients, there is a relationship between MRS and 5 
QSI measures and disability, as reflected by newer spinal-cord specific clinical scores, 6 
alongside standard MS clinical scales, suggesting that early spinal cord neurodegeneration is 7 
linked with clinical impairment in PPMS. 8 
 9 
5.2 MATERIALS AND METHODS 10 
5.2.1 Study participants 11 
I prospectively recruited patients with an established diagnosis of PPMS (Polman et al., 12 
2005), aged between 18 – 65 years, within 6 years from disease onset, along with, age and 13 
gender matched healthy controls. On the day of the MRI, patients were clinically assessed. 14 
All subjects provided written, informed consent prior to taking part in the study which was 15 
approved by our local research ethics committee. 16 
 17 
5.2.2 Clinical Assessments 18 
All patients were assessed using conventional clinical scales, including the EDSS (Kurtzke, 19 
1983), 9-Hole Peg Test (HPT) (Goodkin et al., 1988) and Timed 25-foot Walk Test (TWT) 20 
(Cutter et al., 1999). For the purpose of statistical analysis, the average of two trials of the 21 
TWT and the average of four trials of the HPT (averaged as reciprocals of the mean times 22 
from two trials for each hand) (Fischer et al., 1999) were calculated. We also used the 23 
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Multiple Sclerosis Walking Scale-12 (MSWS-12) (Hobart et al., 2003), and the Modified 1 
Ashworth Scale (MAS) (Bohannon and Smith, 1987). The MAS values from 16 muscle 2 
groups in the upper and lower limbs were converted from a 0–4 scale (which includes a value 3 
of 1+ between scores of 1 and 2) to a 0 –5 scale; the resulting values were summated to 4 
obtain an overall score ranging from 0 to 80 (Stein et al., 2007).   5 
 6 
Clinical scales that are expected to be more sensitive to spinal cord pathways injury than 7 
conventional scores were used, including the mean grip strength from both upper limbs, using 8 
the Jamar hydraulic dynamometer (Sammons Preston Incorporated, Bolingbrook, IL, USA) 9 
(Svens and Lee, 2005), and the vibration perception thresholds (VPTs), which were measured 10 
from all 4 limbs at the lateral malleoli and ulna styloid processes using the biosthesiometer 11 
(Bio-Medical Instrument Company, Newbury, Ohio). Mean VPTs were calculated and used 12 
in the analysis. Finally, postural stability was assessed using a modified version of a recently 13 
described protocol for quantifying stance instability (Bunn et al., 2013). Subjects were asked 14 
to stand relaxed and still, facing a blank wall at a distance of 1 metre, in a well-lit room, for 15 
40 second-long trials. Three trials under each of the four conditions were recorded, consisting 16 
of 2 stance widths (inter-malleolar distance of 32 cm and 4 cm) under 2 visual conditions 17 
(eyes either open or closed). Body sway was measured using a 3-D orientation sensor (MTx: 18 
Xsens, Enschede, NL), which was fixed to the skin, just below the C7 spinous process. The 19 
device measured the instantaneous angular position of the trunk in the anteroposterior (pitch) 20 
and mediolateral (roll) planes and was sampled at 100Hz. Summary measures were made on 21 
these signals using custom scripts written in Matlab (The Mathworks, Natick, MA USA). The 22 
raw data were low-pass filtered at 10Hz using a zero-phase, 5th order Butterworth filter. The 23 
amount of angular motion was then calculated separately for the roll and pitch body sway 24 
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data and from the combined motion given by square root (pitch-motion
2
 + roll-motion
2
), 1 
termed total sway. All three signals were summarised by summing the sample-to-sample 2 
absolute change in signal and then dividing by the duration of the trial to yield average 3 
angular speeds of body sway reported in degrees/second. The mean of the three trials per 4 
condition were used for statistical analysis. An index of exacerbation of sway on eye closure 5 
was obtained from the Romberg quotient calculated as sway eyes closed/sway eyes open at 6 
both stance widths. 7 
 8 
5.2.3 MRI Protocol  9 
All scans were performed using a 3T Achieva system (Philips Medical Systems, Best, 10 
Netherlands) and all participants wore a cervical collar as described earlier.  11 
 12 
Using the manufacturer’s 16-channel neurovascular coil (Phillips Healthcare Systems), single 13 
voxel MRS was acquired as described in Section 4.2.2.2.  14 
 15 
For cord mean cross-sectional area (CSA) measurements, the cervical cord was imaged in the 16 
axial plane, perpendicular to the longitudinal axis of the cord using a fat-suppressed 3D slab-17 
selective fast field echo (FFE) sequence as described in section 4.3.2.2. In order to match the 18 
position and orientation of the volumetric scan to the spectroscopy voxel, the prescription 19 
values used for the MRS acquisition were copied and manually entered by the operator when 20 
setting up the 3D-FFE scan (Figure 4.8).  21 
 22 
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Using the manufacturer’s 32-channel receive coil (Philips Medical Systems, Best, 1 
Netherlands), each subject underwent a cardiac gated DWI acquisition [parameters: voxel 2 
size=1×1×5 mm
3
 (interpolated in k-space to a 0.5 x 0.5mm
2
 in-plane resolution) FOV = 64 × 3 
64mm
2
; TR = 9RR, TE = 129ms] performed with the volume centred on the C2/C3 disc to 4 
ensure similar coverage as the spectroscopy voxel (Figure 5.1). A ZOOM sequence was used 5 
with outer-volume suppression to minimise artefacts (Wilm et al., 2007). Thirty DWI 6 
volumes with equally spaced 𝐪-values (Schneider and Wheeler-Kingshott, 2014) and two 7 
non-diffusion weighted (b0) volumes were acquired with diffusion weighting in two 8 
perpendicular (x and y) and one parallel (z) direction to the main axis of the spinal cord 9 
[parameters: diffusion pulse duration δ=11.4 ms, diffusion time Δ=75ms, gradient strength G 10 
linearly increased in 31 steps from 0 to 87.5mT/m in x and y direction and 62mT/m in z 11 
direction].  12 
 13 
To achieve the maximum possible gradient strength on the scanner, we exploited the 14 
combination of parallel gradient amplifiers in the scanner, which each generate a maximum 15 
diffusion gradient strength of 62mT/m along the major axis of the scanner bore. Assuming 16 
axial symmetry of the axons along the long axis of the spinal cord, we applied gradient 17 
amplifiers in two orthogonal directions that maximise gradient strength perpendicular to axis 18 
of the spinal cord (Figure 5.2). This allowed us to generate a guaranteed maximum gradient 19 
strength of √2*62mT/m in the xy direction. In the z direction we use a maximum gradient of 20 
62 mT/m. q-value were the same in xy and z direction, but the increase in gradient strength 21 
allowed us to use a smaller gradient pulse duration of 11.4ms in xy direction (16ms in z), 22 
which has been shown in experimental models (Latt et al., 2007a; Latt et al., 2007b), to 23 
provide more accurate estimations of displacement.  24 
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 1 
 2 
 3 
 4 
 5 
A 
C 
B 
D 
Figure 5.1: Planning of spectroscopy voxel and DWI volume. Above: sagittal (A) and 
coronal (B) T2w images of the cervical cord with spectroscopy voxel centred on C2/3 
intervertebral disc. Below: sagittal (C) and coronal (D) T1w image of the cervical cord 
showing DWI volume coverage centred on the C2/3 disc. 
 
Figure 5.2: Illustration of gradient direction scheme used for x and y QSI encoding. 
The QSI gradient directions are chosen to maximise the diffusion encoding gradient 
strength in the perpendicular plane to the spinal cord (red arrows). Figure reproduced 
with permission from Dr Torben Schneider 
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For calculation of brain T2 lesion volumes, PD/T2 weighted images were acquired using a 1 
dual-echo TSE sequence [parameters: TR = 3500 ms; TE = 15/85 ms; flip angle α = 90°; 2 
FOV= 240 x 180 mm
2
; voxel size = 1 x 1 x 3 mm
3
; NEX = 1; 50 axial contiguous slices]. For 3 
calculation of brain tissue volumes a 3D T1-weighted magnetisation-prepared gradient-echo 4 
sequence was used [TR = 6.9 ms; TE = 3.1 ms; TI = 824 ms; flip angle α = 8°; FOV= 256 x 5 
256 mm
2
; voxel size = 1 x 1 x 1 mm
3
; NEX = 1; 180 sagittal contiguous slices].  6 
 7 
5.2.4 Post processing 8 
Spinal cord metabolite quantification:  9 
Metabolite concentrations were quantified using the user-independent LCModel (version 6.3) 10 
package (Provencher, 1993) and a set of basis spectra simulated using GAMMA (Smith et 11 
al., 1994) as previously described (Section 4.2.2.3). tNAA, tCho, tCr, Ins and Glx 12 
concentrations were quantified using the unsuppressed water signal obtained from the same 13 
voxel as a reference (Gasparovic et al., 2006) and formed the focus of our analysis. The 14 
signal-to-noise ratio (SNR) and full width of half maximum (FWHM) of the tNAA peak 15 
provided by LCModel were used to assess spectral quality and Cramér–Rao Lower Bounds 16 
(CRLB) values of <20% for tNAA, tCr, tCho and Ins and <30% for Glx were used to confirm 17 
the reliability of the spectral fit (Provencher, 2014). Poor quality spectra were excluded from 18 
the analysis. Criteria for exclusion were poor water suppression or FWHM > 0.13 with SNR 19 
< 3.   20 
 21 
 22 
 23 
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Spinal cord area measurement:  1 
Image segmentation and CSA measurements were performed using the 3D-FFE dataset in 2 
Jim 6.0 Software (Xinapse systems, Northants, England). Three contiguous 5mm axial slices, 3 
centred on the C2/3 disc were segmented using the active surface model method (Horsfield et 4 
al., 2010). The mean cross-sectional area of these three slices was then calculated. 5 
 6 
Post processing of DWI and ROI analysis:  7 
The two perpendicular diffusion directions were averaged (xy) to increase the signal-to-noise 8 
ratio. The diffusion dPDF was computed using inverse Fast Fourier Transformation. To 9 
increase the resolution of the dPDF, the signal was extrapolated in Q-space to a maximum 10 
q=200mm
−1
 by fitting a bi-exponential decay curve to the DWI data (Farrell et al., 2008). 11 
 12 
Data was corrected for motion using reg_aladin from the NiftyReg toolkit (Ourselin et al., 13 
2000). Registration was performed between the interleaved b=0 acquisitions of the xy and z 14 
protocol using the first b=0 of the xy protocol as reference. The estimated registration was 15 
then applied to the intermediate DWI images. The quality of the motion correction was 16 
assessed in each subject and mis-registered slices/subjects were excluded from the study. 17 
 18 
Voxel-wise maps of the full width at half maximum (FWHM); which represents the width of 19 
the displacement distribution function and the zero displacement probability (P0); 20 
representing the height of the displacement distribution function, were derived from the 21 
dPDF for xy and z. Conventional Apparent diffusion coefficient (ADC) maps were also 22 
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derived from the low b-value part of the decay curve (b < 1100s/mm
2
) for both xy and z 1 
directions using a constrained non-linear least squares fitting algorithm. 2 
 3 
To assess region specific differences in QSI metrics, the whole 60mm length of cervical 4 
spinal cord was first extracted from CSF and other tissue types, and four regions of interest 5 
(ROIs) were created using the ROI tool in JIM 6.0 and drawn on the b0 images for each axial 6 
slice. ADC and QSI indices were measured from ROIs in the anterior, right lateral, left lateral 7 
and posterior columns, as well as whole cord (Figure 5.3). No statistical differences were 8 
found between Q-space indices from the right and left lateral columns; therefore for ease of 9 
analysis a mean value from both columns was calculated for each of the Q-space indices. 10 
 11 
 12 
 13 
 14 
 15 
 16 
Figure 5.3 Axial b0 image of the cervical spinal cord showing the location of regions of 
interest (ROIs) placed in the anterior (A), right lateral (R), left lateral (L) and posterior (P) 
columns. After ROI’s were drawn on the b0 images, they were overlaid onto the QSI and ADC 
maps. 
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Brain grey matter and white matter volumes:  1 
To avoid segmentation errors due to white matter (WM) lesions, an automated lesion-filling 2 
technique was employed (Chard et al., 2010). Lesion masks were created based on 3D-T1 3 
weighted sequences. The lesion-filled images were segmented into WM, grey matter (GM) 4 
and cerebrospinal fluid (CSF), using the ‘new segment’ option in SPM8 (statistical 5 
parametric mapping; Wellcome Trust Centre for Neuroimaging, University College London 6 
(UCL) Institute of Neurology, London). Segmentations were reviewed to exclude errors. WM 7 
and GM fractional (WMF and GMF) volumes, relative to total intracranial volume (the sum 8 
of GM, WM and CSF volumes), were calculated.  9 
 10 
Brain T2 Lesion Volumes: 11 
Brain T2-lesion volume (T2LV) was calculated by outlining lesions on T2-weighted MRI 12 
scans using a semi-automated edge finding tool (JIM v. 6.0). Total lesion volume was 13 
recorded in mLs for each subject. 14 
 15 
5.2.5 Statistical analysis 16 
Analyses were performed in Stata 13.1 (Stata Corporation, College Station, Texas, USA). 17 
Adjusted differences between patients and controls were obtained by multiple regression of 18 
the relevant measure on a subject type indicator with age, gender and CSA as covariates 19 
(except for the difference in mean cord area itself, which just controlled for age and gender). 20 
This analysis was then repeated to evaluate the adjusted difference between controls and 21 
patients with and without spinal cord lesions within the C1-3 region of interest. 22 
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In patients, univariable associations between metabolites and whole cord QSI metrics were 1 
examined with Pearson correlations. Associations between spinal cord measures and EDSS, 2 
Summated MAS, peg test and vibration perception were examined with multiple regression 3 
of the clinical variable on the spinal cord measure as predictor, with the following potential 4 
confounders as covariates: age, gender, mean cord area, brain T2 lesion volume, GM fraction 5 
and WM fraction; because of the large number of covariates, these were entered singly into 6 
the model, and the unadjusted association is only reported where it was not materially 7 
affected by entering any of these covariates.  Where regression residuals showed signs of 8 
non-normality (e.g. for EDSS), the non-parametric bias corrected and accelerated bootstrap 9 
was used (1000 - 5000 replicates, depending on the p-value resolution required), and then, if 10 
more precise determination was too computer intensive, the P-value was reported as a range.  11 
 12 
For associations between spinal cord measures and measures of postural stability, 13 
multivariate regression was used because of the highly related nature of the clinical measures: 14 
by performing joint tests of association, the danger of spurious significant results was 15 
minimised by reporting associations only where the joint test was significant; where the joint 16 
test is not significant, there is no global evidence for any of the individual associations tested, 17 
in which case these are not reported as significant even when individually P<0.05.  The 18 
multivariate associations were carried out with potential confounders entered as described 19 
above. 20 
 21 
 22 
  23 
 
 
160 
 
5.3 RESULTS  1 
5.3.1 Participant demographics and characteristics 2 
Twenty-three patients with early PPMS and 26 healthy controls were recruited. One patient 3 
was unable to tolerate the scan and was excluded; a second patient’s scans were excluded 4 
from final analysis due to severe motion-related image degradation. Two control subjects 5 
were excluded from the study due to unexpected abnormalities on structural imaging. 6 
Therefore data from 21 patients and 24 healthy controls were included in the final analysis. 7 
Patients had short disease duration and mild to moderate levels of disability. Conventional 8 
MRI of the cervical cord identified lesions in 18 out of 21 patients. Of the 18 patients with 9 
cervical cord lesions, 12 patients had lesions within the C1 to C3 segments covered by the 10 
MRS and QSI volumes. Patient characteristics, disability and conventional MRI findings are 11 
summarised in table 5.1. Spinal cord imaging findings and disability scores presented 12 
patient-by-patient are summarised in table 5.2. 13 
 14 
  15 
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 1 
 Healthy Controls                                  
(n = 24) 
PPMS Patients              
(n = 21) 
Mean age (SD) 42.1 (11.5) years 48 (7.9) years 
Gender 19F: 5M 12F: 9M 
Mean CSA (SD) 81.8 (8.1) mm
2
 77.5 (9.6) mm
2
 
Mean GMVF (SD) 0.48 (0.01) 0.47 (0.01) 
Mean WMVF (SD) 0.34 (0.01) 0.33 (0.01) 
Mean brain parenchymal fraction (SD) 0.82 (0.02) 0.80 (0.02) 
Mean T2 lesion volume (SD)  11.6 (9.4) ml 
Mean disease duration (SD)  3.9 (1.5) years 
Median EDSS (range)  5.0 (3.0 - 6.5) 
Mean TWT (SD)  8.1 (5.9) seconds 
Mean MSWS-12 (SD)  44.4 (11.4) 
Mean summated MAS (SD)  7.2 (9.3) 
Mean HPT (SD)  30.0 (13.3) seconds  
Mean grip strength (SD)  50.2 (26.4) lbs force 
Mean vibration perception threshold (SD)  10.7 (10.6) 
Mean sway, 32cm, EO (SD)   0.87 (0.37) deg/s 
Mean sway, 32cm, EC (SD)  1.07 (0.46) deg/s 
Mean sway, 4cm, EO (SD)   0.98 (0.38) deg/s 
Mean sway, 4cm, EC (SD)  1.28 (0.58) deg/s 
 2 
         Table 5.1: Demographic and clinical characteristics of patients and volunteers 3 
 4 
 5 
  6 
Abbreviations: GMVF = brain grey matter volume fraction, WMVF = brain white matter volume fraction. 
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Patient Gender Age 
(years) 
Disease duration 
(years) 
MRI findings cervical cord 
1 F 39 4 Single lesion anterior cord at level of C3/4 
disc 
2 F 42 5 Normal appearing cervical cord 
3 F 52 2 Patchy signal change C2 – C5 
4 F 46 3 Posterior lesion at C2 and anterior lesion at 
C4 
5 F 57 2 Posterior lesion C3/4 and C6 
6 F 38 2.5 Patchy change at C3-4 and a posterior lesion 
at T3 
7 M 44 5 Diffuse signal change C2-6 
8 F 50 3 Patchy signal change C6-7 anteriorly 
9 M 45 6 Anterior lesions at C3, C4 and C6 
10 F 57 2.5 Normal appearing cervical cord 
11 M 54 3 Small anterior lesion at C3/4 and a posterior 
lesion at C6/7 
12 F 44 2 Posterior lesion at C6 
13 M 57 4 Central lesion C2 and posterior lesions C5 
and C6 
14 M 55 5 Anterior lesion at C6/7 
15 M 50 3 Anterior lesion C5/6 
16 M 36 6 Small posterior lesion at C2 and diffuse 
change C2-C7 
17 F 63 6 Anterior lesion C2/3 posterior lesion C3/4 
18 M 35 6.5 Anterior lesion T1 
19 F 56 5 Patchy lesion at C2/3 and focal anterior 
lesions at C4 and C7 
20 M 42 3 Anterior lesion at C1 and patchy signal 
change C3-C5 
21 F 45 3 Lesion at C1 and C7 with patchy signal 
abnormality C3-4. 
 1 
  2 
Table 5.2:  Patients’ demographic data and MRI findings 
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5.3.2 Differences in qMRI measures between patients and controls 1 
After adjusting for age and gender there was no significant difference in CSA between 2 
patients and controls (P = 0.092).  Patients had lower spinal tNAA (mean 5.31 vs 4.01 3 
mmol/L, P = 0.02) and Glx (mean 5.93 vs 4.65 mmol/L, P = 0.04) concentrations than 4 
healthy controls, after correction for age, gender and CSA, and this was most marked in 5 
patients with spinal cord lesions within the spectroscopic volume (Table 5.3 and Figure 5.4). 6 
Ins concentrations were borderline significantly higher in patients than healthy controls 7 
(mean 4.49 vs 5.55 mmol/L, P = 0.08), but were significantly elevated in patients with a C1-8 
C3 lesion (Table 5.3).  9 
 10 
 11 
Tables 5.3 and 5.4 summarise mean values for QSI indices and gives P-values for the 12 
adjusted comparisons between patients and controls. Patients had significantly higher 13 
perpendicular diffusivity than controls, as reflected in both ADCxy and QSI metrics 14 
(FWHMxy and P0xy) in the whole cord and white matter tracts, and a significant increase in 15 
parallel diffusivity confined to the posterior columns compared to controls, when adjusting 16 
for age, gender and CSA (Table 5.4 and Figure 5.4). Perpendicular diffusivity derived from 17 
QSI indices (FWHMxy and P0xy), but not ADCxy was also significantly higher in patients 18 
with normal appearing spinal tissue compared with healthy controls (Table 5.3). 19 
 20 
 21 
  22 
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Cord 
Measure  
Healthy Controls    
(n = 24) 
Patients without C1-3 
lesion (n = 9) 
Patients with 
C1-3 lesion    
(n= 12) 
All Patients      
(n = 21) 
tNAA  
(mmol/L) 
5.31 (1.47) 4.23 (0.86) 
P=0.206 
3.89 (1.31) 
P=0.102 
4.01 (1.16) 
P=0.020 
 
tCho 
(mmol/L)  
1.31 (0.41) 1.12 (0.22) 
P=0.241 
1.33 (0.38) 
P=0.852 
1.26 (0.34) 
P=0.610 
tCr 
(mmol/L) 
 
3.76 (1.13) 3.04 (0.35) 
P=0.099 
4.22 (1.73) 
P=0.908 
3.79 (1.48) 
P=0.963 
Ins 
(mmol/L) 
4.49 (1.23) 4.25 (1.17) 
P=0.287 
6.26 (1.84) 
P=0.006 
5.55 (1.88) 
P=0.081 
Glx 
(mmol/L) 
5.93 (1.66) 5.01 (1.90) 
P=0.170 
4.50 (0.71) 
P=0.047 
4.65 (1.11) 
P=0.043 
ADCxy        
(µm
2
/ms) 
0.390 (0.09) 0.421 (0.05) 
P=0.151 
0.481 (0.10) 
P=0.002 
0.454 (0.08) 
P=0.006 
ADCz          
(µm
2
/ms) 
1.783 (0.10) 0.183 (0.01) 
P=0.123 
0.183 (0.02) 
P=0.119 
1.834 (0.14) 
P=0.123 
FWHMxy    
(µm x 10
2
) 
0.236 (0.02) 0.251 (0.01) 
P=0.020 
0.276 (0.04) 
P<0.001 
0.265 (0.03) 
P=0.001 
FWHMz      
(µm x 10
2
) 
0.550 (0.03) 0.553 (0.03) 
P=0.427 
0.560 (0.03) 
0.019 
0.557 (0.03) 
P=0.120 
P0xy            
(a.u) 
0.202 (0.02) 0.188 (0.01) 
P=0.025 
0.174 (0.03) 
0.001 
0.180 (0.02) 
P=0.001 
P0z              
(a.u) 
0.113 (0.004) 0.112 (0.003) 
P=0.278 
0.113 (0.004) 
P=0.481 
0.113 (0.004) 
P=0.470 
 1 
 2 
 3 
 4 
Table 5.3: Summary of mean (SD) metabolite concentrations and QSI indices from the cervical 
cord of patients and controls and P-values for adjusted group comparisons after correcting for 
age, gender and mean cord cross-sectional area. 
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 1 
 2 
 3 
 4 
 5 
 6 
 7 
  8 
Figure 5.4: PDF, QSI maps and post-processed spectra from patients and controls. Differences in height and 
width of the dPDF from the posterior and lateral columns between a healthy control and patient are shown on 
the far left. Grouped P0xy maps, FWHMxy maps and post-processed spectra from 3 controls (central) and 3 
patients (far right) demonstrate lower probability of zero net displacement (P0xy) and increased diffusion 
distribution (FWHMxy) in the patients. The spectra show reduced tNAA and Glx levels in the patients 
compared to the controls 
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  1 
Region of 
interest 
Diffusion measure PPMS Patients 
(n=21) 
Healthy 
Controls 
(n=24) 
P-value 
Anterior  
Column 
ADCxy        (µm
2
/ms) 0.497 (0.15) 0.388 (0.12) 0.028 
ADCz          (µm
2
/ms) 1.921 (0.20) 1.867 (0.17) 0.331 
FWHMxy    (µm x 10
2
) 0.266 (0.04) 0.229 (0.02) 0.001 
FWHMz      (µm x 10
2
) 0.562 (0.03) 0.600 (0.04) 0.159 
P0xy            (a.u) 0.180 (0.03) 0.210 (0.02) 0.002 
P0z              (a.u) 0.111 (0.004) 0.111 (0.01) 0.411 
Posterior 
Column 
ADCxy        (µm
2
/ms) 0.458 (0.16) 0.368 (0.10) 0.017 
ADCz          (µm
2
/ms) 2.181 (0.26) 2.092 (0.14) 0.050 
FWHMxy    (µm x 10
2
) 0.261 (0.06) 0.229 (0.03) 0.029 
FWHMz      (µm x 10
2
) 0.610 (0.04) 0.602 (0.04) 0.122 
P0xy            (a.u) 0.185 (0.03) 0.208 (0.03) 0.018 
P0z              (a.u) 0.102 (0.004) 0.103 (0.004) 0.045 
Mean 
Lateral 
Columns 
ADCxy        (µm
2
/ms) 0.416 (0.11) 0.319 (0.10) 0.001 
ADCz          (µm
2
/ms) 1.989 (0.26) 1.979 (0.12) 0.581 
FWHMxy    (µm x 10
2
) 0.254 (0.04) 0.214 (0.02) < 0.001 
FWHMz      (µm x 10
2
) 0.579 (0.02) 0.579 (0.03) 0.318 
P0xy            (a.u) 0.189 (0.03) 0.224 (0.03) < 0.001 
P0z              (a.u) 0.108 (0.007) 0.106 (0.004) 0.757 
 2 
Table 5.4: Summary of mean (SD) Q-space imaging (QSI) indices and apparent diffusion 
coefficients (ADC) from the major white matter tracts of patients and controls.  P-values given 
for adjusted group comparisons after correcting for age, gender and CSA. 
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5.3.3 Univariable analysis of spinal cord metabolite concentrations and QSI metrics in 1 
patients 2 
In patients, spinal cord tNAA concentration was negatively correlated with whole cord 3 
ADCxy (r = - 0.581, p = 0.011) and FWHMxy (r = - 0.636, p = 0.005) and positively 4 
correlated with whole cord P0xy (r = 0.646, p = 0.004) (Figure 5.5). Other spinal metabolite 5 
concentrations did not correlate significantly with each other, or with cord QSI indices. 6 
 7 
 8 
 9 
 10 
5.3.4 Associations between whole cord qMRI measures and clinical disability 11 
Associations between whole cord qMRI measures and EDSS, summated MAS scores, 1/HPT, 12 
grip strength and vibration perception threshold are summarised in table 5.5 and associations 13 
with truncal stability measures are shown in table 5.6. A significant association was seen 14 
between lower spinal tNAA concentrations and increased physical disability, increased 15 
spasticity, and worsening vibration sensory function and postural stability (as reflected by 16 
higher EDSS, summated MAS scores, vibration perception threshold and postural sway 17 
respectively) (tables 5.5 and 5.6). Lower spinal Glx and higher Ins were both independently 18 
Figure 5.5: Scatter graphs showing correlation between spinal tNAA concentration and whole cord 
P0xy (left), FWHMxy (centre) and ADCxy (right) 
 
 
 
168 
 
associated with increased postural instability. Higher tCho concentrations were independently 1 
associated with impairment in upper limb function as reflected by 9HPT. Increased 2 
perpendicular diffusivity, indicating increased movement of water in the direction 3 
perpendicular to the main axis of the cord, was associated with higher summated MAS 4 
scores, higher vibration perception threshold and increased postural instability. There was 5 
also a borderline association between lower P0xy, which reflects an increase in perpendicular 6 
diffusivity and reduced grip strength.  7 
 8 
  9 
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Clinical Score Spinal Cord Measure Regression Coefficient 95 % Confidence Interval P-value 
EDSS tNAA -0.41 -1.06, 0.34 0.01 < P < 0.05 * 
Summated MAS tNAA 
P0xy 
FWHMxy 
ADCxy 
-3.78 
-283.72 
191.30 
63.64 
-16.49, 2.16 
-444.26, -123.19 
86.36, 269.24 
18.89, 103.39 
0.01 < P < 0.05 * 
0.002 
0.001 
0.008 
1/HPT tCho -0.013 -0.03, 0.00 0.05 * 
Mean grip P0xy 435.96 -61.67, 933.59 0.081 
Vibration perception 
threshold 
tNAA 
P0xy 
FWHMxy 
ADCxy 
-4.37 
-344.27 
226.49 
88.06 
-8.08, -0.66 
-512.61, -175.93 
115.73, 337.26 
49.02, 127.10 
0.021 
0.001 
0.001 
< 0.001 
Table 5.5: Associations between whole cord measures (predictors) and clinical scores (response variables). Unstandardised regression coefficients 
for imaging measures are reported with 95% confidence intervals and p-values. The regression models were adjusted for age, gender and mean cord 
area.  * Bootstrap P-values. 
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 Sway                                  
Coefficient  (95% CI; P-value) 
Pitch                                
Coefficient  (95% CI; P-value) 
Roll                                        
Coefficient  (95% CI; P-value) 
Romberg Quotient      
Coefficient  (95% CI; P-value) 
tNAA P < 0.001 
4EO: -0.057 (-0.188, 0.074; P = 0.393) 
4EC: -0.192 (-0.416, 0.033; P = 0.094) 
32EO: -0.072 (-0.118,-0.022; P = 0.004) 
32EC: -0.086 (-0.221, 0.048; P = 0.208) 
P < 0.0001 
4EO: -0.036 (-0.144, 0.073; P = 0.517) 
4EC: -0.137 (-0.277, 0.003; P = 0.056) 
32EO: -0.047 (-0.099, 0.006; P = 0.082) 
32EC: -0.063 (-0.192, 0.066; P = 0.338) 
P = 0.005 
4EO: -0.039 (-0.111, 0.033; P = 0.286) 
4EC: -0.103 (-0.256, 0.049; P = 0.184) 
32EO: -0.044 (-0.069,-0.018; P = 0.001) 
32EC: -0.046 (-0.083,-0.009; P = 0.014) 
P  = 0.003 
4cm: -0.112 (-0.191,-0.033; P = 0.006) 
32cm: -0.191 (-0.123, 0.085; P = 0.718) 
 
Glx P = 0.017 
4EO: -0.171 (-0.301, -0.042; P = 0.010) 
4EC: -0.320 (-0.564, -0.076; P = 0.010) 
32EO: -0.057 (-0.127, 0.014; P = 0.114) 
32EC: -0.163 (-0.310,-0.015; P = 0.031) 
P < 0.001 
4EO: -0.110 (-0.227, 0.007; P = 0.065) 
4EC: -0.204 (-0.360, -0.049; P = 0.010) 
32EO: -0.033 (-0.103, 0.038; P = 0.366) 
32EC: -0.134 (-0.279, 0.010; P = 0.069) 
P = 0.012 
4EO: -0.108 (-0.171, -0.046; P = 0.001) 
4EC: -0.207 (-0.367, -0.046; P = 0.012) 
32EO: -0.039 (-0.076,-0.002; P = 0.039) 
32EC: -0.062 (-0.104, 0.020; P = 0.004) 
P  < 0.0001 
4cm: -0.134 (-0.236,-0.032; P = 0.010) 
32cm: -0.140 (0.232,-0.048; P = 0.003) 
 
Ins P < 0.0001 
4EO: 0.062 (-0.061, 0.185; P = 0.324) 
4EC: 0.100 (-0.102, 0.303; P = 0.332) 
32EO: 0.019 (-0.065, 0.103; P = 0.660) 
32EC: 0.090 (-0.010, 0.191; P = 0.078) 
P = 0.014 
4EO: 0.068 (-0.324, 0.170; P = 0.184) 
4EC: 0.062 (-0.078, 0.201; P = 0.388) 
32EO: 0.026 (-0.045, 0.097; P = 0.477) 
32EC: 0.093 (0.004, 0.183; P = 0.040) 
P = 0.440 P = 0.046 
4cm: 0.031 (-0.052, 0.113; P = 0.467) 
32cm: 0.086 (-0.019, 0.153; P = 0.012) 
 
tCho P = 0.545 P = 0.144 P = 0.979 P = 0.113 
tCr P = 0.306 P = 0.237 P = 0.821 P = 0.363 
ADCxy  4EC: 2.48 (0.44, 4.51; P = 0.017) 32EO: 0.93 (0.34, 1.52; P = 0.002) 
32EC: 1.24 (0.28, 2.21; P = 0.011) 
4cm: 1.41 (0.24, 2.59; P = 0.023) 
FWHMxy  4EC: 5.57 (0.02, 11.12; P = 0.049) 32EO: 2.25 (0.56, 3.94; P = 0.009)  
P0xy   32EO: -3.80 (-6.14, -1.46; P = 0.001) 
32EC: -5.01 (-8.84,-1.18; P = 0.010) 
 
 
Table 5.6: Associations between whole cord imaging measures and truncal stability. A multivariate analysis was used to assess associations between metabolite predictors 
and the multiple stability scores as response variables. P-values for the joint test of the metabolite predictor are shown in bold. Metabolite regression coefficients, 95% 
confidence intervals and p-values are shown for the individual stability variables, and these are only shown where the joint test was significant. The regression models 
adjusted for age, gender and mean cord area. 
EC = eyes closed;  EO = eues open. 
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5.3.5 Associations between column-specific QSI metrics and clinical disability 
When examining the results of the ROI-specific analysis, significant associations between 
QSI and clinical disability were found in all columns, although some columns showed 
preference for specific clinical tests. Increased spasticity was predicted by lower P0xy in the 
anterior, lateral and posterior columns; increased FWHMxy in the anterior and lateral 
columns and increased ADCxy in the lateral columns. Reduced vibration sensation was 
predicted by increased perpendicular diffusivity (reduced P0xy and increased FWHMxy and 
ADCxy) in the anterior, lateral and posterior columns. Instability in the roll plane was 
predicted by reduced P0xy (increased perpendicular diffusivity) in the posterior column, 
while instability in the pitch plane was predicted by increased ADCxy (increased 
perpendicular diffusivity) in the anterior column. A summary of associations is presented in 
table 5.7. 
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Clinical Score Region of interest Diffusion Measure Regression Coefficient 95 % Confidence Interval P-value 
Summated MAS 
 
Lateral Column 
 
 
Anterior Column 
 
Posterior Column 
P0xy 
FWHMxy 
ADCxy 
P0xy 
FWHMxy 
P0xy 
-205.16 
171.80 
50.66 
-185.96 
157.38 
-136.56 
-322.34, -87.97 
91.34, 252.27 
16.50, 84.83 
-316.30, -55.62 
64.03, 250.72 
-267.09, -6.03 
0.002 
< 0.001 
0.006 
0.008 
0.002 
0.04 
Vibration 
Lateral Column 
 
 
Anterior Column 
 
 
Posterior Column 
P0xy 
FWHMxy 
ADCxy 
P0xy 
FWHMxy 
ADCxy 
P0xy 
FWHMxy 
ADCxy 
-268.54 
223.44 
67.20 
-239.01 
200.74 
40.73 
-219.76 
101.77 
46.29 
-421.03, -116.05 
125.91, 320.90 
28.07, 106.33 
-384.52, -93.50 
106.07,295.41 
7.82, 73.64 
-353.71, -85.80 
32.47, 171.08 
22.24, 70.34 
0.002 
< 0.001 
0.002 
0.003 
0.001 
0.02 
0.003 
0.007 
0.001 
32EO Sway Anterior Column ADCxy 0.81 0.12, 1.50 0.021 
32EO Roll Posterior Column  P0xy -2.16 -4.07, -0.26 0.026 
32EO Pitch  Anterior Column ADCxy 0.69 0.15, 1.23 0.013 
32EC Roll Posterior Column P0xy -3.85 -6.58, -1.12 0.006 
32EC Pitch Anterior Column ADCxy 1.04 0.12, 1.94 0.026 
4EO Pitch Anterior Column ADCxy 1.02 0.13, 1.91 0.025 
4EC Pitch Anterior Column ADCxy 1.54 0.47, 2.63 0.005 
4cm Romberg  Lateral Column ADCxy 1.18 0.20, 2.16 0.023 
Table 5.7:  Associations between tract-specific diffusion indices (predictors) and clinical scores (response variable). Unstandardised regression 
coefficients for imaging measures are reported with 95% confidence intervals and p-values. The regression models were adjusted for age, gender 
and mean cord area 
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5.4 Discussion 1 
By applying novel spinal qMRI techniques this study has demonstrated that there is lower 2 
tNAA and Glx, and increased QSI-derived perpendicular diffusivity (seen as an increase in 3 
FWHMxy and a decrease in P0xy) in the cervical cords of patients with early PPMS 4 
compared to controls. These findings suggest that neuronal loss, metabolic dysfunction and 5 
changes in the glutamatergic pathway, occur in the spinal cord in the early stages of the 6 
disease. Significant associations between spinal cord tNAA, Glx and QSI-derived 7 
perpendicular diffusivity and newer measures of clinical disability, such as postural stability 8 
and VPT, suggest that these imaging measures reflect the abnormalities that contribute to 9 
clinical impairment.  10 
 11 
These results could suggest that neurodegeneration occurs early in the spinal cord, in the 12 
absence of extensive spinal cord atrophy. These qMRI abnormalities correlated with clinical 13 
impairment and could provide insights into the pathological events that occur in PPMS. This 14 
study provides justification for further developing these qMRI measures and for their 15 
validation as useful biomarkers of disease progression and treatment response in clinical 16 
trials.  17 
 18 
Differences in qMRI between patients and controls 19 
The lower tNAA concentrations in the spinal cord of PPMS patients when compared with 20 
healthy controls are consistent with metabolite abnormalities in the brain, where tNAA is 21 
lower in cortical grey matter and NAWM early in PPMS (Sastre-Garriga et al., 2005). In 22 
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addition, findings from this study are qualitatively similar to those seen in acute (Ciccarelli et 1 
al., 2007; Henning et al., 2008; Ciccarelli et al., 2010a) and chronic (Marliani et al., 2010; 2 
Ciccarelli et al., 2013) spinal cord lesions in RRMS. The majority of the early PPMS patients 3 
included in the present study (N=12) had a lesion (or part of a lesion) within the 4 
spectroscopic voxel and in these patients, spinal tNAA concentrations were lower than 5 
patients without a lesion. There were too few subjects in the study to detect a statistically 6 
significant difference in tNAA concentrations between patients with and without spinal 7 
lesions within the spectroscopic voxel: we estimated that the sample size required to detect a 8 
difference between those two groups with 80% power (alpha 0.05) using the spectroscopy 9 
protocol described in this study would be 168 subjects per group; this finding suggests that 10 
tNAA concentration is lowest in the lesional tissue of the spinal cord, but reduced less 11 
dramatically, in the normal-appearing white matter when compared with the healthy tissue, 12 
which is similar to what has been previously been demonstrated in the brain (Caramanos et 13 
al., 2005). 14 
 15 
Glx, which represents the sum of Glu and its precursor Gln, was also significantly lower in 16 
patients than controls. These changes were most significant in patients with spinal cord 17 
lesions within the spectroscopic voxel and likely reflect changes in the spinal glutamatergic 18 
pathways. As discussed previously, because Glu, which is predominantly found in the 19 
synaptic terminals makes up the majority of the Glx signal, it is possible that lower spinal Glx 20 
in this patient group could, in part, be explained by neuro-axonal degeneration. In the brains 21 
of patients with early PPMS, similar findings have been reported; Glx is reduced in the 22 
cortical grey matter, but not the NAWM (Sastre-Garriga et al., 2005). Similarly, in patients 23 
with clinically stable RRMS, Glu and Glx are both reduced in grey matter regions (Muhlert et 24 
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al., 2014). Together these results would suggest that the reductions in Glx reflect reduced 1 
synaptic density in the grey matter secondary to neuronal loss. In contrast to the control group 2 
(see section 4.2), in patients, we found that Glx did not correlate well with tNAA, which 3 
suggests that impairment of glutamatergic metabolism as well as neuroaxonal loss may occur 4 
in early PPMS, and these metabolites reflect different aspects of the underlying tissue 5 
changes.  6 
 7 
QSI-derived diffusivity was measured parallel and perpendicular to the long axis of the spinal 8 
cord which showed significantly increased perpendicular diffusivity in patients compared 9 
with controls. Data from animal studies suggests that increased perpendicular diffusivity 10 
using QSI is not specific to demyelination (Farrell et al., 2010), as has been reported with 11 
DTI (Song et al., 2002). Instead, the changes in the dPDF shape in this patient group are 12 
likely to reflect a breakdown in myelin and axonal membranes which both act as 13 
microstructural barriers to perpendicular diffusion (Beaulieu, 2002) and corresponds to what 14 
would be expected based on findings from murine and canine models of aberrant myelination 15 
and axonal loss (Biton et al., 2006; Farrell et al., 2010; Wu et al., 2011; Anaby et al., 2013), 16 
as well as to what has previously been reported in patients with relapse-onset MS (Assaf et 17 
al., 2002; Farrell et al., 2008).  18 
 19 
The differences in QSI measures between patients and controls are in agreement with the 20 
tNAA and Glx changes and provide corroborating evidence for early neuroaxonal injury in 21 
the cervical cord. Importantly, in patients with normal appearing spinal tissue within the 22 
diffusion imaging volume, FWHMxy and P0xy remained significantly different to controls, 23 
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whereas ADCxy did not, suggesting that QSI indices are more sensitive to microstructural 1 
injury than conventional ADC measures. 2 
 3 
Interestingly, spinal CSA, a measure of tissue loss, which is often used as an imaging 4 
surrogate of axonal loss (Kearney et al., 2013b) was not significantly different between 5 
patients and controls despite earlier studies with larger sample sizes (Bieniek et al., 2006) and 6 
those which included patients with longer disease duration (Losseff et al., 1996), 7 
demonstrating significant cord atrophy in PPMS. It is therefore likely the reason we did not 8 
detect significant differences in CSA between patients and controls in the current study was 9 
that the sample size was small and patients were selected on the basis of short disease 10 
duration. Based on CSA measures from our cohort of patients and controls, we estimate that 11 
the sample size required to detect significant differences in CSA in early PPMS, using the 12 
method described in this study with 80% power (alpha = 0.05), is 68 subjects per group. 13 
Using measurements obtained from another study of cord atrophy in PPMS (Ruggieri et al., 14 
2015), 41 subjects per group would be required to detect significant group differences. Our 15 
study comprises early duration PPMS, in whom mean cord area differed from controls by 16 
only 4.3mm
2
, compared to a difference of 7.0 mm
2
 in the study by Ruggieri et al, in which 17 
disease duration of the patient group is not reported although patients had similar disability 18 
on EDSS, TWT and HPT as our patient group.  19 
This would suggest that much smaller sample sizes are required to detect group differences 20 
early in the disease course with newer qMRI measures that reflect neurodegenerative 21 
processes other than atrophy alone. We cannot exclude that alternative image segmentation 22 
methods, such as the edge detection and partial volume correction method proposed by Tench 23 
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et al (Tench et al., 2005) may have enabled detection of significant cord atrophy in this 1 
patient group and this merits further study in future. In order to validate these new measures 2 
for clinical trials, it is important to test whether or not these qMRI measures and metabolite 3 
concentrations are sensitive to changes occurring over time and predict clinical outcome at 4 
follow-up. 5 
 6 
In addition to the differences in tNAA, Glx and QSI-derived perpendicular diffusivity 7 
between groups, we found that patients had higher spinal Ins levels than controls but this 8 
finding did not reach statistical significance. We calculated that for Ins, to have 80% power to 9 
detect a patient vs control difference of the size observed (which is about two thirds of a 10 
standard deviation) at 5% significance, 40 subjects per group would be necessary. Patients 11 
with a spinal cord lesion within the spectroscopic voxel did have significantly elevated Ins 12 
concentrations, which is likely to reflect astrocytic proliferation and activation (or gliosis) 13 
occurs in spinal cord lesions in early PPMS. Previous studies have suggested that gliosis is an 14 
early pathological process in MS, and gliosis may be an important mechanism of disease 15 
progression (Ciccarelli et al., 2014). Our results suggest this process is more active in lesional 16 
than non-lesional tissue. With regard to tCho, which is a marker of inflammation and 17 
membrane turnover (Henning et al., 2008; Marliani et al., 2010), since the observed 18 
differences between groups is less than 15% of the SD, it would take hundreds of subjects per 19 
arm to detect such a small difference, suggesting that this metabolite is unlikely to be useful 20 
for distinguishing patients from healthy controls in future studies. 21 
 22 
 23 
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Association between spinal cord metabolites and diffusion indices 1 
The modifications to gradients and pulse lengths necessary to perform QSI on clinical 2 
scanners have the effect of exaggerating the contribution of slow diffusing water to QSI 3 
metrics (Assaf et al., 2002), consequently, diffusion of intra-axonal water is highly 4 
represented (Assaf and Cohen, 2000; Assaf et al., 2000; Assaf et al., 2005) and it has 5 
therefore been suggested that QSI metrics make useful markers of axonal integrity. 6 
Interestingly, in our study, spinal tNAA concentration which reflects axonal integrity 7 
correlated more strongly with QSI derived indices of perpendicular diffusivity than ADC 8 
suggesting these indices are more indicative of axonal integrity. 9 
 10 
Associations between whole cord qMRI measurements and clinical disability 11 
When applying new clinical scales, there is a significant association between increased 12 
clinical disability and lower spinal tNAA and Glx and higher spinal tCho and Ins 13 
concentrations (tables 5.5 and 5.6). Lower Glx and tNAA may be a reflection of neuroaxonal 14 
loss, which is known to be an important substrate for clinical disability in MS (Bjartmar et 15 
al., 2000; Tallantyre et al., 2010). In RRMS, low spinal tNAA has also been shown to 16 
correlate with increased disability scores (Blamire et al., 2007; Ciccarelli et al., 2007) but to 17 
the best of my knowledge, this is the first time spinal Glx concentrations have been reported 18 
in MS. 19 
 20 
Although tCho concentrations were not significantly different between patients and controls 21 
in this cohort, higher tCho in patients did correlate with disability. This is in contrast to 22 
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findings in patients with RRMS, where higher spinal tCho concentrations have been reported 1 
(Henning et al., 2008; Marliani et al., 2010). In RRMS, spinal tCho has been shown to 2 
correlate with higher EDSS scores (Ciccarelli et al., 2007) and it has previously been 3 
proposed that elevated tCho levels reflect breakdown of membranes and ongoing 4 
remyelination within spinal plaques (Marliani et al., 2010).  5 
 6 
Increased perpendicular diffusivity reflects breakdown of myelin and axonal microstructure 7 
which are important determinants of disability. In their feasibility study, Farrell et al 8 
demonstrated that there was an increase in the width and a decrease in the height of the dPDF 9 
in spinal lesions but did not report on correlations with clinical scores (Farrell et al., 2008). 10 
Increased whole cord perpendicular diffusivity in our study, was independently associated 11 
with increased spasticity, vibration perception thresholds and postural instability which 12 
suggests that whole cord QSI may be a potentially useful imaging biomarker of disease 13 
progression. Although it is can be assumed that QSI metrics coming from lesional spinal cord 14 
tissue reflect in part tissue damage at the site of lesions, the contribution of tissue changes 15 
secondary to tract-mediated Wallerian degeneration in axons that traverse lesions at a distant 16 
site, either in the brain or spinal cord (Evangelou et al., 2005) could not reliably be 17 
quantified. 18 
 19 
Associations between column-specific diffusion indices and disability 20 
There were several significant associations which were expected based on a priori knowledge 21 
of spinal WM tract function. Namely, increased perpendicular diffusivity within the anterior 22 
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and lateral corticospinal tracts independently predicted spasticity, whilst instability in the roll 1 
plane and vibration perception threshold was predicted by increased perpendicular diffusivity 2 
in the posterior columns. It is interesting that the effect emerges with the feet wider apart 3 
when the body is normally more stable. It has previously been suggested that part of this 4 
increased stability with increasing stance width arises from hip proprioceptors being 5 
increasingly able to signal lateral sway because of the mechanical linkage between hips and 6 
ankles (Day et al., 1993) which may be degraded when there is posterior column pathology. 7 
Higher ADCxy in the anterior column predicted instability in the pitch plane which suggests 8 
that pitch plane abnormalities are predominantly due to problems of motor organisation or 9 
coordination. The coordination of joints is probably more demanding in the sagittal (pitch) 10 
plane since there are more degrees of freedom due to independent action of leg joints. In 11 
contrast, in the frontal (roll) plane the knees cannot contribute much to instability while the 12 
ankle and hips are no longer independent (Day et al., 1993).  13 
 14 
 15 
Limitations  16 
There are a number of limitations of the current study which should be noted. Firstly, there is 17 
a subtle age and gender mismatch between the patient and control groups despite best efforts 18 
to match the groups. The age difference between the groups was not statistically significant 19 
and when assessing group differences in MRI measures, I used a regression analysis 20 
correcting for age and gender which will have corrected for these small differences. 21 
 22 
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Secondly, although the MRS protocol reliably quantified Glx (Glu + Gln) in the spinal cord 1 
for the first time in an MS patient group, separate information about Glu and Gln could not be 2 
derived. Strategies for separating Glu and Gln at 3T have already been discussed in Chapter 3 
4; future technical developments should aim to allow direct measurement of Glu with no Gln 4 
overlap in order to allow a more specific evaluation of the role of Glu in MS 5 
pathophysiology. 6 
Thirdly, although we acknowledge there is always a risk of spuriously significant results at 7 
5%, with Type 1 error, we have not corrected for multiple comparisons within this study. 8 
Corrections for multiple comparisons are typically appropriate when there is a single null 9 
hypothesis which is tested using a number of comparisons, and where the significance of any 10 
one of these comparisons is sufficient to reject the single hypothesis or when multiple tests 11 
are individually reported or highlighted not because of their relevance to prior individual 12 
hypotheses of interest, but because of being statistically significant (Rothman, 1990; 13 
Perneger, 1998). In the current  study we were not examining a single null hypotheses, but 14 
several; we are reporting significant and non-significant results, and highlighting the former 15 
in relation to prior and plausible hypotheses. Where similar tests were used (eg. in the case of 16 
the postural stability measures), a multivariate statistical approach was used to reduce the risk 17 
of Type 1 errors. It should also be noted that methods employed for multiple comparison 18 
corrections such as the Bonferroni test do not completely eliminate the risk of Type 1 error 19 
and could potentially eliminate genuinely significant results as spurious and in the context of 20 
scientifically exploratory, hypothesis-generating context, the consequences of Type 2 error 21 
can be at least as important as Type 1 error (Rothman, 1990; Perneger, 1998). We therefore 22 
prefer to consider any borderline significant results as hypothesis-generating which can form 23 
the basis for future research.  24 
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Finally, although a state-of-the-art spinal cord QSI sequence was used in this study, the 1 
smaller gradients and longer gradient pulses needed to perform QSI on a clinical scanner 2 
have the effect of narrowing the PDF produced by Q-space analysis, leading to an under-3 
estimate of the FWHM. As discussed in earlier chapters, it has therefore been proposed that 4 
these should be considered as, apparent values (Assaf et al., 2005; Farrell et al., 2008). 5 
Therefore direct comparison with previously published studies should be made with care, and 6 
only after taking into account differences in gradient settings. 7 
 8 
Future directions 9 
A future longitudinal extension of the current study should investigate whether QSI and MRS 10 
measures are predictive of future disability and cord atrophy. Further work is still needed to 11 
assess how closely longitudinal changes in imaging measures reflect clinical change in order 12 
to validate the use of these advanced spinal cord imaging protocols as potential imaging 13 
biomarkers of the future. 14 
 15 
 16 
 17 
  18 
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 1 
  2 
Chapter Six 
Mechanisms of spinal neurodegeneration and repair in 
RRMS 
As discussed in Chapter 1, data from earlier pathological, imaging and animal studies have identified a 
number of viable disease mechanisms to explain the neurodegenerative and repair pathways in multiple 
sclerosis which are responsible for clinical outcomes. Within Chapter 6, by utilising the imaging 
measures used in Chapter 5, within a longitudinal study design, I will aim to determine the contribution 
of spinal neuroaxonal loss and dysfunction, glutamate-mediated excitotoxicity, gliosis and repair 
mechanisms to clinical outcomes following spinal cord relapse in RRMS. 
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6.1 Introduction 1 
Relapsing remitting multiple sclerosis (RRMS) is characterised by episodic clinical relapses, 2 
associated with inflammatory plaque formation within the central nervous system. 3 
Inflammatory demyelination, axonal transection and oedema associated with acute lesions 4 
cause transient interruption to normal salutatory conduction, giving rise to clinical symptoms. 5 
With time, clinical recovery can occur but may be incomplete or even absent, depending 6 
upon a complex interaction between neurodegenerative and repair mechanisms(Compston 7 
and Coles, 2002).  8 
 9 
In early RRMS, clinical relapses are often followed by complete recovery, whereas in later 10 
disease, there is increased chance disability will persist and even, evolve to secondary, 11 
disability progression (Confavreux et al., 2000; Lublin et al., 2003; Confavreux and Vukusic, 12 
2006b). Imaging and pathology studies suggest neuroaxonal loss is the substrate for disability 13 
progression (De Stefano et al., 1998; Bjartmar et al., 2000; Frischer et al., 2009; Tallantyre et 14 
al., 2010). In contrast, resolution of inflammation, remyelination, and electrophysiological 15 
adaptation may underlie clinical recovery (Craner et al., 2004a; Black et al., 2007; Hartley et 16 
al., 2014; Olsen and Akirav, 2014). Understanding the mechanisms of neurodegeneration and 17 
repair following clinical relapses is critically important as they may represent modifiable 18 
biological processes which can be targeted by novel therapies.  19 
 20 
Inflammatory demyelination is thought to account for a proportion of axonal damage (Trapp 21 
et al., 1998; Reynolds et al., 2011) and in early disease, there is some evidence that 22 
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aggressive immunomodulation may slow the neurodegeneration underlying disability 1 
progression (Coles et al., 2008). However, as discussed in Chapter 1, evidence from 2 
epidemiological, imaging and laboratory studies suggest that non-inflammatory mechanisms 3 
also play an important role.  4 
 5 
Measurements obtained using high b-value Q-space imaging (QSI) and 
1
H-MR spectroscopy 6 
(
1
H-MRS), as discussed earlier (Chapter 2), reflect biological processes which may be 7 
important in spinal neurodegeneration and repair following acute attacks. In the current study, 8 
I will therefore employ a combination of spinal MRS and QSI to investigate four important 9 
biological mechanisms and their effect on disability following acute spinal cord relapse; 10 
specifically: 11 
1. The effect of spinal tNAA and perpendicular diffusivity, which reflect neuronal 12 
density, mitochondrial function and myelination on acute disability following spinal 13 
cord relapse and disability progression over 6 months. 14 
2. The effect of spinal glutamate-glutamine (assessed using MRS) on disability 15 
following spinal cord relapse and disability progression over 6 months. 16 
3. The effect of spinal inositol, an imaging marker of gliosis (assessed using MRS) on 17 
disability following spinal cord relapse and disability progression over 6 months. 18 
4. The relationship between temporal QSI changes which may reflect underlying 19 
remyelination and repair on clinical recovery following spinal cord relapse.   20 
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6.2 MATERIALS AND METHODS 1 
6.2.1 Study participants 2 
Patients with an established diagnosis of RRMS (Polman et al., 2011), aged between 18 – 65 3 
years, within 4 weeks of developing symptoms consistent with cervical cord relapse were 4 
prospectively recruited, along with, age and gender matched healthy controls. All subjects 5 
provided written, informed consent prior to taking part in the study. 6 
 7 
6.2.2 Clinical Assessments 8 
Patients were clinically assessed at baseline, 1,3 and 6 months as described in chapter 5 with 9 
the EDSS (Kurtzke, 1983), 9-Hole Peg Test (HPT) (Goodkin et al., 1988), Timed 25-foot 10 
Walk Test (TWT) (Cutter et al., 1999), Multiple Sclerosis Walking Scale-12 (MSWS-12) 11 
(Hobart et al., 2003), Modified Ashworth Scale (MAS) (Bohannon and Smith, 1987), mean 12 
grip strength using the Jamar hydraulic dynamometer (Sammons Preston Incorporated, 13 
Bolingbrook, IL, USA) (Svens and Lee, 2005), VPTs using the biosthesiometer (Bio-Medical 14 
Instrument Company, Newbury, Ohio) and postural instability (Bunn et al., 2013).  15 
 16 
6.2.3 MRI Protocol  17 
Patients and controls were scanned at baseline, 1, 3 and 6 months using a 3T Achieva system 18 
(Philips Medical Systems, Best, Netherlands), whilst wearing a cervical collar as described in 19 
earlier chapters.  20 
At each of the 4 time points, patients and controls were scanned with the following protocol: 21 
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1. Single voxel spinal MRS protocol (Section 4.2.2.2). 1 
2. Fat-suppressed 3D slab-selective fast field echo (FFE) spinal cord sequence (Section 2 
4.3.2.2).  3 
3. Spinal cord QSI (Section 5.2.3). 4 
4. Pre-contrast brain PD/T2 weighted dual-echo TSE sequence (Section 5.2.3). 5 
5. Pre-contrast brain 3D T1-weighted magnetisation-prepared gradient-echo sequence 6 
(Section 5.2.3). 7 
 8 
In patients only, post-gadolinium scans of the brain and cervical spine (Figure 6.1) were 9 
acquired at baseline, five minutes after administration of 0.2ml per kg Dotarem (Guerbet, 10 
France). The purpose of the post-contrast images was to confirm that relapse symptoms were 11 
due to a new inflammatory lesion within the cervical spinal cord. Post-contrast images of the 12 
spinal cord were acquired using a sagittal T1-weighted TSE sequence [parameters: TR = 502 13 
ms; TE = 8 ms; flip angle α = 90°; FOV= 259 x 160 mm2; voxel size = 0.8 x 1 x 3 mm3; NEX 14 
= 3; 14 axial contiguous slices]. Post contrast brain images were acquired using an axial 15 
oblique T1-weighted spin echo sequence [parameters: TR = 625 ms; TE = 10 ms; flip angle α 16 
= 90°; FOV= 240 x 180 mm
2
; voxel size = 1 x 1 x 3 mm
3
; NEX = 1; 50 axial contiguous 17 
slices].   18 
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 1 
 2 
 3 
 4 
 5 
6.2.4 Post processing 6 
Spinal cord metabolite quantification:  7 
Metabolite concentrations were quantified using the user-independent LCModel (version 6.3) 8 
package (Provencher, 1993) and a set of basis spectra simulated using GAMMA (Smith et 9 
al., 1994) as previously described (Section 4.2.2.3). tNAA, tCho, Cr, Ins and Glx 10 
concentrations were quantified using the unsuppressed water signal obtained from the same 11 
voxel as a reference (Gasparovic et al., 2006) and formed the focus of our analysis. Overall 12 
spectral quality was assessed as described in chapter 5 (Section 5.2.4). 13 
 14 
Figure 6.1 Pre and post-contrast spinal and brain images from a patient participating in the study. 
A) Shows a sagittal proton density scan showing spinal cord lesion at the level of C2/3 with 
associated swelling. B) Shows sagittal T1w post-contrast scan showing patchy contrast 
enhancement. C) Shows a single axial slice from the T1w post –contrast brain scan which confirms 
the absence of any active inflammatory lesions but the presence of hypointense lesions, in 
agreement with a diagnosis of MS. 
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Spinal cord area measurement:  1 
Image segmentation and CSA measurements were performed as described in Section 5.2.4. 2 
The mean cross-sectional area of three slices was then calculated. 3 
 4 
Post processing of DWI and ROI analysis:  5 
Post-processing of DWI data is fully described in Section 5.2.4. Voxel-wise maps of the full 6 
width at half maximum (FWHM), zero displacement probability (P0), and apparent diffusion 7 
coefficient (ADC) were derived for both xy and z directions using a constrained non-linear 8 
least squares fitting algorithm. 9 
 10 
To assess region specific differences in QSI metrics, the whole 60mm length of cervical 11 
spinal cord was first extracted from CSF and other tissue types, and four regions of interest 12 
(ROIs) were created using the ROI tool in JIM 6.0 and drawn on the b0 images for each axial 13 
slice. ADC and QSI indices were measured from ROIs in the anterior, right lateral, left lateral 14 
and posterior columns, as well as whole cord. No statistical differences were found between 15 
Q-space indices from the right and left lateral columns; therefore for ease of analysis a mean 16 
value from both columns was calculated for each of the Q-space indices. 17 
 18 
Brain grey matter and white matter volumes:  19 
WM and GM fractional (WMF and GMF) volumes, relative to total intracranial volume (the 20 
sum of GM, WM and CSF volumes), were calculated as described in Section 5.2.4.  21 
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Brain T2 Lesion Volumes: 1 
Brain T2-lesion volume (T2LV) was calculated as described in Section 5.2.4. 2 
 3 
6.2.5 Statistical analysis  4 
Cross-sectional adjusted differences in spinal cord imaging measures between patients and 5 
controls at the four time points were estimated from linear mixed models over all four time 6 
points with random coefficients for subject id intercept and time: the variable compared was 7 
regressed on categorical time point indicators, a group indicator, a group X time interaction 8 
term, and age and gender, from which differences at each time points were estimated.  The 9 
advantage of such models, compared to separate models at each time point, is that all 10 
available data points contribute to estimation, and adjustment for age and gender is better 11 
estimated when all time points are simultaneously modelled.  12 
 13 
Associations between baseline spinal cord imaging measures and acute disability at baseline 14 
were examined with multiple regression of the clinical variables on the spinal cord imaging 15 
measure as predictor, with the following potential confounders as covariates: age, gender, 16 
mean cord area, brain T2 lesion volume, GMF and WMF; because of the large number of 17 
covariates, these were entered singly into the model. Where significant univariate 18 
associations were not materially affected by entering confounders into the model as 19 
described, the unadjusted association is reported. Where entering any of the covariates 20 
resulted in confounding of the association, the association is regarded as non-significant and 21 
has not been reported.  22 
 23 
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In order to examine temporal changes in imaging measures associated with repair, patients 1 
were classed as “improvers” (EDSS change of ≤ -0.5 over 6 months), or “non-improvers” (no 2 
improvement on EDSS). Adjusted differences between improvers and controls, as well as, 3 
non-improvers and controls were obtained by multiple regression of the relevant imaging 4 
measure on a subject type indicator, with age, gender and CSA as covariates. A similar 5 
analysis was then repeated but instead of patients being divided based on EDSS change, they 6 
were categorised based on imaging findings, as either, “radiologically confirmed relapse” 7 
(includes patients with acute spinal cord swelling or enhancement at baseline, or those in 8 
whom C1-3 lesions had resolved by 6 month follow up) or “radiologically ambiguous cases” 9 
(static spinal MRI appearances during 6 month follow up).  10 
 11 
Associations between baseline spinal cord imaging measures and changes in clinical scores 12 
examined using linear mixed models as above, but with the clinical score as response variable 13 
and, as predictors, time point indicators, the centred baseline imaging variable, and the 14 
interaction terms between the baseline imaging variable and time points. The following 15 
potential confounders were added separately to the models as covariates: age, gender, CSA, 16 
brain T2 lesion volume, GMF and WMF.  In such models the time point coefficients estimate 17 
the change in clinical score over the relevant time period in subjects with average levels of 18 
the baseline imaging variable (because the centred imaging variable has the mean value 19 
subtracted so that it takes the value zero at its average); and the interaction terms represent 20 
the association between the baseline imaging variable and the clinical change over the 21 
relevant time period.  22 
 23 
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Associations between extent of change in imaging measures and the extent of change in 1 
clinical scores was examined using linear mixed models identical to the above except that 2 
instead of the centred baseline imaging predictor, the centred baseline to six-month change in 3 
the imaging predictor was used.  In such models the time point coefficients estimate the 4 
change in clinical score over the relevant time period in subjects with average six-month 5 
change in the imaging variable; and the interaction terms represent the association between 6 
six-month change in imaging variable and the clinical score change over the relevant time 7 
period.  The same potential confounders as above were added separately to models. 8 
 9 
6.3 Results 10 
 11 
6.3.1 Participant demographics and characteristics 12 
Twenty patients with RRMS and 24 healthy controls were recruited. Two healthy control 13 
subjects were excluded from the study due to incidental spinal pathology identified on 14 
structural imaging. Therefore data from 20 patients and 22 healthy controls were included in 15 
the final analysis (Table 6.1). Due to participant drop out/ non-availability for follow-up, 18, 16 
16 and 15 patients were scanned at 1 month, 3 months and 6 months respectively and 19, 21 17 
and 20 controls were scanned at 1 month (mean 33, SD 7 days), 3 months (mean 95, SD 10 18 
days) and 6 months (mean 184, SD 10 days) respectively.  19 
 20 
Patients had a wide range of disease duration (1 to 27 years) and mild to moderate levels of 21 
disability; further details on patient characteristics, disability and conventional brain MRI are 22 
summarised in Table 6.1. Relapse symptoms, relapse history and disease modifying therapy 23 
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at baseline, presented patient-by-patient are summarised in table 6.2. Nineteen out of 20 1 
patients were treated with three days pulsed IV Methylprednisolone prior to scanning and one 2 
patient (Patient 12, table 6.2), with predominantly sensory symptoms was managed 3 
conservatively.  4 
 5 
Conventional MRI of the cervical cord identified lesions between the level of C1-3 in all 6 
patients. At baseline, cord swelling was seen in four patients and gadolinium enhancement of 7 
spinal lesions was seen in three out of 19 patients receiving contrast (Table 6.3). During the 6 8 
month follow up period, five patients had a further relapse (Patients 1,2,5,9 and 15). Changes 9 
in conventional spinal MRI between baseline and 6 months in patients who completed the 10 
study are summarised in table 6.3. 11 
  12 
 
 
  
194 
 
 Healthy Controls 
(n = 22) 
RRMS Patients 
(n = 20) 
Mean age (SD) 43.7 (11.5) years 40.8 (9.6) years 
Gender 17F: 5M 14F: 6M 
Mean CSA (SD) 82.0 (8.3) mm
2
 75.0 (9.4) mm
2
 
Mean GMF (SD) 0.48 (0.01) 0.48 (0.02) 
Mean WMF (SD) 0.34 (0.01) 0.33 (0.01) 
Mean T2 lesion volume (SD)  7.1 (7.0) ml 
Mean brain parenchymal fraction (SD)  0.80 (0.02) 
Mean disease duration (SD)  8.3 (7.5) years 
Median EDSS (range)  4.5 (2.5 - 6.5) 
Mean TWT (SD)  7.2 (3.4) seconds 
Mean MSWS-12 (SD)  46.5 (12.3) 
Mean summated MAS (SD)  7.9 (8.7) 
Mean HPT (SD)  25.8 (9.5) seconds  
Mean grip strength (SD)  40.1 (24.3) lbs force 
Mean vibration perception threshold (SD)  14.5 (14.1) 
Mean sway, 32cm, EO (SD)   1.30 (1.01) deg/s 
Mean sway, 32cm, EC (SD)  2.41 (2.92) deg/s 
Mean sway, 4cm, EO (SD)   2.62 (3.49) deg/s 
Mean sway, 4cm, EC (SD)  4.90 (9.64) deg/s 
 2 
Table 6.1: Demographics and clinical characteristics of patients and controls at baseline. 3 
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Table 6.2: Description of relapse symptoms, relapse history and current disease modifying therapy of individual patients at baseline. 
Patient Age Disease 
duration 
(years) 
Relapses in 
past 2 
years 
Current DMT Relapse symptoms Time between 
symptom onset and 
baseline scan (days) 
1 41 7 0 Glatiramer acetate Deteriorating mobility, pain, limb weakness, falls. 29 
2 37 2 3 Interferon beta-1a Paraesthesia in all limbs, urinary urgency 30 
3 30 3 2 Nil Decreased sensation in limbs, incoordination, risk of falls. 13 
4 37 3 3 Nil Numbness below costal margin, hands, and slowed walking 19 
5 57 27 0 Interferon beta-1a Stiffness both legs and decreased dexterity hands  47 
6 42 11 0 Glatiramer acetate Bilateral leg heaviness and paraesthesia in hands 19 
7 48 12 2 Interferon beta-1a Bilateral arm and leg heaviness and pains 21 
8 38 11 2 Nil Altered sensation in legs, intermittent arm/finger shaking 16 
9 46 17 5 Nil L’hermitte, Right arm and leg weakness 14 
10 63 23 2 Interferon beta-
1a44mcg 
Bilateral leg weakness and spasms, left hand weakness. 23 
11 43 10 2 Nil Cervical Brown-Sequard syndrome 15 
12 30 1 2 Nil Sensory symptoms below chest, l’hermitte 9 
13 32 2 2 Nil Weakness in legs and increased numbness/decreased dexterity 
in hands 
20 
14 35 3 5 Interferon beta-
1a44mcg 
Weakness both arms and legs – falls 8 
15 45 2 3 Interferon beta-1a Weakness right hand and bilateral leg weakness, decreased 
mobility 
22 
16 47 14 3 Glatiramer acetate Reduced balance with leg spasms. Weak, numb hands  24 
17 25 2.5 4 Glatiramer acetate L’hermittes sign, left arm and leg numbness 27 
18 28 4 0 Nil Bilateral arm and leg weakness, decreased balance 14 
19 42 1.5 4 Interferon beta-1a Bilateral upper and lower limb sensory impairment and pain 9 
20 49 9 0 Nil L’hermittes sign, mild bilateral leg weakness 22 
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Patient Baseline spinal imaging Baseline spine + 
GAD 
Baseline brain + 
GAD 
6 month spinal imaging 
1 Cord atrophied. Large lesion 
at C3/4 and small lesion at 
C1 posteriorly. Patchy signal 
change at C2 anteriorly.  
No enhancement No enhancement Didn’t complete study 
2 Anterior C3/4 lesion with 
local swelling and patchy 
signal change at C4-6. 
No enhancement No enhancement Patchy signal change C4-6 
3 Posterior C1/2 lesion and 
patchy C3-5 change 
No enhancement No enhancement Incomplete resolution of 
C1/2 lesion. Patchy signal 
unchanged 
4 Posterior C3 and C4 lesions 
with mild swelling. Patchy 
change at C5-6 posteriorly. 
Enhancing C3 
lesion 
No enhancement Posterior C3-4 lesions, 
confluent signal change 
C3-5 
5 Predominantly posterior 
lesion at C2. Patchy signal 
change at C3/4. 
No enhancement No enhancement Unchanged 
6 Posterior C3 and C6 lesions 
and anterior C3/4 lesion. 
No enhancement Enhancing lesion 
supraventricular 
WM (left). 
Didn’t complete study  
7 C2 lesion, patchy C3-4 signal 
change. 
Enhancing C2 
lesion. 
No enhancement Some regression of C2 
lesion, otherwise 
unchanged. 
8 Posterior C2/3 lesion No enhancement No enhancement Radiological  resolution 
9 Lesions C2 and C3 
anteriorly. 
No enhancement No enhancement Patchy signal C2-3 with 
remnant of C2 and C3 
lesions. 
10     
11 Large flame lesion C2/3, 
swollen cord. 
Enhancing C2/3 
lesion 
Enhancing lesion 
in left centrum 
semi-ovale 
Small residual signal 
abnormality at C2. 
12 Posterior C3 lesion No enhancement No enhancement Unchanged 
13 Posterior lesion at C1 with 
patchy signal change C2-4. 
No enhancement No enhancement Patchy signal C2-4, partial 
resolution of C1 lesion. 
14 Lesion at C1/2. No enhancement No enhancement Unchanged 
15 Anterior C2 lesion No enhancement No enhancement Unchanged 
16 Posterior C2, C4 lesions No enhancement No enhancement Unchanged 
17 Large posterior lesion C2-3. No enhancement No enhancement Didn’t complete study 
18 Posterior lesions at C3, C4/5 
and C5/6. 
No enhancement No enhancement Didn’t complete study 
19 Posterior C2 lesion No enhancement No enhancement Unchanged 
20 Anterior C3 and posterior C2 
lesions 
Contrast not given (patient withheld 
consent) 
Didn’t complete study 
 
 
Table 6.3: Summary of conventional brain and cervical cord imaging in all patients at baseline and 6 months. 
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6.3.2 Differences in spinal cord measures between patients and controls over the six 
month follow-up period 
 
Reported differences in spinal cord measures between groups are corrected for age, gender 
and CSA at all 4 time points. Differences in CSA were corrected for age and gender only.  
 
Patients had lower CSA at baseline and showed a significant decrease in CSA over 6 months 
(Table 6.4). Patients had lower spinal tNAA at baseline, 1 month and 6 months (but not 3 
months) compared to controls (Figure 6.2 and Table 6.5).  Patients had significantly higher 
spinal Glx concentrations than controls at baseline, but concentrations begin to normalise by 
1 month (Table 6.5). On the diffusion measures, patients had significantly higher 
perpendicular diffusivity (reflected by increased ADCxy and FWHMxy and reduced P0xy) in 
the whole cord and the anterior, posterior and lateral columns, compared with controls at 
baseline. Perpendicular diffusivity remained higher in patients at each time point, reaching 
statistical significance in the whole cord and anterior column at 1 month, anterior, posterior 
and lateral columns at 3 months and all regions of interest at 6 months (Tables 6.6, 6.7, 6.8 
and 6.9).  
 
Time Point 
(months) 
Healthy Controls RRMS Patients  
 
Adjusted difference (95% CI) P-value 
0 
1 
3 
6 
82.02 (8.30) 
82.14 (8.35) 
81.94 (8.42) 
81.97 (8.73) 
75.01 (9.40) 
75.51 (9.45) 
75.53 (8.42) 
75.18 (7.41) 
-7.0087 (-12.36, -1.65) 
-7.3110 (-12.62, -2.01) 
-7.5467 (-12.79, -2.31) 
-9.0139 (-14.20, -3.83) 
0.010    
0.007     
0.005 
0.001  
 
 
Table 6.4: Summary of mean (SD) mean cord cross sectional area (mm
2
) from the cervical cord of 
patients and controls over 6 months and P-values for adjusted group comparisons after correcting 
for age and gender. 
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 Metabolite  Time Point 
(months) 
Healthy 
Controls   
RRMS 
Patients 
Adjusted difference (95% CI) P-value 
tNAA  0 
1 
3 
6 
4.96 (1.62) 
5.22 (1.47) 
4.87 (1.01) 
5.74 (1.56) 
3.32 (1.90) 
4.09 (0.91) 
4.01 (1.88) 
4.00 (1.03) 
-1.3033 (-2.21, -0.40) 
-1.2075 (-2.20, -0.21) 
-0.6802 (-1.68, 0.32) 
-1.8037 (-2.77, -0.83) 
0.005 
0.017 
0.181 
<0.001 
tCho  0 
1 
3 
6 
1.25 (0.46) 
1.33 (0.32) 
1.14 (0.28) 
1.33 (0.27) 
1.21 (0.34) 
1.13 (0.37) 
1.53 (0.55) 
1.09 (0.18) 
-0.0604 (-0.33, 0.21) 
-0.1771 (-0.46, 0.10) 
0.3226 (0.06, 0.59) 
-0.2254 (-0.45, 0.00) 
0.664 
0.213 
0.017 
0.054 
tCr 0 
1 
3 
6 
3.70 (1.23) 
3.69 (1.25) 
3.42 (1.12) 
4.28 (1.00) 
3.43 (0.94) 
3.41 (0.69) 
3.86 (1.57) 
3.24 (1.19) 
-0.3177 (-1.03, 0.40) 
-0.1314 (-0.94, 0.68) 
0.5941 (-0.26, 1.45) 
-1.0770 (-1.94, -0.21) 
0.384 
0.751 
0.174 
0.014 
Ins 0 
1 
3 
6 
4.63 (1.64) 
4.48 (1.64) 
5.12 (2.41) 
5.42 (1.19) 
4.97 (1.72) 
5.00 (1.94) 
6.87 (3.65) 
5.93 (2.13) 
0.2872 (-1.15, 1.73) 
0.5282 (-1.14, 2.19) 
2.3203 (0.70, 3.94) 
0.4520 (-1.16, 2.07) 
0.696 
0.534 
0.005 
0.583 
Glx 0 
1 
3 
6 
5.10 (2.18) 
6.50 (1.96) 
6.46 (2.58) 
7.05 (2.62) 
 
 
 
7.60 (3.71) 
8.10 (3.58) 
6.58 (3.23) 
6.94 (3.08) 
2.534 (0.04, 5.03) 
1.8812 (-0.68, 4.44) 
-0.0232 (-2.18, 2.14) 
-0.1202 (-2.32, 2.08) 
0.047 
0.149 
0.983 
0.915 
 
 
 
 
  
Table 6.5: Summary of mean (SD) metabolite concentrations (mmol/L) from the cervical cord 
of patients and controls over the 6 month follow up and p-values for adjusted group comparisons 
after correcting for age, gender and mean cord area. 
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Figure 6.2: Exemplary post-processed spectra from three healthy controls (A-C) and three patients (D-F) 
acquired at baseline showing reduced tNAA in patients compared to controls. 
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Changes in whole cord QSI indices over 6 months 
QSI Index  Time Point 
(months) 
Healthy 
Controls 
RRMS 
Patients 
 
Adjusted difference (95% CI) P-value 
ADCxy 0 
1 
3 
6 
0.373 (0.05) 
0.397 (0.09) 
0.398 (0.11) 
0.388 (0.08) 
 
0.532 (0.22) 
0.435 (0.09) 
0.456 (0.12) 
0.500 (0.20) 
 
0.1615 (0.08, 0.24) 
0.0305 (-0.05, 0.11) 
0.0357 (-0.05, 0.12) 
0.0998 (0.01, 0.19) 
 
 
<0.001 
0.462 
0.424 
0.026 
 
FWHMxy  0 
1 
3 
6 
0.235 (0.02) 
0.240 (0.02) 
0.242 (0.03) 
0.237 (0.02) 
0.275 (0.03) 
0.261 (0.03) 
0.263 (0.03) 
0.270 (0.04) 
0.0409 (0.02, 0.06) 
0.01922 (0.00, 0.04) 
0.0172 (-0.00, 0.04) 
0.0327 (0.014, 0.05) 
 
 
 
<0.001 
0.030 
0.071 
<0.001 
P0xy 0 
1 
3 
6 
0.204 (0.02) 
0.200 (0.02) 
0.199 (0.03) 
0.202 (0.02) 
 
0.173 (0.02) 
0.184 (0.02) 
0.183 (0.02) 
0.178 (0.03) 
 
-0.0308 (-0.04, -0.02) 
-0.0135 (-0.03, -0.00) 
-0.0133 (-0.03, -0.00) 
-0.0238 (-0.04, -0.01) 
 
<0.001 
0.049 
0.070 
0.002 
ADCz 0 
1 
3 
6 
1.761 (0.08) 
1.760 (0.08) 
1.749 (0.09) 
1.743 (0.07) 
 
 
1.773 (0.11) 
1.773 (0.11) 
1.751 (0.08) 
1.827 (0.32) 
 
 
0.0079 (-0.06, 0.07) 
-0.0801 (-0.15, -0.01) 
-0.0090 (-0.10, 0.08) 
0.0830 (-0.04, 0.20) 
 
 
 
0.811 
0.030 
0.842 
0.173 
FWHMz 0 
1 
3 
6 
0.547 (0.03) 
0.556 (0.03) 
0.546 (0.02) 
0.544 (0.03) 
0.548 (0.02) 
0.547 (0.04) 
0.549 (0.04) 
0.564 (0.06) 
0.0020 (-0.01, 0.02) 
-0.0084 (-0.03, 0.01) 
0.0026 (-0.02, 0.23) 
0.0241(-0.00, 0.05) 
 
0.806 
0.349 
0.802 
0.062 
P0z 0 
1 
3 
6 
0.114 (0.003) 
0.113 (0.01) 
0.114 (0.004) 
0.115 (0.004) 
0.115 (0.01) 
0.115(0.01) 
0.114 (0.004) 
0.114( 0.01) 
0.0008 (-0.00, 0.00) 
0.0017 (-0.00, 0.01) 
0.0000 (-0.00, 0.00) 
-0.0010 (-0.01, 0.00) 
 
0.602 
0.281 
0.995 
0.597 
 
Table 6.6: Summary of mean (SD) diffusivity from the cervical cord of patients and controls 
over the 6 month follow up period and P-values for adjusted group comparisons after 
correcting for age and gender. 
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Changes in anterior column QSI indices over 6 months 
QSI Index  Time Point 
(months) 
Healthy 
Controls 
RRMS Patients 
 
Adjusted difference (95% CI) P-value 
ADCxy 0 
1 
3 
6 
0.364 (0.11) 
0.452 (0.11) 
0.444 (0.12) 
0.445 (0.11) 
 
 
0.620 (0.25) 
0.581 (0.18) 
0.486 (0.15) 
0.605 (0.24) 
 
 
0.2681 (0.17, 0.37) 
0.1354 (0.03, 0.24) 
0.0468 (-0.06, 0.15) 
0.1736 (0.07, 0.27) 
 
 
<0.001 
0.010 
0.392 
0.001 
FWHMxy  0 
1 
3 
6 
0.227 (0.02) 
0.241 (0.02) 
0.240 (0.03) 
0.238 (0.02) 
 
 
 
0.281 (0.03) 
0.272 (0.04) 
0.262 (0.03) 
0.276 (0.04) 
 
 
 
0.0558 (0.04, 0.07) 
0.0320 (0.01, 0.05) 
0.0226 (0.00, 0.04) 
0.0435 (0.02, 0.06) 
 
 
 
<0.001 
0.001 
0.024 
<0.001 
P0xy 0 
1 
3 
6 
0.211 (0.02) 
0.197 (0.02) 
0.201 (0.03) 
0.202 (0.02) 
 
0.167 (0.02) 
0.176 (0.03) 
0.185 (0.03) 
0.171 (0.03) 
 
-0.0454 (-0.06, -0.03) 
-0.0234 (-0.04, -0.01) 
-0.0180 (-0.04, -0.00) 
-0.0360 (-0.05, -0.02) 
 
<0.001 
0.003 
0.037 
<0.001 
ADCz 0 
1 
3 
6 
1.820 (0.14) 
1.793 (0.12) 
1.960 (0.13) 
1.979 (0.12) 
 
 
 
1.866 (0.21) 
1.939 (0.23) 
1.885 (0.12) 
2.107 (0.37) 
 
 
 
0.0468 (-.076, 0.17) 
-0.0209 (-0.15, 0.10) 
-0.0806 (-0.21, 0.05) 
0.1196 (-0.02, 0.26) 
 
 
 
0.457 
0.741 
0.215 
0.096 
FWHMz 0 
1 
3 
6 
0.553 (0.04) 
0.575 (0.03) 
0.565 (0.03) 
0.568 (0.04) 
 
0.547 (0.03) 
0.557 (0.05) 
0.561 (0.05) 
0.582 (0.07) 
 
-0.0043 (-0.02, 0.18) 
-0.0166 (-0.04, 0.01) 
-0.0033 (-0.03, 0.02) 
0.0177 (-0.01, 0.05) 
 
0.699 
0.159 
0.797 
0.267 
P0z 0 
1 
3 
6 
0.113 (0.01) 
0.109 (0.01) 
0.110 (0.004) 
0.109 (0.003) 
 
0.114 (0.01) 
0.111 (0.01) 
0.112 (0.01) 
0.109 (0.01) 
 
0.0013 (-0.00, 0.01) 
0.0018 (-0.00, 0.01) 
0.0024 (-0.00, 0.01) 
-0.0009 (-0.00, 0.00) 
 
0.514 
0.396 
0.267 
0.635 
 
Table 6.7: Summary of mean (SD) diffusivity from the anterior column of patients and 
controls over the 6 month follow up period and P-values for adjusted group comparisons after 
correcting for age and gender. 
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Changes in posterior column QSI indices over 6 months 
QSI Index  Time Point 
(months) 
Healthy 
Controls 
RRMS 
Patients 
 
Adjusted difference (95% CI) P-value 
ADCxy 0 
1 
3 
6 
0.361 (0.08) 
0.388 (0.10) 
0.400 (0.11) 
0.397 (0.10) 
 
 
0.528 (0.24) 
0.439 (0.12) 
0.466 (0.15) 
0.488 (0.19) 
 
 
0.1722 (0.09, 0.26) 
0.0480 (-0.04, 0.14) 
0.0475 (-0.04, 0.14) 
0.0771 (-0.01, 0.17) 
 
 
<0.001 
0.288 
0.314 
0.091 
FWHMxy  0 
1 
3 
6 
0.228 (0.03) 
0.235 (0.03) 
0.235 (0.03) 
0.230 (0.03) 
 
 
 
0.278 (0.05) 
0.260 (0.04) 
0.264 (0.04) 
0.266 (0.05) 
 
 
 
0.0474 (0.02, 0.07) 
0.0209 (-0.00, 0.05) 
0.0218 (-0.00, 0.04) 
0.0299 (0.01, 0.05) 
 
 
 
<0.001 
0.103 
0.092 
0.016 
P0xy 0 
1 
3 
6 
0.208 (0.02) 
0.202 (0.02) 
0.202 (0.03) 
0.206 (0.03) 
 
0.176 (0.04) 
0.186 (0.03) 
0.183 (0.03) 
0.182 (0.03) 
 
-0.0301 (-0.05, -0.01) 
-0.0110 (-0.03, 0.01) 
-0.0133 (-0.03, 0.01) 
-0.0200 (-0.04, 0.00) 
 
0.001 
0.258 
0.019 
0.054 
ADCz 0 
1 
3 
6 
2.076 (0.13) 
2.112 (0.15) 
2.051 (0.11) 
2.048 (0.09) 
 
 
 
2.039 (0.16) 
2.041 (0.16) 
2.020 (0.11) 
2.120 (0.50) 
 
 
 
-0.0472 (-0.13, 0.05) 
-0.0708 (-0.17, 0.03) 
-0.0406 (-0.17, 0.09) 
0.0775 (-0.11, 0.27) 
 
 
 
0.372 
0.177 
0.584 
0.418 
FWHMz 0 
1 
3 
6 
0.601 (0.04) 
0.609 (0.03) 
0.596 (0.03) 
0.593 (0.04) 
 
0.602 (0.03) 
0.599 (0.05) 
0.589 (0.06) 
0.612 (0.08) 
 
0.0010 (-0.02, 0.02) 
0.0080 (-0.03, 0.02) 
-0.0099 (-0.04, 0.02) 
0.0218 (-0.01, 0.06) 
 
0.923 
0.506 
0.487 
0.203 
P0z 0 
1 
3 
6 
0.104 (0.004) 
0.103 (0.01) 
0.103 (0.003) 
0.105 (0.003) 
 
0.105 (0.01) 
0.105 (0.01) 
0.106 (0.01) 
0.105 (0.01) 
 
0.0018 (-0.00, 0.00) 
0.0013 (-0.00, 0.00) 
0.0021 (-0.00, 0.01) 
0.0003 (-0.00, 0.00) 
 
0.235 
0.409 
0.242 
0.869 
 
 
Table 6.8: Summary of mean (SD) diffusivity from the posterior column of patients and 
controls over the 6 month follow up period with P-values for adjusted group comparisons 
after correcting for age and gender. 
  
 
 
  
203 
 
Changes in lateral column QSI indices over 6 months 
QSI Index  Time Point 
(months) 
Healthy 
Controls 
RRMS 
Patients 
 
Adjusted difference (95% CI) P-value 
ADCxy 0 
1 
3 
6 
0.317 (0.06) 
0.328 (0.10) 
0.350 (0.11) 
0.324 (0.08) 
 
 
0.502 (0.23) 
0.395 (0.09) 
0.424 (0.12) 
0.440 (0.17) 
 
 
0.1872 (0.11, 0.27) 
0.0589 (-0.02, 0.14) 
0.0497 (-0.04, 0.13) 
0.1066 (0.02, 0.19) 
 
 
<0.001 
0.161 
0.261 
0.013 
FWHMxy  0 
1 
3 
6 
0.215 (0.02) 
0.218 (0.02) 
0.222 (0.03) 
0.203 (0.05) 
 
 
 
0.265 (0.04) 
0.245 (0.03) 
0.249 (0.04) 
0.255 (0.04) 
 
 
 
0.0509 (0.03, 0.07) 
0.0251 (0.004, 0.05) 
0.0230 (-0.001,0.05) 
0.0529 (0.03, 0.08) 
 
 
 
<0.001 
0.018 
0.056 
<0.001 
P0xy 0 
1 
3 
6 
0.221 (0.02) 
0.214 (0.04) 
0.216 (0.03) 
0.223 (0.02) 
 
0.180 (0.03) 
0.196 (0.03) 
0.193 (0.03) 
0.190 (0.03) 
 
-0.0413 (-0.06, -0.02) 
-0.0165 (-0.03, 0.00) 
-0.0195 (-0.04, -0.00) 
-0.0331 (-0.05, -0.01) 
 
<0.001 
0.069 
0.045 
0.001 
ADCz 0 
1 
3 
6 
1.948 (0.11) 
2.012 (0.13) 
1.941 (0.08) 
1.975 (0.10) 
 
 
 
1.817 (0.45) 
1.772 (0.47) 
1.921 (0.13) 
2.012 (0.38) 
 
 
 
-0.1344 (-0.31, 0.04) 
-0.2409 (-0.42, -0.06) 
-0.0375 (-0.23, 0.15) 
0.0884 (-0.14, 0.21) 
 
 
 
0.127 
0.009 
0.695 
0.690 
FWHMz 0 
1 
3 
6 
0.571 (0.03) 
0.587 (0.03) 
0.574 (0.03) 
0.577 (0.04) 
 
0.541 (0.13) 
0.541 (0.15) 
0.572 (0.05) 
0.598 (0.08) 
 
-1.344 (-0.31, 0.04) 
-0.2409 (-0.42, -0.06) 
-0.0375 (-0.23, 0.15) 
0.03524 (-0.14, 0.21) 
 
0.127 
0.009 
0.695 
0.690 
P0z 0 
1 
3 
6 
0.107 (0.00) 
0.106 (0.00) 
0.107 (0.00) 
0.106 (0.00) 
 
0.104 (0.03) 
0.102 (0.03) 
0.108 (0.01) 
0.108 (0.01) 
 
-0.0031 (-0.01, 0.01) 
-0.0039 (-0.01,0.01) 
0.0003 (-0.01, 0.01) 
0.0011 (-0.01, 0.01) 
 
0.511 
0.416 
0.935 
0.782 
 
Table 6.9: Summary of mean (SD) diffusivity from the lateral columns of patients and 
controls over the 6 month follow up period and P-values for adjusted group comparisons after 
correcting for age and gender. 
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6.3.3 Assessment of acute disability with spinal QSI and MRS 
The regression models used in this section were all adjusted for age, gender, CSA, brain T2 
lesion volume, GMF and WMF.   
6.3.3.1 Associations between whole cord imaging measures and disability at baseline 
In patients, higher tCr and Glx concentrations were independently associated with increased 
disability at baseline. Higher spinal Glx concentrations were associated with increased 
postural instability, and higher spinal tCr were associated with increased EDSS and slower 
completion of the timed walk test (Table 6.10).  
 
Table 6.10: Associations between whole cord measures (predictors) and clinical scores 
(response variables). Unstandardised regression coefficients for imaging measures are 
reported with 95% confidence intervals and p-values. The regression models were adjusted 
for age, gender, CSA, brain T2 lesion volume, GMF and WMF.   
 
Clinical Score Spinal Cord 
Measure 
Regression 
Coefficient 
95 % Confidence 
Interval 
P-value 
EDSS tCr 0.83 0.16, 1.50 P = 0.019 
1/TWT tCr -0.05 -0.08, -0.02 P = 0.006 
Sway 4EO 
Sway 32EO 
Sway 32EC 
Glx 
Glx 
Glx 
0.40 
0.21 
0.32 
0.23, 0.57 
0.14, 0.29 
0.13, 0.52 
P = 0.003 
P = 0.002 
P = 0.010 
Pitch 4EO 
Pitch 4EC 
Pitch 32 EO 
Pitch 32EC 
Glx 
Glx 
Glx 
Glx 
0.40 
0.30 
0.17 
0.25 
0.23, 0.57 
0.11, 0.50 
0.11, 0.24 
0.13, 0.37 
P = 0.003 
P = 0.010 
P = 0.002 
P = 0.005 
Roll 4EO Glx 0.21 0.11, 0.30 P = 0.005 
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6.3.3.2 Associations between column-specific QSI indices and disability at baseline 
Increased perpendicular and parallel diffusivity within the anterior and posterior spinal 
columns was associated with increased disability. Specifically, increased parallel diffusivity 
(increased FWHMz and ADCz) in the anterior column was independently associated with 
higher EDSS, MSWS and TWT. Increased perpendicular diffusivity (higher FWHMxy and 
lower P0xy) in the anterior column was associated with higher MSWS. Increased parallel 
diffusivity (increased ADCz and FWHMz) in the posterior column predicted longer timed 
walk. A summary of these associations is presented in Table 6.11. 
  
Table 6.11: Associations between column-specific measures (predictors) and clinical scores 
(response variables). Unstandardised regression coefficients for imaging measures are 
reported with 95% confidence intervals and p-values. The regression models were adjusted 
for age, gender, CSA, brain T2 lesion volume, GMF and WMF.   
Region of 
interest 
QSI index EDSS 
(Coefficient; CI) 
1/TWT 
(Coefficient; CI) 
MSWS 
(Coefficient; CI) 
Anterior 
Column 
FWHMxy   P = 0.026 
189.38 (25.34, 353.42) 
P0xy   P = 0.023 
-269.82 (-497.22, -42.41) 
ADCz P < 0.001 
4.95 (2.78, 7.12) 
P = 0.011 
-0.19 (-0.33, -0.05) 
P = 0.018 
32.70 (6.23, 59.18) 
FWHMz P = 0.024 
20.88 (3.15, 38.60) 
P = 0.001 
-1.44 (-2.20, -0.68) 
P = 0.006 
234.29 (80.87, 387.59) 
P0z   P = 0.016 
-784.73 (-1394.92,-174.53) 
Posterior 
Column 
ADCz  P = 0.022 
-0.23 (-0.41, -0.04) 
 
FWHMz  P =  0.035 
-1.27 (-2.44, -0.10) 
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6.3.4 Assessing mechanisms of spinal neurodegeneration and repair 
 
6.3.4.1 Evolution of imaging changes in improvers on EDSS versus non-improvers 
After correcting for age and gender, spinal tNAA concentrations were significantly lower in 
improvers and borderline significantly lower in non-improvers when compared with controls 
at baseline. By 6 months, tNAA had normalised in improvers but remains low in non-
improvers. In non-improvers, spinal Glx concentrations are elevated at baseline compared to 
controls, then normalise by 1 month, whereas no significant difference in Glx concentration 
between improvers and controls was observed (Table 6.12 and Figure 6.3). A significant 
rise in tCho was observed in non-improvers at 3 months and a significant fall in tCr was seen 
in improvers at 6 months (Table 6.12).  
After correcting for age and gender, perpendicular diffusivity was significantly higher than 
controls in both improvers and non-improvers at baseline. By month 1, QSI indices of 
perpendicular diffusivity, normalise in improvers and remain normal at 6 months, however in 
non-improvers, perpendicular diffusivity remains higher than controls at 6 months (Table 
6.13 and Figures 6.4 and 6.5).   When examining changes in parallel diffusivity in the two 
groups, parallel diffusivity remains normal in improvers and non-improvers between baseline 
and 3 months but by 6 months, there is a significant increase in FWHMz and borderline 
significant (P=0.086) decrease in P0z in non-improvers compared to controls (Table 6.13 
and Figures 6.4 and 6.6). 
 
 
 
 
 
  
207 
 
Metabolite  Time 
Point 
Healthy 
Controls   
 
Improvers 
 
P-value Non-improvers  
 
P-value 
tNAA  0 
1 
3 
6 
4.96 (1.62) 
5.22 (1.47) 
4.87 (1.01) 
5.74 (1.56) 
3.23 (1.02) 
3.91 (0.97) 
4.34 (2.63) 
4.38 (2.63) 
0.024 
0.046 
0.535 
0.090 
3.39 (1.42) 
4.32 (0.84) 
3.73 (1.06) 
3.76 (0.95) 
0.089 
0.239 
0.028 
0.003 
tCho  0 
1 
3 
6 
1.25 (0.46) 
1.33 (0.32) 
1.14 (0.28) 
1.33 (0.27) 
1.18 (0.29) 
1.04 (0.28) 
1.58 (0.88) 
1.05 (0.22) 
0.759 
0.063 
0.080 
0.077 
1.24 (0.40) 
1.29 (0.46) 
1.51 (0.44) 
1.12 (0.16) 
0.953 
0.973 
0.026 
0.081 
tCr 0 
1 
3 
6 
3.70 (1.23) 
3.69 (1.25) 
3.42 (1.12) 
4.28 (1.00) 
3.23 (0.97) 
3.38 (0.40) 
3.27 (2.27) 
2.73 (0.99) 
0.350 
0.302 
0.946 
0.011 
3.65 (0.90) 
3.46 (0.98) 
4.21 (1.06) 
3.67 (1.26) 
0.991 
0.814 
0.137 
0.257 
Ins 0 
1 
3 
6 
4.63 (1.64) 
4.48 (1.64) 
5.12 (2.41) 
5.42 (1.19) 
4.61 (1.07) 
5.41 (2.32) 
7.16 (5.57) 
5.66 (1.71) 
0.764 
0.322 
0.181 
0.735 
5.32 (2.22) 
4.50 (1.46) 
6.66 (1.90) 
6.12 (2.51) 
0.359 
0.869 
0.141 
0.382 
Glx 0 
1 
3 
6 
5.10 (2.18) 
6.50 (1.96) 
6.46 (2.58) 
7.05 (2.62) 
 
 
 
5.68 (1.59) 
8.28 (4.05) 
7.59 (2.29) 
8.01 (3.92) 
0.650 
0.267 
0.438 
0.582 
10.47 (4.34) 
7.88 (3.49) 
6.24 (3.61) 
5.61 (0.72) 
0.005 
0.445 
0.845 
0.278 
 
 
 
 
 
 
 
 
 
 
Table 6.12: Summary of mean (SD) metabolite concentrations (mmol/l) from controls, 
‘improvers’ and ‘non-improvers’ over the follow up period with P-values for adjusted group 
comparisons after correcting for age and gender. 
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Figure 6.3: Graphs showing evolution of spinal Glx (left) and tNAA concentrations (right) 
over 6 months in ‘improvers’ (EDSS change over 6 months of ≤ -0.5) and ‘non-improvers’ 
(EDSS change over 6 months ≥ 0) compared with controls. 
 
 
QSI Index  Time 
Point 
Healthy Controls   
(n = 22) 
Improvers 
(n = 10) 
P-value Non-improvers 
(n = 10) 
P-value 
FWHMxy  0 
1 
3 
6 
0.235 (0.02) 
0.240 (0.02) 
0.242 (0.03) 
0.237 (0.02) 
0.269 (0.03) 
0.256 (0.02) 
0.256 (0.03) 
0.246 (0.01) 
<0.001 
0.097 
0.171 
0.059 
0.282 (0.04) 
0.265 (0.03) 
0.268 (0.04) 
0.291 (0.05) 
<0.001 
0.016 
0.071 
<0.001 
P0xy 0 
1 
3 
6 
0.204 (0.02) 
0.200 (0.02) 
0.199 (0.03) 
0.202 (0.02) 
 
0.176 (0.02) 
0.187 (0.02) 
0.187 (0.02) 
0.194 (0.01) 
0.001 
0.170 
0.158 
0.144 
 
0.170 (0.03) 
0.182 (0.02) 
0.180 (0.03) 
0.164 (0.03) 
<0.001 
0.047 
0.098 
0.001 
FWHMz 0 
1 
3 
6 
0.547 (0.03) 
0.556 (0.03) 
0.546 (0.02) 
0.544 (0.03) 
0.548 (0.03) 
0.538 (0.04) 
0.552 (0.04) 
0.543 (0.05) 
0.802 
0.122 
0.531 
0.969 
0549 (0.02) 
0.553 (0.04) 
0.546 (0.04) 
0.582 (0.07) 
0.908 
0.927 
0.207 
0.049 
P0z 0 
1 
3 
6 
0.114 (0.003) 
0.113 (0.01) 
0.114 (0.004) 
0.115 (0.004) 
0.114 (0.004) 
0.115 (0.01) 
0.114 (0.01) 
0.118 (0.01) 
0.910 
0.239 
0.840 
0.225 
0.115 (0.01) 
0.114 (0.01) 
0.114 (0.003) 
0.110 (0.01) 
0.411 
0.712 
0.966 
0.086 
 
 
  
Table 6.13: Summary of mean (SD) of whole cord QSI indices from controls, ‘improvers’ 
and ‘non-improvers’ over the follow up period with P-values for adjusted group comparisons 
after correcting for age and gender. 
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Figure 6.4: Graphs showing evolution of mean whole cord FWHMxy (top left), P0xy (top 
right), FWHMz (bottom left) and P0z (bottom right)  over 6 months in ‘improvers’ (EDSS 
change over 6 months of ≤ -0.5) and ‘non-improvers’ (EDSS change over 6 months ≥ 0) 
compared with controls (Error bars +/- 1 SE). 
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Figure 6.5: QSI maps and dPDF’s showing longitudinal change in perpendicular diffusivity 
between an improver and non-improver. In the improver (left), perpendicular diffusivity 
restricts over 6 months, reflected by increasing P0xy and decreasing FWHMxy as seen in the 
QSI maps and dPDF. In the non-improver, there is increased perpendicular diffusion over 6 
months, reflected by decreasing P0xy and increasing FWHMxy with shortening and 
broadening of the dPDF. 
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Figure 6.6: QSI maps and dPDF’s showing longitudinal change in parallel diffusivity 
between an improver and non-improver. In the improver (left), parallel diffusivity restricts in 
the posterior columns over 6 months, reflected by increasing P0z and decreasing FWHMz as 
seen in the QSI maps and dPDF. In the non-improver, there is no restriction of diffusion over 
6 months. 
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6.3.4.2 Evolution of imaging changes in patients with and without MRI confirmation of 
acute spinal cord relapse. 
 
In patients with definite MRI evolution, consistent with spinal cord relapse, after correcting 
for age and gender, spinal tNAA concentrations are low throughout the follow up period and 
do not recover (Table 6.14). In this same group of patients, Glx concentrations appeared 
similar to controls throughout the follow up period.  
In patients without clear evidence on MRI of either acute cord changes (swelling or GAD 
enhancement) or lesion resolution over six months, tNAA concentrations remained similar to 
controls despite the presence of a spinal lesion within the region of interest (Table 6.14). In 
this group Glx concentrations were higher than controls but this difference was only 
statistically significant at 1 month follow up. 
After correcting for age and gender, perpendicular diffusivity was significantly higher in 
patients with definite MRI evolution throughout the follow up period but was not 
significantly different to controls in the group without MRI changes (Table 6.15). 
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Metabolite  Time 
Point 
Healthy 
Controls   
(n = 22) 
MRI evidence 
(n= 8) 
P-value No MRI evidence 
(n=6) 
P-value 
tNAA  0 
1 
3 
6 
4.96 (1.62) 
5.22 (1.47) 
4.87 (1.01) 
5.74 (1.56) 
3.06 (1.02) 
3.81 (0.58) 
3.17 (1.14) 
3.72 (1.16) 
 
0.069 
0.014 
0.002 
0.011 
 
4.17 (1.82) 
4.37 (0.49) 
6.05 (2.66) 
4.54 (0.70) 
 
0.725 
0.096 
0.745 
0.081 
tCho  0 
1 
3 
6 
1.25 (0.46) 
1.33 (0.32) 
1.14 (0.28) 
1.33 (0.27) 
1.10 (0.13) 
1.10 (0.48) 
1.36 (0.44) 
1.10 (0.19) 
 
0.537 
0.346 
0.268 
0.205 
1.35 (0.66) 
1.19 (0.14) 
1.70 (0.88) 
1.04 (0.19) 
 
0.524 
0.374 
0.092 
0.128 
tCr 0 
1 
3 
6 
3.70 (1.23) 
3.69 (1.25) 
3.42 (1.12) 
4.28 (1.00) 
2.89 (0.66) 
3.41 (0.76) 
3.09 (1.26) 
3.05 (1.01) 
 
0.216 
0.456 
0.602 
0.012 
3.69 (1.41) 
3.74 (0.94) 
5.56 (0.97) 
3.00 (1.29) 
 
0.888 
0.884 
0.104 
0.068 
Ins 0 
1 
3 
6 
4.63 (1.64) 
4.48 (1.64) 
5.12 (2.41) 
5.42 (1.19) 
4.27 (1.13) 
5.15 (1.21) 
5.57 (2.70) 
5.70 (2.27) 
 
0.902 
0.199 
0.702 
0.296 
5.94 (0.26) 
5.59 (3.55) 
12.02 (5.22) 
6.61 (2.52) 
 
0.280 
0.244 
0.062 
0.176 
Glx 0 
1 
3 
6 
5.10 (2.18) 
6.50 (1.96) 
6.46 (2.58) 
7.05 (2.62) 
 
 
 
5.63 (1.02) 
6.91 (3.68) 
4.80 (2.24) 
5.91 (2.67) 
 
0.625 
0.475 
0.145 
0.781 
9.39 (5.90) 
11.87 (1.07) 
10.93 (2.44) 
8.99 (3.24) 
 
0.060 
0.040 
0.424 
0.615 
 
 
 
 
 
 
 
 
 
 
 
Table 6.14: Summary of mean (SD) metabolite concentrations (mmol/L) from controls and 
patients with and without MRI evidence of acute spinal relapse. P-values for adjusted group 
comparisons after correcting for age and gender. 
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QSI Index  Time 
Point 
Healthy Controls   
(n = 22) 
MRI evidence 
(n= 8) 
P-value No MRI 
evidence 
(n=6) 
P-value 
FWHMxy  0 
1 
3 
6 
0.235 (0.02) 
0.240 (0.02) 
0.242 (0.03) 
0.237 (0.02) 
0.283 (0.02) 
0.267 (0.03) 
0.269 (0.03) 
0.278 (0.03) 
 
<0.001 
0.016 
0.033 
<0.001 
 
0.256 (0.03) 
0.241 (0.02) 
0.238 (0.02) 
0.238 (0.02) 
 
0.061 
0.553 
0.736 
0.227 
P0xy 0 
1 
3 
6 
0.204 (0.02) 
0.200 (0.02) 
0.199 (0.03) 
0.202 (0.02) 
 
0.166 (0.02) 
0.179 (0.02) 
0.177 (0.02) 
0.171 (0.02) 
 
<0.001 
0.038 
0.030 
<0.001 
 
0.185 (0.02) 
0.198 (0.02) 
0.201 (0.02) 
0.201 (0.02) 
 
0.070 
0.657 
0.761 
0.324 
FWHMz 0 
1 
3 
6 
0.547 (0.03) 
0.556 (0.03) 
0.546 (0.02) 
0.544 (0.03) 
0.543 (0.02) 
0.555 (0.02) 
0.551 (0.04) 
0.556 (0.02) 
 
0.638 
0.857 
0.905 
0.271 
0.554 (0.02) 
0.544 (0.04) 
0.557 (0.04) 
0.540 (0.05) 
 
0.442 
0.897 
0.068 
0.773 
P0z 0 
1 
3 
6 
0.114 (0.003) 
0.113 (0.01) 
0.114 (0.004) 
0.115 (0.004) 
0.114 (0.003) 
0.113 (0.003) 
0.113 (0.003) 
0.115 (0.01) 
 
0.425 
0.779 
0.787 
0.639 
0.111 (0.003) 
0.115 (0.01) 
0.112 (0.01) 
0.115 (0.01) 
 
0.271 
0.862 
0.170 
0.969 
 
 
 
 
6.3.4.3 Baseline imaging predictors of clinical recovery over 6 months in patients. 
In patients, following adjustment for age, gender, CSA, brain T2 lesion volume, GMF and 
WMF, higher baseline spinal Glx concentrations predicted greater decline in postural stability 
over 6 months. A trend was also observed for an association between higher Glx at baseline 
and poorer clinical recovery on the EDSS (borderline significance P=0.075). Higher baseline 
Ins concentrations predicted worse postural stability at 6 months and higher tCr at baseline 
was associated with poor recovery on EDSS. Baseline spinal tNAA and tCho concentrations 
were not significant predictors of recovery over 6 months (Table 6.16). 
 
Table 6.15: Summary of mean (SD) QSI indices from controls and patients with and without 
MRI evidence of acute spinal relapse. P-values for adjusted group comparisons after 
correcting for age and gender. 
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Higher perpendicular diffusivity (increased P0xy and lower FWHMxy) within the whole 
cord, lateral columns and anterior column at baseline, predicted worse recovery in grip 
strength over 6 months. There was also a trend towards improvement in spasticity over 6 
months in patients with lower perpendicular diffusivity in the whole cord at baseline (P = 
0.069) (Table 6.16).  
Table 6.16: Associations between baseline imaging measures (predictors) and change in 
clinical scores over 6 months (response variables). Regression coefficients (reflecting 
predicted change in response variable in someone with average baseline predictor) and 
interaction coefficients for imaging measures, representing association between baseline 
imaging vs six-month clinical change are reported with 95% confidence intervals and p-
Spinal Cord 
Measure  
Clinical Score Regression 
Coefficient 
Interaction 
Coefficient 
95 % CI P-value 
Glx EDSS 
Sway 32 EO 
Pitch 32 EO 
Roll 32 EO 
Sway 32 EC 
Pitch 32 EC 
Roll 32 EC 
-0.448 
0.193 
0.141 
0.102 
0.098 
0.181 
0.125 
0.0651 
0.2032 
0.1456 
0.1138 
0.1610 
0.1258 
0.0782 
-0.01, 0.14 
0.10, 0.30 
0.07, 0.22 
0.06, 0.17 
0.09, 0.24 
0.07, 0.18 
0.04, 0.12 
0.075 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
Ins Romberg 4cm -0.281 0.309 0.07, 0.55 0.012 
tCr EDSS -0.500 0.402 0.11,0.70 0.007 
Cord FWHMxy Grip strength 
MAS 
-5.100 
-2.900 
-223.489 
86.0149 
-393.52, -53.45 
-6.61, 178.64 
0.010 
0.069 
Cord P0xy Grip strength -5.449 313.22 54.41, 572.04 0.018 
Anterior FWHMxy Grip strength -4.658 -276.64 -456.30, -96.98 0.003 
Anterior P0xy Grip strength -5.117 375.93 118.66, 633.20 0.004 
Lateral FWHMxy Grip strength -5.289 -205.3352 -336.60, -74.07 0.002 
Lateral P0xy Grip strength -5.741 298.79 90.37, 507.21 0.005 
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values. The regression models were adjusted separately for age, gender, CSA, brain T2 lesion 
volume, GMF and WMF. 
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6.3.4.4 Associations between temporal changes in MRI measures and clinical disability 
In patients, following adjustment for age, gender, CSA, brain T2 lesion volume, GMF and 
WMF, a greater increase in spinal tNAA concentrations over 6 months was associated with 
greater clinical recovery on EDSS, TWT and Romberg’s test. A greater decrease in Glx over 
6 months predicted worse clinical recovery on the EDSS (Table 6.17).  
 
Restriction in perpendicular diffusivity (decreasing FWHMxy and increasing P0xy) from the 
whole cord and anterior and lateral columns was associated with clinical improvement on the 
EDSS over 6 months. Similarly, restriction of perpendicular diffusivity from the posterior 
column was associated with clinical recovery on EDSS, MSWS, VPT and Romberg’s test 
(Table 6.17).  
 
Increasing parallel diffusivity within the whole cord (decreasing P0z and increasing 
FWHMz) over 6 months was associated with slower completion of the TWT, reduction in 
grip strength and increased spasticity. Within the anterior and posterior columns, increasing 
parallel diffusivity (decreasing P0z) was associated with increased spasticity scores over 6 
months and increasing parallel diffusivity in the posterior columns resulted in slower 
completion of timed walk and loss of grip strength (Table 6.17).  
 
 
  
218 
 
  
Spinal Cord 
Measure  
Clinical Score Regression 
Coefficient 
Interaction 
Coefficient 
95 % CI P-value 
Glx EDSS -0.500 -0.1059 -0.18, -0.04 0.003 
tNAA EDSS 
1/TWT 
Romberg 32cm 
-0.522 
0.012 
-0.397 
-0.5216 
0.0237 
-0.7171 
-0.79, 0.25 
0.01, 0.04 
-1.33, -0.10 
<0.001 
0.006 
0.022 
Cord FWHMxy EDSS -0.560 17.7701 8.19, 27.35 <0.001 
Cord P0xy EDSS -0.564 -23.68672 -36.17, -11.20 <0.001 
Cord FWHMz 1/TWT 
MAS 
Grip 
0.018 
-1.845 
-5.089 
-0.295 
63.567 
-130.299 
-0.53, -0.056 
7.74, 119.39 
-244.29, -16.30 
0.016 
0.026 
0.025 
Cord P0z MAS 
Grip  
-1.860 
-3.595 
-414.027 
1215.655 
-742.47, -85.59 
285.14, 2146.17 
0.013 
0.010 
Anterior FWHMxy EDSS -0.575 9.1622 2.50, 15.82 0.007 
Anterior P0xy EDSS -0.572 -11.4197 -20.58, -2.25 0.015 
Anterior P0z MAS -1.795 -357.904 -687.80, -28.01 0.033 
Posterior FWHMxy MSWS 
VPT 
Romberg 32cm 
-11.850 
-2.068 
-0.719 
-166.6823 
74.9179 
19.1002 
-286.12, -47.25 
14.55, 135.28 
5.43, 32.77 
0.006 
0.015 
0.006 
Posterior P0xy EDSS 
MSWS 
Mean vibration 
Romberg 32cm 
-0.540 
-11.780 
-1.634 
-0.611 
-13.0379 
268.4052 
-101.6042 
-23.0482 
-22.96, -3.11 
81.78, 455.03 
-185.99, -17.21 
-42.78, -3.31 
0.010 
0.005 
0.018 
0.022 
Posterior FWHMz 1/TWT 
Grip 
0.018 
-5.432 
-0.255 
-109.160 
-0.45, -0.06 
-197.70, -20.62 
0.010 
0.016 
Posterior P0z 1/TWT 
Grip 
0.018 
-4.912 
1.685 
960.839 
0.20, 3.17 
167.84, 1753.84 
0.026 
0.018 
Lateral FWHMxy EDSS -0.574 16.5759 6.71, 26.44 0.001 
Lateral P0xy EDSS -0.577 -24.4868 -35.59, -13.38 <0.001 
Lateral P0z MAS -2.495 -178.334 -289.20, -67.47 0.002 
Table 6.17: Associations between rate of change in imaging measures (predictors) and rate of change in clinical 
scores over 6 months (response variables). Unstandardised regression coefficients (reflecting predicted change in 
response variable in someone with average change predictor over 6 months) and interaction coefficients for 
imaging measures representing association between six-month imaging change vs six-month clinical change, are 
reported with 95% confidence intervals and p-values. The regression models were adjusted for age, gender, 
CSA, brain T2 lesion volume, GMF and WMF. 
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6.4 Discussion 
By combining spinal cord QSI and MRS techniques, this longitudinal study has provided 
novel insights into the mechanisms of spinal cord neurodegeneration and repair following 
spinal cord relapse in RRMS.  Results from this study suggest that neurodegeneration with 
demyelination may be important substrates for persistent disability following spinal cord 
relapse and that glutamate excitotoxicity and axonal metabolic dysfunction may contribute to 
observed disability progression. Based on the findings of the study we propose restoration of 
normal axonal metabolism and remyelination of spinal axons may be important repair 
mechanisms associated with clinical recovery. 
  
Spinal total N-acetyl aspartate (tNAA), its temporal evolution and role in spinal 
neurodegeneration and repair 
At baseline, spinal tNAA concentrations were lower in patients than controls, reflecting 
axonal loss and/or axonal metabolic dysfunction. This finding is in keeping with changes 
seen in the PPMS cohort (Chapter 5) and previous MRS studies assessing acute changes 
associated with MS relapse (De Stefano et al., 1995a; De Stefano et al., 1998; Ciccarelli et 
al., 2010a; Ciccarelli et al., 2010b). Over the 6 month follow up period, tNAA concentrations 
were seen to rise, and normalise by month 3, in keeping with previous studies which also 
demonstrated reversible decreases in tNAA during recovery from acute MS brain lesions 
(Davie et al., 1994; De Stefano et al., 1995b; Mader et al., 2000; Tiberio et al., 2006), acute 
disseminated encephalomyelitis (ADEM) (Bizzi et al., 2001) and acute MS spinal lesions 
(Ciccarelli et al., 2010a; Ciccarelli et al., 2010b). The current study differs from earlier 
studies in that tNAA concentrations fell again at month 6 (Table 6.4). This difference can be 
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understood by looking at the sub-group analysis (‘improvers’ versus ‘non-improvers’), which 
confirms that the recovery in tNAA concentrations which is sustained in ‘improvers’ at 6 
months, whereas, in ‘non-improvers’, tNAA concentrations remain lower than controls at 3 
and 6 months (Table 6.12, Figure 6.3). The fall in tNAA in the ‘non-improvers’ is likely to 
reflect metabolic/structural changes occurring as a consequence of a second relapse event in 
that group (occurring in 5 out of 10 patients within the sub-group). Within the second sub-
group analysis, tNAA concentrations were significantly lower in the group of patients with 
imaging changes most consistent with the clinical diagnosis of acute cervical spine relapse 
(acute cord swelling/GAD enhancement or resolution of C1-3 lesion on 6 month follow up), 
whereas changes in tNAA did not reach statistical significance in the six patients without 
those changes (Table 6.14). It might be expected that tNAA changes are greatest in patients 
with the greatest/ most dynamic changes on conventional imaging which might account for 
this difference. Alternatively, it is possible that relapse symptoms reported by patients were 
caused by a lesion at a site other than C1-3. In those six patients, five had new neurological 
symptoms in both arms and legs, which clinically is highly suggestive of cervical cord 
relapse. The sixth patient (patient 12) reported a new upper thoracic sensory level and 
L’hermitte’s symptoms and it may be possible symptoms in this patients case were caused by 
a lesion in the upper thoracic cord. 
 
Unlike in early PPMS (Chapter 5), lower spinal tNAA concentrations at onset of spinal cord 
relapse did not correlate with disability, nor did they predict recovery from relapse, which is 
in keeping with findings from previous studies of acute spinal relapse (Ciccarelli et al., 
2010a). However, the recovery in tNAA concentrations over 6 months was an important 
determinant of clinical recovery; recovery in tNAA was associated with recovery on EDSS, 
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TWT and postural stability (Table 6.17, Figure 6.3).  In similarly designed studies, reversal 
of tNAA in the brain (De Stefano et al., 1998) and spinal cord (Ciccarelli et al., 2010a; 
Ciccarelli et al., 2010b) were also associated with clinical recovery, suggesting that tNAA 
changes reflect a clinically important biological process.  
 
As discussed in earlier chapters, tNAA is considered a marker of neuronal density and 
mitochondrial metabolism. Given that axonal regeneration seems an unlikely explanation for 
the recovery in tNAA, the two most plausible explanations are either; a) there is resolution of 
transient axonal metabolic dysfunction or b) the initially low tNAA concentrations are due to 
a dilutional effect, occurring as a consequence of tissue oedema and resolution of oedema 
results in restoration of normal concentrations. Although in the current study, it was not 
feasible to correct for water content directly, a similarly designed study, examining changes 
in water content and tNAA concentrations in new MS brain lesions over six months found 
that water content changes were insufficient to account for all of the recovery of tNAA 
following relapses (Vavasour et al., 2011). In the current study, we corrected for the effect of 
oedema on metabolite quantification, indirectly, by co-varying CSA in the statistical model. 
We observed a significant relative reduction in CSA in patients at 6 months (mean annualised 
rate of cord atrophy of 4.02mm
2
) compared to baseline which could reflect, either, axonal 
loss, resolution of vasogenic oedema, or a combination of the two. The annualised rate of 
atrophy observed in our patient cohort is greater than those reported in early RRMS cohorts 
(mean -0.890mm
2
 per annum) (Rashid et al., 2006) and in RRMS treatment trials (mean -
1.9mm
2
 in interferon-beta treatment arm and -2.2mm
2
 in placebo arm) (Lin et al., 2003). This 
would suggest the reduction in CSA seen in our patient group represents a combination of 
axonal loss and resolution of oedema. The reduction in tNAA observed in patients at 
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baseline, and subsequent recovery, occurred independently of CSA, suggesting that oedema 
alone, if present, would not fully explain these changes.  
 
Autopsy studies have shown that in acute MS lesions, intra-axonal mitochondrial complex IV 
function is impaired and correlates with the numbers of microglia and infiltrating 
inflammatory cells (Mahad et al., 2008). This inhibitory effect is thought to be mediated 
through reactive oxygen species (Friese et al., 2014) and in fact, in animal models of MS, 
exogenous anti-oxidants are able to ameliorate this observed mitochondrial dysfunction (van 
Horssen et al., 2012). Taken together, these findings suggest axonal mitochondrial function 
might be impaired during an acute inflammatory episode but could be restored following 
resolution of inflammation. Evidence that this transient metabolic dysfunction is sufficient to 
cause symptoms comes from an imaging study which modelled the metabolic component of 
the tNAA resonance from the spinal cord following spinal cord relapse; the study found that 
the metabolic component of tNAA was closely associated with disability measured on the 
EDSS (Ciccarelli et al., 2010b). Restoration of neuronal metabolism may therefore be an 
important process for repair and recovery. Where this recovery does not take place, it is 
thought it will eventually lead to axonal loss (Friese et al., 2014), which would account for 
the persistent disability in patients whose tNAA concentrations remain low. 
 
Other potential explanations for the recovery in tNAA concentrations could be that a change 
in tissue chemistry during a relapse has a reversible effect on tNAA relaxation time. 
However, if this were the case, it might be expected that similar temporal evolution is seen 
with other metabolites which was not the case.  Alternatively, it has previously been proposed 
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that a proliferation of oligodendrocyte progenitor cells (which  also contain NAA),  necessary 
for remyelination and repair may explain the increase (Davie et al., 1994).  
 
Glutamate-glutamine (Glx), its temporal evolution and role in spinal neurodegeneration 
and repair 
At baseline, spinal Glx concentrations were elevated compared with controls and associated 
with acute disability (Table 6.10). Similar increases in Glx (Cianfoni et al., 2007) and Glu 
(Srinivasan et al., 2005) have been reported in acute MS brain lesions but associations with 
acute disability have not, to our knowledge, previously been assessed. In the current study, 
Glx concentrations normalise by 1 month, then remain at normal levels for the remainder of 
the follow-up period (Table 6.4). From the sub-group analysis, it is evident that the rise in 
Glx at baseline is largely driven by patients who did not recover from their relapse; whom 
display a roughly 2-fold increase in spinal Glx when compared with healthy controls (Table 
6.12, Figure 6.3). This finding mirrors earlier reports of a 2 to 3 fold increase in CSF 
glutamate concentrations in RRMS patients during acute relapses and normal concentrations 
in clinically stable patients (Stover et al., 1997; Sarchielli et al., 2003). The temporal 
evolution of Glx observed in the current study would also be in keeping with current 
understanding of glutamate-mediated excitotoxicity in MS (discussed in more detail in 
Chapter 1). Experimental and animal models suggest that excitotoxic injury to neurones in 
MS may be mediated through prolonged activation of NMDA and AMPA/kainite receptors 
(Piani et al., 1991; Piani et al., 1992), and that the source of excess glutamate is likely to be 
infiltrating, inflammatory cells (Piani et al., 1991; Werner et al., 2000; Werner et al., 2001). 
It would therefore be expected that glutamate levels will be at their highest at the onset of a 
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clinical relapse when inflammation is greatest and that concentrations would decline as 
inflammation ebbs. 
 
Elevated Glx at baseline was an important predictor of clinical status at 6 months; higher 
baseline concentrations of spinal Glx predicted a deterioration in postural stability over 6 
months (Table 6.16) and was associated with poorer recovery on the EDSS, though this 
association did not reach statistical significance (P=0.075) (Table 6.16). Decline in Glx 
concentrations over 6 months was associated with a fall in EDSS score of 0.5 (in patients 
experiencing an average decline in Glx) (Table 6.17). Where there were greater falls in Glx 
over 6 months (indicating higher baseline Glx concentration, rather than lower concentrations 
at 6 month follow-up), there was significantly less recovery on EDSS (Table 6.17). 
Assuming, infiltrating, inflammatory cells are the source of excess Glx, it could be inferred 
that acute spinal cord inflammation is an important predictor of disability at 6 months. 
However, there are two important caveats to bear in mind. Firstly, natural history cohorts 
have shown that relapses (the clinical correlate of acute inflammation), do significantly 
impact on disability, but only in early disease (Confavreux et al., 2003; Tremlett et al., 2009), 
and are less relevant to disability progression in later disease (Tremlett et al., 2009; Scalfari 
et al., 2010). Within our cohort, baseline spinal Glx concentrations were higher in patients 
with early (< 5 years) disease (n=10) compared to later (> 5 years) disease (n=10); mean 9.4 
vs 5.7 mmol/l respectively, which supports the epidemiological data and would suggest that 
inflammation may be an important predictor of disability in early disease, and less important 
in later disease. Secondly, how disability is measured is important; natural history cohorts 
which have assessed the relationship between relapses and disability have measured disability 
with the DSS or EDSS, which due to their nonlinearity, are disproportionately insensitive to 
 
 
  
225 
 
smaller clinical changes in advanced disease (Chapter 1). Within our study, the relationship 
between baseline Glx and change in EDSS over 6 months did not reach statistical 
significance, whereas when a more linear measure of disability, such as postural stability is 
employed, the predictive value of baseline Glx is much more significant.  
 
Taken together, these results provide evidence to support one of two hypotheses; either 
i)glutamate-mediated excitotoxic injury occurs in some patients during the initial stage of 
lesion formation and subsequent axonal injury is the key determinant of clinical outcomes or 
ii) measured rises in Glx simply reflect inflammation and inflammatory damage to axons 
(Trapp et al., 1998) determines clinical outcomes. These findings may have important clinical 
implications when planning neuroprotective trials as the administration of glutamate-receptor 
antagonists might only be of neuroprotective benefit in the acute phase. 
Total creatine (tCr), its temporal evolution and role in spinal neurodegeneration and 
repair 
At baseline, tCr concentrations were not significantly different to controls, but higher 
baseline tCr was associated with increased baseline disability measured on the EDSS and 
TWT (Table 6.10), in keeping with findings from earlier, similarly designed studies 
(Ciccarelli et al., 2007) and worse recovery on the EDSS over 6 months (Table 6.16). During 
the follow up period, tCr concentrations fall at 6 months (Table 6.4); with the greatest 
decline in tCr occurring in patients who recover from their relapse (Table 6.12), suggesting 
that either, falling tCr is a marker of repair or persistently raised tCr reflects a 
neurodegenerative pathway. 
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The tCr resonance represents the sum of creatine (Cr) and phosphocreatine (PCr) (Chapter 
2), which are intermediaries in the ATP-generating, creatine kinase reaction. Neuronal 
concentrations of Cr and PCr are thought to remain fairly stable in healthy individuals 
(Saunders et al., 1999) but are increased in relapsing and progressive forms of MS (Inglese et 
al., 2003; Tur et al., 2014), which may reflect a neuronal metabolic response to structural 
tissue damage (Tur et al., 2014). Glial cells can contain between two to four times the 
concentrations of tCr found in neurons (Urenjak et al., 1993) and the variability in tCr 
concentrations in MS has therefore been regarded by some as a marker of gliosis (Inglese et 
al., 2003). Based on the findings of the current study, two hypotheses could be generated to 
explain the temporal changes in tCr; one potential explanation is that higher tCr in acute 
lesions reflects a metabolic response to an acute tissue damage and as tissue repair occurs, the 
metabolic requirement decreases, and is seen as a fall in tCr (in improvers). Where repair 
does not occur (non-improvers), tCr remains persistently elevated. Alternatively, astrocyte 
proliferation seen histologically within newly formed MS plaques (Popescu et al., 2013), 
might partly determine acute disability and predicts whether or not recovery and repair can 
take place. Persistent astrogliosis is one of the features of chronically demyelinated plaques in 
which substantial loss of axons and oligodendrocytes has occurred (Popescu and Lucchinetti, 
2012; Popescu et al., 2013) and it is possible that persistently elevated tCr in patients who do 
not recover reflects this pathological process. 
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Myo-inositol (Ins), its temporal evolution and role in spinal neurodegeneration and 
repair 
In the brain, elevated Ins is seen in NAWM (Fernando et al., 2004) and acute lesions 
(Srinivasan et al., 2005). In RRMS, elevated Ins concentrations has been reported in chronic 
spinal cord lesions (Marliani et al., 2010), but this finding has not been replicated in other 
studies (Kendi et al., 2004; Blamire et al., 2007; Ciccarelli et al., 2007). In the current study, 
spinal Ins concentrations in patients were not significantly elevated at baseline but higher Ins 
was associated with deterioration of postural stability over 6 months (Table 6.16). This is in 
keeping with an earlier study, which found higher spinal Ins at onset of relapse was 
associated with higher EDSS scores (Ciccarelli et al., 2007).  
 
Ins is considered a marker of astrocytic activation and proliferation (Brand et al., 1993) and 
taken together, the observation of higher baseline Ins and tCr predicting disability at 6 
months suggest that there is a relationship between gliosis and spinal neurodegeneration 
following spinal cord relapse. The precise role of astrogliosis in MS, however, remains 
poorly understood; whilst gliosis and neurodegeneration appear inter-related processes, it is 
unclear whether gliosis is the cause or consequence of neurodegeneration. Future work 
should aim to address this important question.  
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Total Choline (tCho), its temporal evolution and role in spinal neurodegeneration and 
repair 
In the brain, elevated tCho concentration is almost ubiquitous in MS and elevated levels have 
been reported in acute T2 lesions (De Stefano et al., 1995a; Srinivasan et al., 2005), chronic 
T2 lesions (He et al., 2005) , T1 hypointense lesions (He et al., 2005) and NAWM (Inglese et 
al., 2003; He et al., 2005). However, in the spinal cord, only a single study has reported 
elevated tCho in the spine, in patients with chronic spinal lesions (Marliani et al., 2010). 
Other studies have shown no difference in spinal tCho between patients and controls; in 
cohorts of patients with normal appearing spinal cords (Kendi et al., 2004), acute spinal 
lesions (Ciccarelli et al., 2007; Ciccarelli et al., 2010a; Ciccarelli et al., 2010b) and those 
with a mixture of spinal changes on MRI (Blamire et al., 2007). 
 
In the current study, spinal tCho concentrations in patients were not significantly different to 
controls at baseline, but during the follow up period, concentrations were significantly higher 
than controls at 3 months before normalising again at 6 months (Table 6.4). From the sub-
group analysis, it is evident that the rise in tCho only reaches statistical significance in non-
improvers (Table 6.12). This may reflect active demyelination and remyelination (Marliani et 
al., 2010), following a second relapse event. One limitation of this interpretation is that if the 
group difference at 3 months reflects active demyelination in only 5 patients, why is there no 
significant rise in tCho observed across the cohort at baseline? Timing of the scans may be 
important; at baseline, patients were scanned on average 20 days after the onset of relapse 
symptoms by which time, myelin debris which contributes to the tCho resonance may have 
been partially cleared by macrophages and inflammatory cells. 
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QSI-derived perpendicular diffusivity, its temporal evolution and role in spinal 
neurodegeneration and repair 
At baseline, QSI-derived perpendicular diffusivity is increased in the whole cord, as well as 
the anterior, posterior and lateral columns and remains elevated at 6 months (Tables 6.6-6.9). 
The changes in the dPDF shape in patients at baseline (Figure 6.5) are similar to those seen 
in the PPMS cohort (Chapter 5) and are likely to reflect a breakdown in myelin and axonal 
membranes which act as microstructural barriers to perpendicular diffusion (Beaulieu, 2002). 
These findings also correspond to previous reported changes in the brain and spinal cords of 
patients with relapse-onset MS (Assaf et al., 2002; Farrell et al., 2008) as well as what we 
known about MS pathology (Chapter 1).  
 
The microstructural abnormalities accounting for the differences in perpendicular diffusivity 
at baseline reflect acute disability and predict recovery from clinical relapse; elevated QSI-
derived perpendicular diffusivity in the anterior column at baseline was associated with 
impaired mobility (Table 6.11); and higher baseline perpendicular diffusivity in the whole 
cord, anterior column and lateral columns predicted a decline in grip strength over 6 months 
(Table 6.16). There was also a borderline association (P=0.069) of developing increased 
spasticity over 6 months in patients with higher baseline FWHMxy in the whole cord (Table 
6.16). 
 
Perpendicular diffusivity in the whole cord evolved differently in patients who recover from 
their relapse compared with those that do not. In patients who recover, perpendicular 
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diffusivity begins to restrict by 1 month and remains comparable to controls at 6 months, 
whereas, in patients who do not recover, the perpendicular diffusivity remains high at 6 
months (Table  6.13, Figures 6.4 and 6.5), suggesting that restriction of perpendicular 
diffusivity following a relapse reflects a tissue repair process in MS. In fact, restriction of 
perpendicular diffusivity was an important predictor of clinical recovery; decreasing 
perpendicular diffusivity in the whole cord, anterior column and lateral columns was 
associated with recovery on the EDSS over 6 months (Table 6.17) and restriction of 
perpendicular diffusivity in the posterior columns was associated with clinical recovery on 
the EDSS, MSWS, VPT and Romberg’s test at a stance width of 32cm (Table 6.17).  
Within the second sub-group analysis, in keeping with observed changes in tNAA, 
perpendicular diffusivity was significantly increased in patients with imaging changes most 
consistent with the clinical diagnosis of acute cervical spine relapse (acute cord 
swelling/GAD enhancement or resolution of C1-3 lesion on 6 month follow up), whereas 
perpendicular diffusivity within the six patients without those imaging changes was not 
significantly different to controls (Table 6.15). Again, it might be predicted that there will be 
greater tissue damage and hence greatest breakdown of barriers to perpendicular diffusion in 
patients with the greatest/most dynamic changes on conventional imaging which might 
account for this difference. Alternatively, it is possible that relapse symptoms reported by 
patients were caused by a lesion at a site other than C1-3 as discussed earlier.  
 
Reinstatement of a physical barrier to perpendicular diffusion in the patients who improve 
must account for this reparative process. Axonal regeneration is unlikely to explain these 
changes, and therefore the most likely explanation is that the changes in QSI indices reflect 
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remyelination. This is supported by existing data from animal studies, which as discussed in 
Chapter 3, have shown that myelin has a significant effect on the restriction of QSI-derived 
perpendicular diffusivity (Assaf et al., 2000; Cohen and Assaf, 2002; Biton et al., 2005; 
Biton et al., 2006; Biton et al., 2007; Bar-Shir et al., 2009).  
In patients who fail to recover from their relapse, there is an increase of perpendicular 
diffusivity by 6 months (Table 6.13), which may reflect a neurodegenerative process with or 
without ongoing demyelination which accounts for disability. 
 
QSI-derived parallel diffusivity, its temporal evolution and role in spinal 
neurodegeneration and repair 
At baseline, QSI-derived parallel diffusivity in the whole cord, and major spinal cord tracts 
was very similar to healthy controls but by 6 months, there was a trend (P=0.062) towards 
higher FWHMz (increased parallel diffusivity) in the whole cord (Table 6.6).When looking 
at the sub group analysis, at 6 months, parallel diffusivity in the whole cord is significantly 
higher than controls in patients with a persistent deficit, but not in those who recover (Table 
6.13), suggesting that increasing parallel diffusivity reflects a pathological process associated 
with disability. In fact, increasing parallel diffusivity over 6 months in the whole cord was 
associated with deteriorating grip strength, walking speed and increased spasticity (Table 
6.17) and increasing parallel diffusivity in the anterior and lateral columns was associated 
with increasing spasticity while in the posterior column it was associated with deterioration in 
walking speed and grip strength (Table 6.17). 
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It is possible that the increase in diffusion parallel to the cord seen in the current cohort 
reflects degenerative axonal loss and mirrors findings from a DTI study of acute optic 
neuritis, where axial (parallel) diffusivity is restricted at symptom onset but increases over 12 
months (Naismith et al., 2012). It is also possible that the increase in parallel diffusivity 
simply reflects resolution of inflammation, which results in decreased viscosity of the 
extracellular fluid, allowing increased diffusion of water parallel to the cord. Whilst these 
findings appear to contradict the QSI studies of axotomy in rodents discussed in Chapter 3 
(Farrell et al., 2010) and DTI studies in EAE (Kim et al., 2006; Budde et al., 2009), which all 
report a correlation between restricted parallel diffusivity and axonal loss, increased axial 
(parallel) diffusivity has been widely reported in both MS lesions and NAWM (Bammer et 
al., 2000; Reich et al., 2010; Wood et al., 2012) and is thought to reflect axonal loss 
following a demyelinating episode. It has been proposed that parallel diffusion can be 
restricted at the onset of a relapse owing to an increase in intra-axonal viscosity and axonal 
swelling, but as oedema resolves and macrophages and inflammatory cells clear myelin 
debris, there are fewer barriers to diffusion, allowing water to move more freely, parallel to 
the orientation of axons (Naismith et al., 2012; Wood et al., 2012). 
 
In conclusion, data from this study suggest that neuroaxonal loss and metabolic dysfunction, 
which were assessed using tNAA concentrations and QSI indices, may be important 
determinants of acute disability and clinical outcome following spinal cord relapse. We have 
described an association between spinal Glx concentrations at baseline and clinical outcomes 
which suggest glutamate mediated excitotoxic injury maybe an important mechanism of 
disability progression. Increased inositol concentrations, which in part reflect astrocyte 
activation and proliferation, at the onset of spinal relapse was a poor prognostic marker and 
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predicted poor recovery over six months. Finally, restriction of QSI-derived perpendicular 
diffusivity, which reflects reinstatement of perpendicular barriers to diffusion, such as myelin 
was associated with clinical recovery following spinal relapses. 
 
Study limitations  
Limitations of the QSI and MRS protocols used in the current experiment and the reasons for 
not performing corrections for multiple comparisons have previously been discussed in 
Chapter 5.4. Additional limitations with respect to the current study were, firstly, that it was 
not feasible to measure metabolite abnormalities within acute lesions specifically, owing to 
the low spatial resolution of single voxel MRS. This would have been of interest as it would 
provide a much more accurate picture of the pathological changes at the onset of a relapse 
and identify if abnormalities persist for longer within lesions than surrounding tissue. In the 
future it may be possible to address this by designing spinal spectroscopy studies using MRSI 
which has been piloted previously (Edden et al., 2007). Secondly, some patients did not 
complete the study but by employing a mixed effect statistical model, it was possible to 
include all available data points into the statistical analysis, which is an approach which has 
been used successfully in other longitudinal studies. Thirdly, due to the delayed presentation 
of some patients in the study, it is possible that hyper-acute changes (eg. raised tCho or 
restricted parallel diffusion), had they been present, may have been missed. Finally, it is 
possible that ‘hyper-acute’ changes associated with an acute spinal cord relapse were difficult 
assess in the current study for 2 reasons; firstly 19 out of 20 patients were treated with high 
dose steroids before their first scan and secondly, the mean time to baseline scan from onset 
of symptoms was 20 days. 
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Future directions 
Data from this study suggests that spinal neurodegeneration is the key substrate for persisting 
disability following MS relapse and that glutamate-mediated excitotoxicity, and axonal 
metabolic dysfunction may be important mechanisms of neurodegeneration.  Future work 
should therefore aim to establish the relative contribution of these pathways to axonal loss in 
MS, with a view to developing neuroprotective agents which will limit disability progression. 
  
Future studies should also aim to validate the use of QSI as a biomarker of remyelination. In 
recent years, there has been a resurgence of interest in remyelination enhancing therapies 
(Keough and Yong, 2013; Munzel and Williams, 2013; Franklin and Gallo, 2014; Hartley et 
al., 2014; Olsen and Akirav, 2014). Early phase trials of the anti-LINGO-1 antibody, 
BIIB033 (NCT01864148), and human monoclonal IgM antibody 22 (rHIgM22) 
(NCT01803867) which aim to improve remyelination in patients with MS are already 
underway, in spite of this lack of a robust biomarker of remyelination (Munzel and Williams, 
2013). If QSI derived perpendicular diffusivity was proven to reliably reflect remyelination, it 
would allow for a much more accurate evaluation of these new therapies.  
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Chapter Seven 
Conclusions and future directions 
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7.1 Conclusions 
The spinal cord is a clinically eloquent structure, commonly affected in MS, causing 
significant disability. However, spinal cord pathology in MS has been relatively under-
studied, using advanced MRI techniques due to the technically challenging nature of MRI 
within this region. The aim of this thesis was therefore to use a combination of advanced 
quantitative MRI techniques to investigate spinal neurodegeneration and repair in PPMS and 
RRMS in vivo.  
 
This thesis has combined single-voxel MRS and QSI, two advanced MRI techniques which 
have increased pathological specificity for neurodegeneration and myelin, and allow 
quantification of metabolites that reflect biological mechanisms, which I hypothesised, may 
be involved in neurodegenerative and repair pathways. By combining these imaging 
techniques with new clinical measures, which reflect spinal cord functions more closely than 
conventional clinical tests, the relationship between spinal cord structure-metabolism and 
function has been evaluated in greater detail than has previously been the case. 
 
In relation to spectroscopy, this work has built on earlier spinal cord studies in MS which 
have used protocols which were not optimised for quantification of Glx (Chapter 3). One 
limitation of earlier studies has been that they have not addressed the potential contribution of 
glutamate-mediated excitotoxicity in the spinal cord in MS pathology. This has largely been 
due to the technical challenges associated with quantifying Glu or Glx from the spinal cord. 
Optimisation experiments performed in Chapter 4.1 were therefore aimed at developing a 
novel spinal MRS protocol capable of quantifying Glx. A short-TE PRESS MRS sequence 
 
 
  
237 
 
gave the best results which is broadly in keeping with earlier work carried out by Hancu, who 
found that short-TE PRESS was optimal for Glx detection in the brain (Hancu, 2009). The 
effects of age and gender on normative metabolite concentrations obtained from the healthy 
spinal cord were assessed in Chapter 4.2. Important associations between advancing age and 
declining concentrations of tNAA and Glx were identified, which likely reflect age-related 
neurodegeneration and is in keeping with age-related changes reported in the brain. This 
association represents an important consideration in any longitudinal follow up of patients 
using spinal MRS and will allow differentiation between changes due to pathology and those 
occurring as a consequence of normal ageing. Spinal Glx concentrations were lower in 
female subjects than males, even after correcting for age. Similar findings have previously 
been observed in some, but not all brain regions, in earlier studies, and it has been suggested 
that hormonal factors may be responsible for gender differences in Glx (Batra et al., 2008; 
Zlotnik et al., 2011). However, it should be noted that of the 22 subjects included in the final 
analysis, only 7 were males and this finding will therefore need to be confirmed in future 
studies with larger sample sizes. 
 
In section 4.3, differences in spinal GMVF between healthy subjects were assessed. A large 
degree of variability in GMVF was seen in healthy controls (range 16.1 to 24.8%). In fact, the 
degree of variability is much greater than that seen in the brains of the same healthy controls 
in Chapter 5 (range 46 to 50.5%). Increasing GMVF (or decreasing WMVF) was associated 
with increasing tNAA/Cr and Glx/Cr ratios which suggests that there must be higher 
concentrations of tNAA and Glx and/or lower concentrations of tCr in the spinal grey matter 
compared to the white matter. This becomes relevant when studying neurodegenerative 
diseases in which there is tissue-specific volume loss in the spinal cord such as MS (where 
 
 
  
238 
 
spinal cord atrophy occurs predominantly because of white matter volume loss). GMVF 
should therefore, when possible, be calculated in patients and corrected for in spinal MRS 
studies. This is difficult in MS because, when using currently available imaging protocols, 
there isn’t sufficient contrast, on axial images, between spinal grey matter and white mater 
lesions to allow reliable segmentation of the grey matter. More work is therefore required to 
develop techniques for accurate spinal grey matter segmentation in patients with spinal cord 
lesions. 
 
Chapter 5 applied the newly developed MRS protocol together with QSI of the cervical cord 
to patients with early PPMS. The hypotheses being tested were that these imaging techniques 
would be more sensitive than spinal cord cross sectional area for detecting early 
neurodegenerative changes and that those changes in MRS and QSI metrics would reflect 
disability. The results suggest that QSI and MRS are promising techniques for detecting early 
disease changes; there were significant differences in QSI-derived perpendicular diffusivity, 
spinal tNAA and spinal Glx between patients and controls, which reflect changes in 
neuroaxonal integrity, axonal metabolic function and glutamatergic neurotransmitter pool. 
These changes were detectable despite there being no significant differences in cord area 
between the two groups. This increased sensitivity for detection of microstructural changes 
earlier, is important because there is currently an unmet need for sensitive imaging 
biomarkers of spinal neurodegeneration in progressive forms of MS; for more accurate 
assessment of disease progression and as an imaging outcome measure in clinical trials of 
new neuroprotective agents. Patients with spinal cord lesions within the spectroscopy voxel 
were also observed to have significantly elevated Ins concentrations compared with controls, 
which reflects astrocyte activation and gliosis; which correlates with histological observation 
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of persistent astrogliosis in chronically demyelinated plaques (Popescu and Lucchinetti, 
2012; Popescu et al., 2013). Ins levels in normal appearing spinal cord were comparable to 
controls which raises questions about the role of gliosis in neurodegeneration; whether gliosis 
drives neurodegeneration or is the inevitable consequence of neurodegeneration needs to be 
investigated further. 
 
Lower spinal tNAA and Glx, and higher spinal Ins were all associated with increased 
disability. Taken together, these findings suggest that neuroaxonal loss, axonal metabolic 
dysfunction, alterations in glutamatergic neurotransmitter pool and astrocyte proliferation 
could contribute to early clinical disability in PPMS. These hypotheses were supported by the 
QSI data; increased QSI-derived perpendicular diffusivity in the cord, reflecting reduced 
axonal integrity and/or demyelination also correlated with disability. This was also true when 
assessing the relationship between QSI indices in spinal white matter tracts and clinical 
scores which reflect the motor or sensory functions conveyed within those tracts, suggesting a 
strong structure-function relationship between axonal microstructure and disability. 
 
In Chapter 6, spinal MRS and QSI were applied to a cohort of RRMS patients. The study was 
designed to investigate the role of neurodegeneration and repair in the spinal cord on 
disability following acute spinal cord relapse. The specific mechanisms under investigation 
were the role of a) neuroaxonal loss and dysfunction, b) glutamate-excitotoxicity, c) gliosis 
and d) resolution of inflammation and repair mechanisms on acute disability and recovery.  
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Increasing QSI-derived perpendicular and parallel diffusivity over 6 months was associated 
with no recovery following spinal cord relapse, suggesting that neuroaxonal degeneration 
following acute relapses determines clinical outcomes. Glutamate mediated excitotoxicity 
may also be important; higher spinal Glx at onset of relapse was significantly associated with 
accumulation of disability. This builds on earlier work by Baranzini et al which demonstrated 
that patients with higher brain glutamate concentrations exhibited greater declines in tNAA 
(reflecting axonal loss) over 1 year (Baranzini et al., 2010). In the spinal cord, normalisation 
of Glx concentrations occurred in all patients by 1 month, irrespective of recovery, which 
suggests that injury caused by excess glutamate is most likely to occur during the acute 
phase. This finding has potential implications for future therapeutic interventions which 
target glutamate mediated injury in MS; as effectiveness of glutamate blocking agents may be 
dependent on immediate administration at the onset of relapse symptoms. 
 
Spinal tNAA concentrations which reflect neuronal density and metabolism showed two 
distinct patterns of evolution in the 6 month follow up period; a) in patients whom recovered 
there was an initial decline in tNAA, followed by recovery and b) in patients who did not 
recover, tNAA concentrations remained low. The reversibility of tNAA was associated with 
recovery on clinical scores and is likely to reflect reversal of axonal metabolic dysfunction, 
without which, recovery does not occur. Myelin repair (remyelination), assessed on 
restriction of perpendicular diffusivity over 6 months was also significantly associated with 
clinical recovery, as might be expected. Enhancing these biological processes should 
therefore be targeted by potential future therapies. 
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MRS and QSI measures at baseline were predictive of clinical outcomes at 6 months; in 
particular baseline spinal Glx, Ins and tCr concentrations and QSI-derived perpendicular 
diffusivity, which suggests either individual imaging measures or muti-parametric models 
consisting of multiple measures, could be used in the future to stratify risk for incomplete 
recovery and to identify patients who would benefit from early therapeutic interventions. 
 
In summary, spinal MRS and QSI provide a sensitive and non-invasive means to quantify 
metabolic and microstructural tissue changes on a longitudinal basis in the cervical cord. 
MRS and QSI changes occur early in PPMS, prior to the development of spinal atrophy and 
closely related to clinical disability and likely reflect important pathological processes. 
Following spinal cord relapses, disability may not be attributable to a single pathologic 
process; this work has generated hypotheses about disease mechanisms that require more 
detailed evaluation; glutamate-mediated excitotoxicity and neurodegeneration are suggested 
as important mechanisms of disability progression and reversal of axonal metabolic 
dysfunction and remyelination could, in part underlie clinical recovery. This improved 
accessibility to assessing tissue damage in the cervical cord together with increased 
pathological specificity of advanced imaging techniques means that advanced quantitative 
MRI of the spinal cord should be considered as a potentially valuable component of future 
trials looking at recovery and neuroprotection in MS. 
 
7.2 Suggested directions for future research 
There is an increasing body of evidence, which has been added to by this thesis, to support a 
potential role for glutamate mediated excitotoxicity in MS pathophysiology. As discussed in 
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Chapter 4, future work should therefore now focus on developing improved MRS protocols, 
capable of reproducible quantification of spinal Glu concentrations in the cervical cord to 
allow this potentially modifiable disease process to be studied in greater detail and on a larger 
scale, in vivo. Using a 3T system, Hurd et al. reported reproducible Glu quantification in the 
brain, with good visual separation of Glu from Gln using a TE-averaged PRESS sequence 
(Hurd et al., 2004). However, to achieve similar results the spinal cord will require ultra-high 
field strengths or much longer scanning times. The latter may prevent simultaneous 
acquisition of other sequences within acceptable scan times. Alternatively, employing 
spectral editing techniques such as J-editing, which have allowed reproducible quantification 
of strongly coupled resonances in the brain (O'Gorman et al., 2011) within acceptable scan 
times at 3T, may be more suited to the spinal cord.  
 
One important methodological consideration in future spinal MRS studies in MS will be the 
segmentation of spinal grey matter to calculate GMVF. Spinal grey matter segmentation in 
MS patients might be possible when higher resolution axial imaging, which provides 
improved contrast between lesions and grey matter, is available in the future; again work is 
now needed to develop this. The double inversion recovery (DIR) and phase-sensitive 
inversion recovery (PSIR) sequences give improved contrast between lesions and grey matter 
in the brain (Sethi et al., 2012) and the DIR sequence has recently been adapted for the 
cervical cord and shows improved detection of MS lesions (Riederer et al., 2014), but further 
work is required to determine whether these sequences could be adapted for spinal grey 
matter segmentation in future. 
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The significance of elevated spinal Ins in PPMS needs further evaluation. Results in Chapter 
5 have shown that Ins is elevated in early PPMS but that this increase is driven by data 
collected from patients with lesions within the spectroscopic voxel. More work is therefore 
needed to decipher whether gliosis is the end-stage hallmark of chronic lesions or whether it 
contributes to neurodegeneration. This question would be best answered through a 
longitudinal extension of the study in Chapter 5 which is currently ongoing. In the 3 year 
longitudinal study we will also look at the prognostic value of baseline Ins and other imaging 
measures on progression of disability and imaging measures of neurodegeneration such as 
cord atrophy, spinal tNAA concentrations and QSI metrics. 
 
It was beyond the scope of this thesis to establish whether or not QSI indices are more 
sensitive to spinal microstructural changes, than the more established DTI-derived indices 
such as fractional anisotropy (FA), radial (RD) and axial (AD) diffusivity. Non-Gaussian 
models such as QSI have theoretical advantages over DTI which may mean they are better 
suited/more sensitive for detecting early and longitudinal pathological changes. This could 
have important implications for future diagnostic criteria in MS, allowing earlier evaluation 
of ‘dissemination in space’, in macroscopically normal CNS sites, as well as disease 
monitoring and clinical trials. Although earlier work has attempted to answer this question in 
the brain (Assaf et al., 2002; Assaf et al., 2005), future studies should look at making direct 
comparisons between QSI and DTI models in the spinal cord in MS.  
 
Multi-parametric imaging models in demyelinating disorders have been used with some 
success recently and may provide important information about microstructural spinal cord 
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changes and better explain the substrates of disability (Pichiecchio et al., 2011; Oh et al., 
2013b). Studies in the future should aim to incorporate spinal QSI and MRS along with MTR 
and cord atrophy to improve our understanding of the interaction between structural and 
metabolic abnormalities that best explains disability in MS. 
 
The need to develop neuroprotective drugs in MS is arguably the most urgent challenge 
facing the MS research community. Results from Chapter 6 support existing evidence for two 
particularly important and potentially modifiable mechanisms of neurodegeneration 
following spinal cord relapse; specifically, glutamate mediated excitotoxicity and axonal 
metabolic (mitochondrial) dysfunction. Results from this thesis, along with earlier studies 
suggest that metabolic dysfunction can be reversible and as such, should be considered an 
important therapeutic target for new neuroprotective agents. Similarly, the evidence for 
glutamate mediated damage is growing and represents a potentially modifiable disease 
pathway. When these findings are taken in the context of supporting data from animal 
studies, there is a strong case to be made for designing clinical trials which use existing 
drugs, with acceptable risk profiles that target the glutamatergic and mitochondrial pathways 
implicated in neurodegeneration, similar to trials already conducted using sodium channel 
blockers in MS (Kapoor et al., 2010; Raftopoulos et al., 2014). 
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